



IN THE CLAIMS:

1. (Presently Amended): A method of treating or preventing stasis in all or any part or parts of the stomach of a patient in need of such treatment, wherein said stasis results from hypomotility in said stomach or part thereof, comprising administering to said patient a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to restore normal motility to said patient, wherein said PDE4 inhibitor comprises a compound of Formula (IA) or (IB):



(IA)



(IB)

and to pharmaceutically acceptable salts thereof, wherein:

-R is a member independently selected from the group consisting ~~essentially~~ of hydrogen, (C₁-C₉) alkyl; -(CH₂)_n(C₃-C₁₀) cycloalkyl wherein n is ~~an integer selected from~~ 0, 1, ~~and or~~ 2; (C₁-C₆) alkoxy(C₁-C₆) alkyl; (C₂-C₆) alkenyl; -(CH₂)_n(C₃-C₉) heterocyclyl wherein n is ~~an integer selected from~~ 0, 1, ~~and or~~ 2; and -(Z¹)_b(Z²)_c(C₆-C₁₀) aryl wherein b and c are ~~integers~~ independently ~~selected from~~ 0 ~~and or~~ 1, Z¹ is (C₁-C₆) alkylene or (C₂-C₆) alkenylene, and Z² is O, S, SO₂, or NR¹¹⁹; and further wherein said heterocyclyl is a member independently selected from the group consisting ~~essentially~~ of acridinyl; benzimidazolyl; benzodioxolane; 1,3-benzodioxol-5-yl; benzo[b]furanyl; benzo[b]thiophenyl; benzoxazolyl; benzthiazolyl; carbazolyl; cinnolinyl; 2,3-dihydrobenzofuranyl; 1,3-dioxane; 1,3-dioxolane; 1,3-dithiane; 1,3-dithiolane; furanyl; imidazolidinyl; imidazolynyl; imidazolyl; 1H-indazolyl; indolinyl;


indolyl; 3H-indolyl; isoindolyl; isoquinolyl; isothiazolyl; isoxazolyl; morpholyl; 1,8-naphthyridinyl; oxadiazolyl; 1,3-oxathiolane; oxazolidinyl; oxazolyl; oxiranyl; parathiazinyl; phenazinyl; phenothiazinyl; phenoxazinyl; phthalazinyl; piperazinyl; piperidinyl; pteridinyl; pyranyl; pyrazinyl; pyrazolidinyl; pyrazolyl; pyrazolo[1,5-c]triazinyl; pyrazolyl; pyridazinyl; pyridyl; pyrimidinyl; pyrimidyl; pyrrolyl; pyrrolidinyl; purinyl; quinazolinyl; quinolyl; 4H-quinolizinyl; quinoxalinyl; tetrazolidinyl; tetrazolyl; thiadiazolyl; thiazolidinyl; thiazolyl; thienyl; thiomorpholyl; triazinyl; and triazolyl; wherein said aryl is a carbocyclic moiety which is a member independently selected from the group consisting essentially of benzyl; *cis*- and *trans*-decahydronaphthalenyl; 2,3-1H-dihydroindenyl (indanyl); indenyl; 1-naphthalenyl; 2-naphthalenyl; phenyl; and 1,2,3,4-tetrahydronaphthalenyl; wherein said alkyl, alkenyl, alkoxyalkyl, heterocyclyl, and aryl moieties defining said R groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting essentially of bromo, chloro, or fluoro; hydroxy; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; (C₁-C₅) alkoxy; (C₃-C₆) cycloalkoxy; mono-, di-, and tri-fluoromethyl; nitro; -C(=O)OR¹¹⁹, -C(=O)NR¹¹⁹R¹²⁰, -NR¹¹⁹R¹²⁰ and -S(=O)₂NR¹¹⁹R¹²⁰;

-R¹ is a member independently selected from the group consisting essentially of hydrogen; (C₁-C₉) alkyl; (C₂-C₃) alkenyl; phenyl; (C₃-C₇) cycloalkyl; and (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; wherein said alkyl, alkenyl and phenyl moieties defining said R¹ groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting essentially of methyl; ethyl; mono-, di-, and tri-fluoromethyl; ~~and bromo, chloro, or~~ bromo; chloro; and fluoro; and


-R²_a and R²_b are independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, but not both of R²_a and R²_b must be independently selected as hydrogen, wherein said substituents comprise moieties of the groups (- I -) through (- V -):

--(- I -)


--a moiety of partial Formulas (1.0.0), (1.0.1), (1.0.2), and (1.0.3):




(1.0.0)



(1.0.1)



(1.0.2)



(1.0.3)

---wherein the dashed lines in partial Formulas (1.0.0) and (1.0.1) independently and optionally represent a single or double bond, provided that in formula (1.0.0) both dashed lines cannot both represent double bonds at the same time;

---m is ~~an integer selected from~~ 0, 1, 2, 3, and or 4, and when 2, may apply to a single carbon atom on the ring;

---R¹¹³ is a member selected from the group consisting essentially of H; ~~bromo, chloro, or~~ bromo; chloro; fluoro; cyano; (C₂-C₄) alkynyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting essentially of phenyl, pyridyl and pyrimidinyl; (C₁-C₄) alkyl substituted by 0 to 6 bromo, chloro, or fluoro; -CH₂NHC(=O)C(=O)NH₂; cyclopropyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting essentially of R¹²¹; R¹²⁷;

CH₂OR¹¹⁹; NR¹¹⁹R¹²⁰; CH₂NR¹¹⁹R¹²⁰; C(=O)OR¹¹⁹; C(=O)NR¹¹⁹R¹²⁰; C≡CR₁₁; C(Z)H; and -CH=CR¹²¹R¹²¹; provided that R¹¹³ is H in Formula (1.0.0) when the dashed line for the ring carbon of R¹¹³ attachment represents a double bond;

---R¹¹⁴ is a member selected from the group consisting essentially of H; R¹¹⁶; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰SR¹²⁴; CR¹¹⁹R¹²⁰S(O)_nR¹²⁵ where n is an integer selected from 0, 1, and or 2; CR¹¹⁹R¹²⁰NR¹²⁴R¹²⁷; CR¹¹⁹R¹²⁰NR¹²⁷S(=O)₂R₁₅; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)OR¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(CR¹¹⁹NO₂)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰C(=O)OR¹²⁵; CR¹¹⁹R¹²⁰C(Y)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰C(NR¹²⁷)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰CN; CR¹¹⁹R¹²⁰C(NOR¹²⁰)R¹²⁴; CR¹¹⁹R¹²⁰C(NOR¹²⁴)R¹²⁰; CR¹¹⁹R¹²⁰NR¹²⁷C(NR¹²⁷)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰NR¹²⁷C(NR¹²⁷)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)C(=O)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)C(=O)OR¹²⁴; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; CR¹¹⁹R¹²⁰(tetrazolyl); CR¹¹⁹R¹²⁰(thiazolyl); CR¹¹⁹R¹²⁰(imidazolyl); CR¹¹⁹R¹²⁰(imidazolidinyl); CR¹¹⁹R¹²⁰(pyrazolyl); CR¹¹⁹R¹²⁰(thiazolidinyl); CR¹¹⁹R¹²⁰(oxazolyl); CR¹¹⁹R¹²⁰(oxazolidinyl); CR¹¹⁹R¹²⁰(triazolyl); CR¹¹⁹R¹²⁰(isoxazolyl); CR¹¹⁹R¹²⁰(oxadiazolyl); CR¹¹⁹R¹²⁰(thiadiazolyl); CR¹¹⁹R¹²⁰(morpholinyl); CR¹¹⁹R¹²⁰(piperidinyl); CR¹¹⁹R¹²⁰(piperazinyl); and CR¹¹⁹R¹²⁰(pyrrolyl); said heterocyclic groups being substituted by 0 to 3 substituents R¹²⁴;

---R¹¹⁵ is a member selected from the group consisting essentially of R¹¹⁹; OR¹¹⁹; -CH₂OR¹¹⁹; cyano; C(=O)R¹¹⁹; C(=O)OR¹¹⁹; C(=O)NR¹¹⁹R¹²⁰; and NR¹¹⁹R¹²⁰; provided that R¹¹⁵ is absent when the dashed line in partial Formula (1.0.0) represents a double bond; or

---R¹¹⁴ and R¹¹⁵ are taken together to form =O or =R¹¹⁸; or

---R¹¹⁵ is hydrogen and R¹¹⁴ is OR¹²⁴; SR¹²⁴; S(O)_nR¹²⁵, where n is an integer selected from 0, 1, or 2; S(=O)₂NR¹²⁷R¹²⁴; NR¹²⁷R¹²⁴; NR¹²⁴C(=O)R¹¹⁹; NR¹²⁷C(Y)R¹²⁴; NR¹²⁷C(=O)OR¹²⁵; NR¹²⁷C(Y)NR¹²⁷R¹²⁴; NR¹²⁷S(=O)₂NR¹²⁷R¹²⁴; NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; NR¹²⁷S(=O)₂R¹²⁵; NR¹²⁷C(CR¹¹⁹NO₂)NR¹²⁷R¹²⁴; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(CR¹¹⁹NO₂)S(C₁-C₄) alkyl; NR¹²⁷C(NR¹²⁷)NR¹²⁷R¹²⁴; NR¹²⁷C(=O)C(=O)NR¹²⁷R¹²⁴; or NR¹²⁷C(=O)C(=O)OR¹²⁴;

---R¹¹⁶ is a member independently selected from the group consisting essentially of methyl and ethyl substituted by 0 to 5 bromo, chloro, or fluoro, wherein m may be 2 with respect to a single ring carbon atom to which R¹¹⁶ is attached;

---R¹¹⁷ is a member independently selected from the group consisting essentially of OR¹²⁴; SR¹²⁴; SO₂NR¹²⁷R¹²⁴; NR¹²⁷R¹²⁴; NR¹²⁴C(=O)R¹¹⁹; NR¹²⁷C(Y)R¹²⁴; NR¹²⁷C(=O)OR¹²⁵; S(O)_nR¹² where n is an integer selected from 0, 1, and 2; OS(=O)₂R¹²²; OR¹²²; OC(=O)NR¹²³R¹²²; OC(=O)R¹²³; OC(=O)OR¹²³; O(CR¹²²R¹²³)_mOR¹²² where m is an integer selected from 0, 1, and 2; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷R¹²⁴; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; and

thiadiazolyl; where the recited heterocyclic groups are substituted by 0 to 3 substituents where said substituent is R^{124} ;

---- R^{118} is a member independently selected from the group consisting ~~essentially~~ of $-NR^{125}$; $-NCR^{119}R^{120}(C_2-C_6)$ alkenyl; $-NOR^{124}$; $-NOR^{129}$; $-NOCR^{119}R^{120}(C_2-C_6)$ alkenyl; $-NNR^{119}R^{124}$; $-NNR^{119}R^{129}$; $-NCN$; $-NNR^{119}C(Y)NR^{119}R^{124}$; $-C(CN)_2$; $-CR^{124}CN$; $-CR^{124}C(=O)OR^{119}$; $-CR^{124}C(=O)NR^{119}R^{124}$; $-C(CN)NO_2$; $-C(CN)C(=O)O(C_1-C_4)$ alkyl; $-C(CN)OC(=O)O(C_1-C_4)$ alkyl; $-C(CN)(C_1-C_4)$ alkyl; $-C(CN)C(=O)NR^{119}R^{124}$; 2-(1,3-dithiane), 2-(1,3-dithiolane), dimethylthio ketal, diethylthio ketal, 2-(1,3-dioxolane), 2-(1,3-dioxane), 2-(1,3-oxathiolane); dimethyl ketal and diethyl ketal;

---- R^{119} and R^{120} are each a member independently selected from the group consisting ~~essentially~~ of hydrogen and (C_1-C_4) alkyl substituted by 0 to 3 fluorine atoms;

---- R^{121} is a member independently selected from the group consisting ~~essentially~~ of fluoro and R^{120} ;

---- R^{122} is a member independently selected from the group consisting ~~essentially~~ of (C_1-C_6) alkyl; (C_2-C_3) alkenyl; (C_3-C_7) cycloalkyl; (C_3-C_7) cycloalkyl (C_1-C_2) alkyl; (C_6-C_{10}) aryl; and (C_3-C_9) heterocyclyl; where said aryl and heterocyclyl are as defined under R above; and where said R^{122} groups are substituted with 0 to 3 substituents independently selected from the group consisting ~~essentially~~ of methyl; ethyl; mono-, di-, and tri-fluoromethyl; and bromo, chloro, or fluoro;

---- R^{123} is a member independently selected from the group consisting ~~essentially~~ of hydrogen and R^{122} ;

---R¹²⁴ is a member independently selected from the group consisting essentially of hydrogen and R¹²⁵; or when R¹²⁴ and R¹²⁷ appear together as NR¹²⁷R¹²⁴ then R¹²⁷ and R¹²⁴ may be taken together with the nitrogen to which they are attached to form a 5- to 7-membered ring optionally containing one additional heteroatom selected from O, N and S;

---R¹²⁵ is a member independently selected from the group consisting essentially of (C₁-C₆) alkyl and -(CR¹¹⁹R¹²⁰)_nR¹²⁶, where n is ~~an integer selected from~~ 0, 1, or 2 and R¹²⁶ and said (C₁-C₆) alkyl are substituted by 0 to 3 substituents where each said substituent is a member independently selected from the group consisting ~~essentially of bromo, chloro, or bromo; chloro;~~ fluoro; nitro; cyano; NR¹²⁰R¹²⁷; C(=O)R¹¹⁹; OR¹¹⁹; C(=O)NR¹²⁰R¹²⁷; OC(=O)NR¹²⁰R¹²⁷; NR¹²⁷C(=O)NR¹²⁷R¹²⁰; NR¹²⁷C(=O)R¹²⁰; NR₁₇C(=O)O(C₁-C₄) alkyl; C(NR¹²⁷)NR¹²⁷R¹²⁰; C(NCN)NR¹²⁷R¹²⁰; C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)NR¹²⁷R¹²⁰; NR¹²⁷S(=O)₂(C₁-C₄) alkyl; S(O)_n(C₁-C₄) alkyl; where n is ~~an integer selected from~~ 0, 1, and or 2; NR¹²⁷C(=O)C(=O)NR¹²⁷R¹²⁰, NR¹²⁷C(=O)C(=O)R¹²⁷; thiazolyl; imidazolyl; oxazolyl; pyrazolyl; triazolyl; tetrazolyl; and (C₁-C₂) alkyl substituted with 0 to 3 fluorine atoms;

---R¹²⁶ is a member independently selected from the group consisting essentially of (C₃-C₇) cycloalkyl; pyridyl; pyrimidyl; pyrazolyl; imidazolyl; triazolyl; pyrrolyl; piperazinyl; piperidinyl; morpholinyl; furanyl; thienyl; thiazolyl; quinolinyl; naphthyl; and phenyl;

---R¹² is a member independently selected from the group consisting ~~essentially~~ of OR¹¹⁹ and R¹²⁰;

---R¹²⁸ is a member independently selected from the group consisting ~~essentially~~ of H; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴;

$C(=O)NR^{119}NR^{119}C(=O)R^{119}$; $C(=O)NR^{119}NR^{127}R^{124}$; $C(NOR^{124})R^{119}$; $C(NR^{119})NR^{127}R^{124}$;
 $C(NR^{124})NR^{119}R^{120}$; $C(NCN)NR^{127}R^{124}$; $C(NCN)S(C_1-C_4)$ alkyl; $CR^{119}R^{120}OR^{124}$;
 $CR^{119}R^{120}SR^{124}$; $CR^{119}R^{120}S(O)_nR^{125}$, where n is an integer selected from 0, 1, and or 2;
 $CR^{119}R^{120}NR^{124}R^{127}$; $CR^{119}R^{120}NR^{127}S(=O)_2R^{125}$; $CR^{119}R^{120}NR^{127}C(Y)R^{124}$;
 $CR^{119}R^{120}NR^{127}C(=O)OR^{125}$; $CR^{119}R^{120}NR^{127}C(Y)NR^{127}R^{124}$;
 $CR^{119}R^{120}NR^{127}C(NCN)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(CR_9NO_2)S(C_1-C_4)$ alkyl; tetrazolyl;
 thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl;
 triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; wherein said recited heterocyclic groups are
 substituted by 0 to 3 substituents where each said substituent is independently selected from
 the group consisting essentially of R^{124} ;

---- R^{129} is a member independently selected from the group consisting essentially of $-C(=O)R^{12}$;
 $-C(=O)NR^{119}R^{124}$; $-S(=O)_2R^{125}$; and $-S(=O)_2NR^{119}R^{124}$;

----Y is O or S; and,

----Z is O; NR^{127} ; NCN ; $C(-CN)_2$; $CR^{119}CN$; $CR^{119}NO_2$; $CR^{119}C(=O)OR^{119}$;
 $CR^{119}C(=O)NR^{119}R^{120}$; $C(-CN)C(=O)O(C_1-C_4)$ alkyl; and $C(-CN)C(=O)NR^{119}R^{120}$;

- or, said substituents defining R_a^2 and R_b^2 comprise: -

--(- II -)


--a member selected from the group consisting essentially of R^{229} ;

$-C(=O)NR^{222}(CHR^{222})_mC(=O)NR^{222}O(CH_2)_q(C_6-C_{10})$ aryl);

$-C(=NR^{242})NH(CH_2)_p(C_6-C_{10})$ aryl; $-C(=O)NR^{218}(CHR^{222})_mC(=O)NR^{222}(CH_2)_pOR^{222}$;

$-C(=O)NR^{222}(CHR^{222})_mS(C_1-C_4) \text{ alkyl}; -C[=NOC(=O)R^{235}]R^{236};$
 $-CR^{227}R^{228}CHR^{238}NR^{219}SO_2(CH_2)_pA;$
 $-CR^{227}R^{228}CHR^{238}NR^{219}P(=O)(OR^{222})C(=O)(C_1-C_4) \text{ alkyl};$
 $-CR^{227}R^{238}CHR^{238}NR^{219}P(=O)[(C_1-C_4) \text{ alkoxy}]_2, -Z^3-R^{217};$ and
 $-(CR^{227}R^{228})_mNR^{219}(C(O))_qR^{220}$ wherein p is an integer selected from 0, 1, and or 2; m is an integer selected from 1, 2, 3, 4, 5, and or 6; and q is an integer selected from 1 and or 2;

- or, said substituents defining R_a^2 and R_b^2 comprise a moiety of
 partial Formulas (2.0.0) through (2.0.8), inclusive: -



---wherein in said partial Formulas (2.0.0)-(2.0.8), the structures of partial Formulas (2.0.5) and (2.0.6) are attached to the nucleus of Formula (IA) or (IB) at carbons 5, 6, or 7 of said partial Formulas (2.0.5) and (2.0.6); the dashed line in partial Formulas (2.0.2) and (2.0.3) indicates

a single bond or double bond, except that R^{216} is absent in partial Formulas (2.0.2) and (2.0.3) where said dashed line indicates a double bond; n is 0 or an integer of 1 or selected from 0, 1, and 2; p is ~~an integer selected from 0, 1, 2, 3, 4, 5, and~~ or 6; and m is ~~an integer selected from 0, and~~ 0 or 1;

--- R^{213} is a member independently selected from the group consisting essentially of

-C(=O)N(CH₃)(OCH₃) and -(CH₂)_nOH, where n is ~~an integer selected from 0, 1, 2, 3, and~~ or 4;

--- R^{214} and R^{215} are independently selected from the group consisting essentially of H; ethyl;

-CO₂H; and -C(=O)NHOH;

--- R^{216} is a member independently selected from the group consisting essentially of H; hydroxy;

(C₁-C₆) alkyl; (C₁-C₆) alkoxy; -OC(=O)(C₁-C₆) alkyl and -OC(=O)(C₆-C₁₀) aryl;

---- R^{217} is a member independently selected from the group consisting essentially of

(C₆-C₁₀) aryl and a 5- to 10-membered heterocyclyl, wherein said R^{217} groups are

substituted by 0 to 3 substituents independently selected from the group consisting

essentially of ~~bromo, chloro, or~~ bromo; chloro; fluoro; trifluoromethyl; cyano; nitro;

-CO₂R²²², (C₁-C₄) alkoxy; -OC(=O)(C₁-C₄) alkyl; -NR²²²C(=O)(C₁-C₄) alkyl; -C(=O)NH₂;

-C(=O)NHOH; -C(=O)O(C₁-C₄) alkyl; (C₁-C₄) alkyl; -S(O)_nR²²² where n is ~~an integer~~

~~selected from 0, 1, and~~ or 2; benzoyl; -NR²²²R²²³, -OR²²², (C₁-C₆) alkanoyl;

-Y¹-(C₆-C₁₀) aryl; -C(=O)O(C₆-C₁₀) aryl; -NH(C₆-C₁₀) aryl; -C(=O)NH(C₆-C₁₀) aryl;

-C(=O)NR²²²O(CH₂)_n(C₆-C₁₀) aryl, where n is ~~an integer selected from 1, 2, and~~ or 3; and or

-SO₂NH(C₆-C₁₀) aryl;

- R²¹⁸ is a member independently selected from the group consisting essentially of H;
(C₁-C₆) alkyl; and -(CH₂)_n(C₆-C₁₀) aryl, where n is an integer selected from 0, 1, 2, 3, and or 4;
- R²¹⁹ is a member independently selected from the group consisting essentially of H; -OR²²²;
-(CH₂)_mA ; and -CH₂O(CH₂)_mA, where m is an integer selected from 0, 1, and or 2;
- R²²⁰ is a member independently selected from the group consisting essentially of
(C₁-C₄) alkyl; -OR²²², -CR²²²R²²³OR²²²; -CR²²²R²²³NR²²²R²²³,
-CR²²²(OR²²³)CR²²²R²²³OR²²²; 2,2-dimethyl-1,3-dioxolan-4-yl; -NR²²²C(=O)NR²²²R²²³,
-S(CR²²²R²²³)_nCH₃ where n is an integer selected from 0, 1, 2, 3, 4, and or 5;
-NR²²²(CH₂)_q(pyridyl) where q is an integer selected from 0 and or 1;
-P(=O)[(C₁-C₄) alkoxy]₂; -NR²²²R²²³; -NR²²²OR²²³; -NR²²²NR²²³R²²¹, -NR²²²CH₂R²²⁴,
-OCH₂NR²²²C(=O)R²²⁴; -OCH₂C(=O)NR²²⁵R²²⁶, -OCHR²²²OC(=O)(C₁-C₄) alkyl;
-OCHR²²²C(=O)(C₁-C₃) alkoxy; -O(CH₂)_mR²²¹; and -NR²²²(CH₂)_mR²²¹ where m is an
integer selected from 0, 1, and or 2;
- R²²¹ is a member independently selected from the group consisting essentially of H and A;
- R²²² and R²²³ are each a member independently selected from the group consisting essentially
of H and (C₁-C₄) alkyl;
- R²²⁴ is a member independently selected from the group consisting essentially of methyl and
phenyl;
- R²²⁵ is a member independently selected from the group consisting essentially of H; methyl;
ethyl; and -CH₂CH₂OH;

---R²²⁶ is a member independently selected from the group consisting essentially of H; methyl; ethyl; -CH₂C(=O)NH₂; and -CH₂CH₂OH;


---R²²⁷ is each a member independently selected from the group consisting essentially of H; hydroxy; cyano; halo; (C₁-C₃) alkyl; (C₁-C₃) alkoxy; -NR²²²R²²³; -C(=O)OR²²²; -C(=O)R²²²; -CH=CR²²²R²²³; -C≡CR²²²; -CH₂NR²²²R²²³; -CH₂OR²²²; -C(=O)NR²²²R²²³; -C(Y⁵)H; and -CH₂NR₁₂C(=O)C(=O)NR²²²R²²³; provided that when R²²⁷ is hydroxy then R²²⁸ is H or (C₁-C₄) alkyl;

---R²²⁸ is each a member independently selected from the group consisting essentially of H; fluoro; cyano; and (C₁-C₄) alkyl; where said methyl is substituted by 0 to 3 substituents each comprising a fluorine atom; or

---R²²⁷ and R²²⁸ are taken together to form an oxo (=O) moiety;

---~~R²²⁹~~ R²²⁹ is a member independently selected from the group consisting essentially of phenyl; naphthyl; pyrrolyl; furanyl; thienyl; oxazolyl; pyridinyl; pyrimidinyl; pyridazinyl; quinolinyl; isoquinolinyl; 5,6,7,8-tetrahydroquinolinyl; and 5,6,7,8-tetrahydroisoquinolinyl, where said R²²⁹ groups, except said phenyl, are substituted by 0 to 3 substituents R²³³, and wherein said phenyl R²²⁹ group is substituted by 0 to 3 substituents independently selected from the group consisting of R²³³ and R²³⁴;

---R²³⁰ is a member independently selected from the group consisting essentially of -C(=O)R²³¹; -C(=O)C(=O)R²³¹; -C(=O)C(Y²)C(=O)R²³¹ and a moiety of partial Formula (2.0.9):



(2.0.9)

wherein:

----R²³¹ is a member independently selected from the group consisting ~~essentially~~ of H; -OR²³²; -NHR²³²; -NHOH; -NHNH₂; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is an integer selected from 0, 1, 2, 3, and or 4;

----R²³² is a member independently selected from the group consisting ~~essentially~~ of H; (C₁-C₈) alkyl; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is an integer selected from 0, 1, 2, 3, and or 4;

----R²³³ is each a member independently selected from the group consisting ~~essentially~~ of ~~bromo, chloro, or bromo; chloro;~~ fluoro; (C₁-C₆) alkyl; (C₁-C₇) alkoxy; (C₂-C₆) alkylenedioxy; trifluoromethyl; -NR²²²R²²³; nitro; -C(NR²²²)NR²²²R²²³; -C(=O)NR²²²R²²³C(=O)R²²²; -C(NOR²²²)R²²³; -C(NCN)NR²²²R²²³; -C(NCN)SR²²²; -(CH₂)_m(CN) where m is an integer selected from 0, 1, 2, and or 3; hydroxy; -C(=O)R²²²; -C(=O)NR²²²OR²²³; -C(=O)NR²²²NR²²²R²²³; -OC(=O)NR²²²R²²³; -NR²²²C(=O)R²²²; -C(=O)C(=O)NR²²²R²²³; -CO₂R²²²; -SO₂R²²²; -SO₂NR²²²R²²³; -C(=O)NR²²²R²²³; -NR²²²SO₂R²²³; and -NR²²²C(=O)NR²²²R²²³;

----R²³⁴ is each a member independently selected from the group consisting ~~essentially~~ of imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl, where each of said foregoing R²³⁴ substituents is substituted by 0 to 3 substituents R²³³;

----R²³⁵ is a member independently selected from the group consisting ~~essentially~~ of -NR²²²R²²³; -NH(C₆-C₁₀) aryl; (C₁-C₆) alkoxy; and (C₆-C₁₀) aryloxy;

-----R²³⁶ is a member independently selected from the group consisting essentially of H;
 (C₁-C₆) alkyl and -(CH₂)_mY⁴(phenyl) where m is ~~an integer selected from~~ 0, 1, 2, 3, and or
 4 and the phenyl moiety of said -(CH₂)_mY⁴(phenyl)R²³⁶ group is substituted by 0 to 3
 substituents independently selected from the group consisting essentially of bromo, chloro,
and or fluoro; -OR²²²; (C₁-C₆) alkanoyloxy; (C₆-C₁₀) aryloxy; -NR²²²R²²³;
 -NH(C₆-C₁₀) aryl; and -NHC(=O)(C₁-C₄) alkyl;

-----R²³⁷ is each a member independently selected from the group consisting essentially of
bromo; chloro; bromo, chloro, or fluoro; -(CH₂)_pNR²²²C(=O)CH₃ where p is an integer
~~selected from~~ of 1, 2, 3, or 4, and; (C₁-C₄) alkoxy; nitro; cyano; -NR²²²R²²³; -CO₂R²²²;
 -OR²²²; -C(Y¹)NR²²²R²²³; -NR²²²C(NCN)S(C₁-C₃) alkyl; -NR²²²C(NCN)NR²²²R²²³;
 -NR²²²C(=O)NR²²²R²²³; -NR²²²C(=O)C(=O)NR²²²R²²³; -C(=NR²²²)NR²²²R²²³; -S(O)_mCH₃
 where m is ~~an integer selected from~~ 0, 1, and or 2; -C(=NR²²²)S(C₁-C₃) alkyl;
 -NR²²²SO₂(C₁-C₃) alkyl; -OC(=O)R²²²; -OC(=O)NR²²²R²²³; -NR²²²SO₂CF₃;
 -NR²²²C(=O)C(=O)OR²²²; -NR²²²C(=O)R²²²; -NR²²²C(=O)OR²²²; imidazolyl; thiazolyl;
 oxazolyl; pyrazolyl; triazolyl; and tetrazolyl;

-----R²³⁸ is a member independently selected from the group consisting essentially of H; fluoro;
 cyano; and (C₁-C₂) alkyl, where said alkyl is substituted by 0 to 3 substituents
 independently selected from the group consisting essentially of ~~bromo, chloro, or bromo;~~
chloro; fluoro; -C(=O)NR²²²R²²³; and -C(=O)OR²²²;

-----R²³⁹ is a member independently selected from the group consisting essentially of phenyl
 substituted by 0 to 2 substituents independently selected from the group consisting of
 -NR²²²R²²³, nitro, halo, -OR²²², -NHR²⁴⁰, -NR²⁴⁰R²⁴¹, and -C(=O)OR²²²;

- R²⁴⁰ and R²⁴¹ are each a member independently selected from the group consisting essentially of (C₁-C₈) alkyl and (C₂-C₈) alkenyl;
- R²⁴² is pyridin-4-yl substituted by 0 to 2 substituents independently selected from the group consisting essentially of bromo, chloro, or fluoro; and (C₁-C₄) alkyl;
- A is each a member independently selected from the group consisting essentially of (C₁-C₆) alkyl; pyridyl; morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; triazolyl; quinolinyl; phenyl; and naphthyl; wherein the foregoing A groups are substituted with 0 to 3 substituents R²³⁷; or A is -(CH₂)_qS(C₁-C₄) alkyl wherein q is an integer of selected from 1 and or 2;
- W is a member independently selected from the group consisting essentially of O; NOH; NNH₂; NOC(=O)CH₃; and NNHC(=O)CH₃;
- Y¹ is O or S;
- Y² is O, NOH or H₂;
- Y³ is a bond or -CH=CH-;
- Y⁴ is a bond, O, S, or -NH-;
- Y⁵ is a member independently selected from the group consisting essentially of O; NR²²²; NOR²²²; NCN; C(CN)₂; CR²²²NO₂; CR²²²C(=O)OR²²²; CR²²²C(=O)NR²²²R²²³; C(CN)NO₂; C(CN)C(=O)OR²²²; and C(CN)C(=O)NR²²²R²²³; and
- Z³ is a member independently selected from the group consisting essentially of -NR²²²-; -(CH₂)_m-; -CH₂C(=O)NH-; -NHCH₂C(=O)-; -CH₂C(Y¹)CH₂-; -CH=CH-; -C≡C-, -CH(Y¹H)-; -C(Y¹)-; -CH₂C(Y¹)-; -C(Y¹)CH₂-; -C(Y₁)C(Y₁)-; -CH₂NR²²²-; -CH₂-Y¹-;


-C(Y¹)NR²¹⁸(CHR²²²)_n-; -NR²¹⁸C(Y¹)(CHR²²²)_n-; -NHCH₂-; -Y¹-CH₂-; -SOCH₂-;
 -CH₂SO-; -SO₂CH₂-; -CH₂SO₂-; -OC(Y¹)-; -N=N-; -NHSO₂-; -SO₂NH-; -C(Y¹)C(Y¹)NH-;
 -NHC(=O)O-; -OC(=O)NH-; and -NHC(=O)NH-; wherein for said Z₃ moieties n is an
 integer selected from 0, 1, 2, 3, and or 4; and m is an integer selected from 1, 2, and or 3;

- or said substituents defining R²_a and R²_b comprise: -


--(- III -)

--a member independently selected from the group consisting essentially of 2-oxo-4-pyrrolyl;
 pyrazolyl; 2-oxo-3,4-dihydro-5-pyrimidyl; 2-oxo-3,4-dihydro-4-pyrimidyl; 2-oxo-tetrahydro-
 4-pyrimidyl; 2-oxo-tetrahydro-5-pyrimidyl; 2-oxo-4-pyrimidyl; and 2-oxo-5-pyrimidyl; wherein
 each of said R²_a and R²_b groups is substituted by 0, 1, 2, 3, or 4 R²³⁶ groups;


- or, said substituents defining R²_a and R²_b comprise a
 moiety of partial Formulas (3.0.0) through (3.0.19), inclusive: -




(3.0.0)




(3.0.1)




(3.0.2)




(3.0.3)




(3.0.4)




(3.0.5)




(3.0.6)




(3.0.7)




(3.0.8)




(3.0.9)




(3.10)




(3.11)




(3.12)




(3.13)




(3.14)




(3.15)




(3.16)



(3.17)



(3.18)



(3.19)

----wherein in said partial Formulas (3.0.0) through (3.0.19), q is ~~an integer selected from 0 and~~
or 1 in partial Formula (3.0.1); n is ~~an integer selected from 0, 1, and or 2~~ in partial Formula
 (3.0.2); and the dashed lines appearing in formulas (3.0.1), (3.0.3), (3.0.6), (3.0.7), (3.0.8),
 (3.0.9) and (3.0.14) represent a double bond or a single bond;

----X¹ is O or S;

----X² in formula (3.0.10) and where the dashed line in formula (3.0.9) represents a double
 bond, is a member independently selected from the group consisting ~~essentially~~ of CR³³⁵;
 CR³³⁶; CR³⁴⁶; and COC(=O)NR³³⁹R³⁴²; or, where the dashed line in formula (3.0.9)

represents a single bond, X^2 is a member independently selected from the group consisting essentially of $CR^{335}R^{339}$, $CR^{336}R^{339}$, and $CR^{346}R^{339}$;

----- X^3 is a member independently selected from the group consisting essentially of $C(=Z^3)$; $C(S)$; and $CR^{336}R^{340}$;

----- X^4 is a member independently selected from the group consisting essentially of $-(CH_2)_m$ where m is an integer selected from 0, 1, and or 2;

----- X^5 is a bond or $-CH_2-$;

----- X^6 is a member independently selected from the group consisting essentially of $-CH_2-$ and $-C(=O)-$;

----- R^{333} is a member independently selected from the group consisting essentially of H; hydroxy; (C_1-C_4) alkoxy; $-CHR^{337}(O)_q(CH_2)_mA$ where q is an integer selected from 0 and or 1, and m is an integer selected from 0, 1, and or 2;

----- R^{334} is a member independently selected from the group consisting essentially of H; hydroxy; (C_1-C_4) alkyl; (C_1-C_2) alkoxy; $-OC(=O)CH_3$; (C_2-C_3) alkenyl; and phenyl (C_1-C_2) alkyl-;

----- R^{335} is a member independently selected from the group consisting essentially of H; hydroxy; $-(CH_2)_mA$ where m is an integer selected from 0, 1, and or 2; (C_1-C_6) alkyl; and (C_2-C_3) alkanoyl; where said alkyl group is substituted by 0 to 3 substituents independently selected from the group consisting essentially of ~~bromo, chloro, or~~ bromo; chloro; fluoro; nitro; $-NR^{340}R^{341}$; $-CO_2R^{340}$; $-OR^{340}$; $-OC(=O)R^{340}$; $-C(=O)R^{340}$; cyano; $-C(=Y)NR^{340}R^{341}$; $-NR^{340}C(=Y)NR^{340}R^{341}$; $-NR^{340}C(=Y)R^{340}$; $-NR^{340}C(=O)OR^{340}$; $-C(NR^{340})NR^{340}R^{341}$; $-C(NCN)NR^{340}R^{341}$; $-C(NCN)SR^{340}$; $-NR^{340}SO_2R^{340}$; $-S(O)_mR^{340}$, where m is an integer

selected from 0, 1, and or 2; $-\text{NR}^{340}\text{SO}_2\text{CF}_3$; $-\text{NR}^{340}\text{C}(=\text{O})\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$;
 $-\text{NR}^{340}\text{C}(=\text{O})\text{C}(=\text{O})\text{OR}^{340}$; imidazolyl; and 1-(NHR^{340})-2-imidazolyl;

----- R^{336} is each a member independently selected from the group consisting essentially of H;
~~bromo, chloro, or bromo; chloro;~~ fluoro; cyano; R^{343} ; cyclopropyl substituted by 0 or 1
substituent independently selected from the group consisting essentially of R^{339} ; $-\text{OR}^{340}$;
 $-\text{CH}_2\text{OR}^{340}$; $-\text{NR}^{340}\text{R}^{342}$; $-\text{CH}_2\text{NR}^{340}\text{R}^{342}$; $-\text{C}(=\text{O})\text{OR}^{340}$; $-\text{C}(=\text{O})\text{NR}^{340}\text{R}^{342}$; $-\text{CH}=\text{CR}^{339}\text{R}^{339}$;
 $-\text{C}\equiv\text{CR}^{339}$; and $-\text{C}(=\text{Z}^3)\text{H}$;

----- R^{337} is a member independently selected from the group consisting essentially of H;
 $-\text{C}(=\text{O})\text{R}^{338}$; imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl;
thiadiazolyl; thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl;

----- R^{338} is each a member independently selected from the group consisting essentially of-
 $-\text{OR}^{340}$; $-\text{NR}^{340}\text{R}^{342}$; and $-\text{R}^{343}$;

----- R^{339} is each a member independently selected from the group consisting essentially of H;
~~bromo, chloro, or bromo; chloro;~~ fluoro; and (C₁-C₄) alkyl substituted by 0 to 3 fluorine
atoms;

----- R^{340} and R^{341} are each a member independently selected from the group consisting
essentially of hydrogen and (C₁-C₄) alkyl;

----- R^{342} is each a member independently selected from the group consisting essentially of
 $-\text{OR}^{340}$ and $-\text{R}^{340}$;

----- R^{343} is (C₁-C₄) alkyl;

-----R³⁴⁴ is each a member independently selected from the group consisting essentially of ~~bromo, chlero, or~~ bromo; chloro; fluoro; nitro; cyano; -NR³⁴⁰R³⁴⁶; -NR³⁴⁶R³⁴²; -C(=Z³)R³³⁸; -S(O)_mR³⁴³ where m is ~~an integer selected from 0, 1, and or 2;~~ -OR³⁴²; -OC(=O)NR³⁴⁰R³⁴²; -C(NR³⁴²)NR³⁴⁰R³⁴²; -C(NR³⁴⁰)SR³⁴³; -OC(=O)CH₃; -C(NCN)NR³⁴⁰R³⁴²; -C(S)NR³⁴⁰R³⁴²; -NR³⁴²C(=O)R³⁴⁷; -C(=O)R³⁴⁷; oxazolyl; imidazolyl; thiazolyl; pyrazolyl; triazolyl; and tetrazolyl;

-----R³⁴⁵ is each a member independently selected from the group consisting essentially of hydrogen and (C₁-C₄) alkyl substituted by ~~01 to 3~~ 0, 1, 2 or 3 fluorine atoms;

-----R³⁴⁶ is each a member independently selected from the group consisting essentially of H; -R³⁴³; -C(=O)R³⁴³; -C(=O)C(=O)R³³⁸; -C(=O)NR³⁴⁰R³⁴²; -S(O)_mR³⁴³ where m is ~~an integer selected from 0, 1, and or 2;~~ -C(NCN)SR³⁴³; -C(NCN)R³⁴³; -C(NR³⁴²)R³⁴³; -C(NR³⁴²)SR³⁴³; and -C(NCN)NR³⁴⁰R³⁴²;

-----R³⁴⁷ is each a member independently selected from the group consisting essentially of -R³⁴³; -C(=O)R³⁴³; oxazolidinyl; oxazolyl; thiazolyl; pyrazolyl; triazolyl; tetrazolyl; imidazolyl; imidazolidinyl; thiazolidinyl; isoxazolyl; oxadiazolyl; thiadiazolyl; morpholinyl; piperidinyl; piperazinyl; and pyrrolyl; where each of said recited R³⁴⁷ heterocyclic groups is substituted by 0 to 2 (C₁-C₂) alkyl groups;

-----R³⁴⁸ is each a member independently selected from the group consisting essentially of H; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; benzyl; and phenethyl;

-----R³⁴⁹ is a member independently selected from the group consisting essentially of H; (C₁-C₅) alkyl; (C₁-C₅) alkanoyl; and benzoyl;

- R³⁵⁰ is a member independently selected from the group consisting essentially of H;
 (C₁-C₄) alkyl; carboxy; aminocarbonyl; (C₁-C₆) alkyl substituted by 0 or 1 carboxy,
 -(CH₂)_mC(=O)(C₁-C₆) alkoxy; or -(CH₂)_m(C₆-C₁₀) aryl; where m is ~~an integer selected from~~
 0, 1, ~~and~~ or 2;
- R³⁵¹ is a member independently selected from the group consisting essentially of H;
 (C₁-C₆) alkyl; -C(=Y)R³⁵²; -C(=Y)NH₃⁵; -C(=O)OR³⁵²; and -(CH₂)_nX⁷(pyridyl) where n is
~~an integer selected from~~ 0, 1, 2, 3, 4, ~~and to~~ or 5; and X⁷ is a bond or -CH=CH-; and where
 said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵² is a member independently selected from the group consisting essentially of
 (C₁-C₆) alkyl (C₃-C₈) cycloalkyl; -(CH₂)_m(C₆-C₁₀) aryl; and -(CH₂)_nX⁷(pyridyl) where n is
~~an integer selected from~~ 0, 1, 2, 3, 4, ~~and~~ or 5; and X⁷ is a bond or -CH=CH-; and where
 said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵³ is a member independently selected from the group consisting ~~essentially~~ of H; -R³⁴⁵;
 (C₁-C₃) alkyl substituted by 0 or 1 ~~substituent~~ hydroxy, or (C₁-C₃) alkoxy(C₁-C₃) alkyl;
- R³⁵⁴ is a member independently selected from the group consisting ~~essentially~~ of H; -R³⁴⁵;
 carboxy; (C₁-C₃) alkoxy(C₁-C₃) alkyl-; (C₃-C₇) cycloalkyl; and (C₁-C₅) alkyl substituted
 by 0 or 1 -NR³⁴⁰R³⁴¹; or
- R³⁵³ and R³⁵⁴ are taken together to form -CH₂OCH₂OCH₂-;
- R³⁵⁵ is a member independently selected from the group consisting ~~essentially~~ of H;
 hydroxy; (C₁-C₄) alkyl substituted by 0 or 1 ~~substituent comprising a member~~
~~independently selected from the group consisting essentially of~~ hydroxy; -C(=O)R³⁴⁰;
 -NR³⁴⁰R³⁴¹; -(CH₂)_mNHC(=O)R³⁴⁰; -(CH₂)_mNHC(=O)R³⁴³; -(CH₂)_mCO₂R³⁴⁰;

$-(\text{CH}_2)_m\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$; $-(\text{CH}_2)_m\text{C}(=\text{O})\text{N}(\text{OH})\text{R}^{340}$; $-(\text{CH}_2)_m\text{SO}_2\text{NR}^{340}\text{R}^{341}$;
 $-(\text{CH}_2)_m\text{PO}_3\text{H}_2$; $-(\text{CH}_2)_m\text{SO}_2\text{NHC}(=\text{O})\text{R}^{343}$; and $-(\text{CH}_2)_m\text{SO}_2\text{NHC}(=\text{O})(\text{phenyl})$, where m is
an integer selected from 0, 1, 2, 3, and or 4;

----- R^{356} is a member independently selected from the group consisting essentially of H;
 $(\text{C}_1\text{-C}_4)$ alkyl; phenyl; $-\text{NR}^{340}\text{R}^{341}$; and $-\text{NR}^{340}(\text{C}_1\text{-C}_4)$ alkanoyl;

----- R^{357} is a member independently selected from the group consisting essentially of $-\text{R}^{340}$;
 $-\text{CH}_2\text{CO}_2\text{R}^{343}$; and $-\text{CH}_2\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$;

----- R^{358} is a member independently selected from the group consisting essentially of
 $-\text{C}(=\text{O})\text{R}^{340}$; $-\text{C}(=\text{O})(\text{C}_6\text{-C}_{10})$ aryl; $-\text{C}(=\text{O})(\text{C}_3\text{-C}_9)$ heteroaryl; $-\text{CO}_2\text{R}^{340}$; $-\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$;
cyano; nitro; $-\text{CH}_2\text{OH}$; $-\text{NR}^{340}\text{SO}_2\text{R}^{340}$; $-\text{NHSO}_2(\text{C}_6\text{-C}_{10})$ aryl; $-\text{NHCO}_2(\text{C}_1\text{-C}_4)$ alkyl;
 $-\text{NR}^{340}\text{C}(=\text{O})\text{R}^{340}$; and $-\text{NHCO}_2(\text{C}_6\text{-C}_{10})$ aryl;

----- R^{359} is a member independently selected from the group consisting essentially of $-\text{R}^{345}$;
cyano; carboxy; formyl; $-\text{C}(=\text{O})\text{R}^{340}$; and $(\text{C}_1\text{-C}_4)$ alkanoyl;

----- R^{360} is a member independently selected from the group consisting essentially of cyano;
 $-\text{NR}^{340}\text{R}^{341}$; $-\text{SO}_2(\text{C}_1\text{-C}_4)$ alkyl; $-\text{SO}_2(\text{C}_6\text{-C}_{10})$ aryl; $-\text{C}(=\text{O})\text{R}^{340}$; $-\text{C}(=\text{O})(\text{C}_6\text{-C}_{10})$ aryl;
 $-\text{C}(=\text{O})(\text{C}_3\text{-C}_9)$ heteroaryl; $-\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$; and $-\text{CO}_2\text{R}^{340}$;

----- R^{361} and R^{362} are each a member independently selected from the group consisting
essentially of H; cyano; nitro; $-\text{CO}_2\text{R}^{340}$; $-\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$; $-\text{CH}_2\text{OH}$; $-\text{C}(=\text{O})\text{R}^{340}$;
 $-\text{NHCO}_2\text{R}^{340}$; and $-\text{NHSO}_2\text{R}^{340}$;

-----A is a member independently selected from the group consisting essentially of pyridyl;
morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; phenyl; and naphthyl;

where each of said A groups is substituted by 0 to 2 substituents R^{344} or by 1 substituent R^{345} ;


----- Z^3 is a member independently selected from the group consisting essentially of O; $-NR^{342}$; NOR^{340} ; $N(CN)$; $C(CN)_2$; $CR^{340}NO_2$; $CR^{340}C(=O)OR^{343}$; $CR^{340}C(=O)NR^{340}R^{341}$; $C(CN)NO_2$; $C(CN)C(=O)OR^{343}$; and $C(CN)C(=O)NR^{340}R^{341}$; and,

-----Y is O or S;

- or said substituents defining R_a^2 and R_b^2

comprise a moiety of partial Formula (4.0.0): -

-(- IV -)



(4.0.0)

---wherein the broken line indicates a single or double bond;

--- X^1 is $-CR^{472}R^{473}$ - where said broken line indicates a single bond; or $-CR^{473}$ - where said broken line indicates a double bond;

--- X^2 is $-CR^{475}R^{477}R^{478}$ - or $-C(=NOR^{481})R^{482}$ - where said broken line indicates a single bond; or $-CR^{477}R^{478}$ where said broken line indicates a double bond;

--- R^{472} is a member independently selected from the group consisting essentially of H; hydroxy; bromo, chloro, or fluoro; and $-OR^{479}$;

----R⁴⁷³ is each a member independently selected from the group consisting essentially of cyano; cyanomethyl; benzyloxy; -R⁴⁷⁵; -CO₂R⁴⁷⁵; -CO₂(CH₂)_n(C₆-C₁₀) aryl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NR⁴⁷⁵(CH₂)_n(C₆-C₁₀) aryl; -(CH₂)_n(C₆-C₁₀) aryl; and -(CH₂)_n(5- to 10-membered heteroaryl); where n is ~~an integer selected from~~ 0, 1, 2, and or 3; each R⁴⁷³ group is substituted by 0 to 3 substituents R⁴⁷⁴; and each R⁴⁷³ group is substituted by 0 or 1 substituent R⁴⁸⁰;

----R⁴⁷⁴ is each a member independently selected from the group consisting essentially of ~~bromo, chloro, or bromo; chloro;~~ fluoro; cyano; nitro; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; -OR⁴⁷⁵; (C₃-C₇) cycloalkoxy; -NR⁴⁷⁵R⁴⁷⁶; -NR⁴⁷⁵OR⁴⁷⁶; -S(O)_mR⁴⁷⁵ where m is ~~an integer selected from or~~ 0, 1, and or 2; -CO₂R⁴⁷⁵; -C(=O)R⁴⁷⁵; -SO₂NR⁴⁷⁵R⁴⁷⁶; -C(=O)NR⁴⁷⁵R⁴⁷⁶; -CR⁴⁷⁵R⁴⁷⁶SO₂NR⁴⁷⁵R⁴⁷⁶; -CR⁴⁷⁵R⁴⁷⁶C(=O)NR⁴⁷⁵R⁴⁷⁶; -NHSO₂R⁴⁷⁵; -NHSO₂NR⁴⁷⁵R⁴⁷⁶; -NHC(=O)NR⁴⁷⁵R⁴⁷⁶; -NHC(=O)(C₁-C₆) alkyl; and -NHC(=O)O(C₁-C₆) alkyl);

----R⁴⁷⁵ and R⁴⁷⁶ are each a member independently selected from the group consisting essentially of H; and (C₁-C₆) alkyl;

----R⁴⁷⁷ is a member independently selected from the group consisting essentially of -R⁴⁷³; 2-oxo-pyridyl; 3-oxo-pyridyl; 4-oxo-pyridyl; 2-oxo-pyrrolyl; 4-oxo-thiazolyl; 4-oxo-piperidyl; 2-oxo-quinolyl; 4-oxo-quinolyl; 1-oxo-isoquinolyl; 4-oxo-oxazolyl; 5-oxo-pyrazolyl; 5-oxo-isoxazolyl; and 4-oxo-isoxazolyl; where each of said R⁴⁷⁷ groups is substituted by 0 to 3 substituents R⁴⁷⁴;

----R⁴⁷⁸ is a member independently selected from the group consisting essentially of -R⁴⁷⁵; cyano; -(CH₂)_p(C₆-C₁₀) aryl; and -(CH₂)_p(5- to 10-membered heteroaryl); where p is ~~an integer selected from~~ 1, 2, and or 3; and where each said R⁴⁷⁸ group is substituted by 0 to 3 substituents R⁴⁷⁴;

-----R⁴⁷⁹ is a member independently selected from the group consisting ~~essentially~~ of formyl; carbamoyl; thiocarbamyl; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₁-C₄) alkoxy(C₁-C₄) alkyl-; and (C₁-C₆) alkanoyl; where said alkyl moieties of each of said R⁴⁷⁹ groups is substituted by 0 to 3 substituents independently selected from the group consisting ~~essentially~~ of ~~bromo, chloro, or bromo; chloro;~~ fluoro; hydroxy; and (C₁-C₄) alkoxy;

-----R⁴⁸⁰ is a member independently selected from the group consisting ~~essentially~~ of cyclobutyl; cyclopentyl; cyclohexyl; 2-cyclobuten-1-yl; 2-cyclopenten-1-yl; 3-cyclopenten-1-yl; 2,4-cyclopentadien-1-yl; 3,5-cyclohexadien-1-yl; pyrrolyl; pyrrolidinyl; dioxolanyl; imidazolyl; oxazolyl; imidazolidinyl; pyrazolyl; pyrazolidinyl; pyranyl; piperidinyl; 1,4-dioxanyl; morpholinyl; 1,4-dithianyl; thiomorpholinyl; piperazinyl; 1,3,5-trithianyl; oxazinyl; isoxazinyl; oxathiazinyl; and oxadiazinyl; where each of said R⁴⁸⁰ groups is substituted by 0 to 2 (C₁-C₂) alkyl;

----R⁴⁸¹ is a member independently selected from the group consisting ~~essentially~~ of H; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₂-C₆) alkynyl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NH(C₆-C₁₀) aryl; -C(Y)(C₁-C₆) alkoxy; -C(Y)(C₆-C₁₀) aryloxy; and -C(Y)(C₁-C₆) alkyl);


----R⁴⁸² is a member independently selected from the group consisting ~~essentially~~ of phenyl and pyridinyl; where each of said R⁴⁸² groups is substituted by 0 to 3 substituents independently selected from the group consisting ~~essentially~~ of ~~bromo, chloro, or bromo; chloro;~~ fluoro; (C₁-C₄) alkyl; hydroxy; (C₁-C₄) alkoxy; -NR⁴⁷⁵R⁴⁷⁶; and -S(O)_mR⁴⁷⁵, where m is ~~an integer~~ ~~selected from 0, 1, and or 2;~~ and,

-----Y is O or S;


- or , said substituents defining R²_a and R²_b comprise a

moiety of partial Formulas (5.0.0) through (5.0.13), inclusive: -


--(- V -)




(5.0.0)




(5.0.1)




(5.0.2)




(5.0.3)




(5.0.4)




(5.0.5)




(5.0.6)




(5.0.7)




(5.0.8)




(5.0.9)




(5.0.10)



(5.0.11)



(5.0.12)



(5.0.13)

2. (Original) A method according to Claim 1 wherein said stasis comprises gastric hypomotility with delayed emptying of the liquid and/or solid contents of the stomach of said patient being treated and said patient is a human.

3. (Withdrawn) A method according to Claim 2 wherein R_a^2 and R_b^2 are as defined under (- IV -) in Claim 1.

4. (Withdrawn) A method according to Claim 3 wherein R^1 is ethyl and R is cyclopentyl, cyclohexyl, or (C₆-C₁₀) aryl.

5. (Withdrawn) A method according to Claim 3 wherein R^{473} is $-(CH_2)_n(C_6-C_{10})$ aryl or $-(CH_2)_n(5\text{- to }10\text{-membered heteroaryl})$, where n is an integer selected from 0, 1, 2, and 3.

6. (Withdrawn) A method according to Claim 5 wherein R^{473} is phenyl or pyridin-4-yl.

7. (Presently Amended) A method according to Claim 2 1 wherein R_a^2 and R_b^2 are as defined under (- I -) ~~in Claim 1~~.

8. (Original): A method according to Claim 7 wherein R is cyclopentyl or cyclohexyl; R¹ is (C₁-C₂) alkyl; one of R²_a and R²_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, m is 0, R¹¹³ and R¹¹⁴ are in a *cis* relationship to each other, R¹¹³ is cyano, R¹¹⁵ is hydrogen, and R¹¹⁴ is carboxy, -CH₂OH, or -CH₂C(=O)NH₂.

9. (Original) A method according to Claim 7 wherein R is phenyl substituted by fluoro; R¹ is (C₁-C₂) alkyl; one of R²_a and R²_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, R¹¹³ is cyano, and R¹¹⁵ and R¹¹⁴ are both hydrogen.

10. (Presently Amended): A method according to Claim 2 1 wherein said compound of Formula (IA) or (IB) ~~as defined in Claim 1~~ is a member independently selected from the group consisting essentially of:

1-(1-Cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-oxocyclohexanecarbonitrile;

Trans-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid
methyl ester;

Cis-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl
ester;

Trans-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Cis-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

1-(1-Cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-oxocyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl ester;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl ester;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazole-6-yl)-4-hydroxymethylcyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid amide;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid amide;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-(1-hydroxy-1-methylethyl)cyclohexanecarbonitrile;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxy-4-methylcyclohexanecarbonitrile;

Trans-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxy-4-methylcyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Trans-4-cyano-4-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

6-Bromo-3-ethyl-1-(4-fluorophenyl)-1H-indazole;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]-4-hydroxycyclohexanecarboxylic acid ethyl ester;

4-Cyano-4-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohexanecarboxylic acid ethyl ester;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohex-3-enecarboxylic acid ethyl ester;

4-Cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-cyclohexanecarboxylic acid ethyl ester;

Cis-4-Cyano-4-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohexanecarboxylic acid;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohex-3-enecarboxylic acid; and

4-(1-Cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarboxylic acid.

11. (Cancelled).

12. (Withdrawn) A method according to Claim 11 wherein R_a^2 and R_b^2 are as defined under (- IV -) in Claim 1.

13. (Withdrawn) A method according to Claim 12 wherein R^1 is ethyl and R is cyclopentyl, cyclohexyl, or (C₆-C₁₀) aryl.

14. (Withdrawn) A method according to Claim 11 wherein R^{473} is $-(CH_2)_n(C_6-C_{10})$ aryl or $-(CH_2)_n(5\text{- to }10\text{-membered heteroaryl})$, where n is an integer selected from 0, 1, 2, and 3.

15. (Withdrawn) A method according to Claim 14 wherein R^{473} is phenyl or pyridin-4-yl.

16. (Presently Amended): A method according to Claim ~~11~~ 42 wherein R^2_a and R^2_b are as defined under (- I -) ~~in Claim 1.~~

17. (Original): A method according to Claim 16 wherein R is cyclopentyl or cyclohexyl; R^1 is (C_1-C_2) alkyl; one of R^2_a and R^2_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, m is 0, R^{113} and R^{114} are in a *cis* relationship to each other, R^{113} is cyano, R^{115} is hydrogen, and R^{114} is carboxy, $-CH_2OH$, or $-CH_2C(=O)NH_2$.

18. (Original): A method according to Claim 16 wherein R is phenyl substituted by fluoro; R^1 is (C_1-C_2) alkyl; one of R^2_a and R^2_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, R^{113} is cyano, and R^{115} and R^{114} are both hydrogen.

19. (Cancelled).

20. (Presently Amended): A method according to Claim ~~19~~ 43 wherein said patient is a human.

21. (Withdrawn): A method according to Claim 20 wherein R^2_a and R^2_b are as defined under (- IV -) in Claim 1.

22. (Withdrawn): A method according to Claim 21 wherein R^1 is ethyl and R is cyclopentyl, cyclohexyl, or (C₆-C₁₀) aryl.

23. (Withdrawn) A method according to Claim 20 wherein R^{473} is $-(CH_2)_n(C_6-C_{10})$ aryl or $-(CH_2)_n(5- \text{ to } 10\text{-membered heteroaryl})$, where n is an integer selected from 0, 1, 2, and 3.

24. (Withdrawn): A method according to Claim 23 wherein R^{473} is phenyl or pyridin-4-yl.

25. (Presently Amended): A method according to Claim ~~20~~ 43 wherein R^2_a and R^2_b are as defined under (- I -) ~~in Claim 1.~~

26. (Original): A method according to Claim 25 wherein R is cyclopentyl or cyclohexyl; R^1 is (C₁-C₂) alkyl; one of R^2_a and R^2_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, m is 0, R^{113} and R^{114} are in a *cis*

relationship to each other, R¹¹³ is cyano, R¹¹⁵ is hydrogen, and R¹¹⁴ is carboxy, -CH₂OH, or -CH₂C(=O)NH₂.

27. (Original): A method according to Claim 25 wherein R is phenyl substituted by fluoro; R¹ is (C₁-C₂) alkyl; one of R²_a and R²_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, R¹¹³ is cyano, and R¹¹⁵ and R¹¹⁴ are both hydrogen.

28. (Original): A method according to Claim 2 wherein there is coadministered with said therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to restore normal motility to said patient being treated, a therapeutically effective amount of an auxiliary therapeutic agent which comprises one or more members independently selected from the group consisting essentially of (1) anti-inflammatory corticosteroids for oral, injectable, topical, ophthalmic, inhalation, or nasal administration useful in treating inflammatory conditions; (2) non-steroidal analgesic, antipyretic and anti-inflammatory active agents; (3) potent opioid agonist analgesics; (4) proteinaceous endogenous and synthetic opioid analgesics comprising enkephalins, endorphins, and dynorphins, which are selective and nonselective agonists and antagonists of the μ , κ , and δ opioid receptor subtypes; (5) leukotriene antagonists; (6) leukotriene biosynthesis (5-lipoxygenase) inhibitors; (7) thromboxane receptor antagonists; (8) anticholinergic agents; (9) autocoids having agonist and antagonist activity useful for the treatment of pain and chronic inflammatory conditions; and (10) cytokines consisting of colony-stimulating factors and interleukins.

29. (Original): A method according to Claim 28 wherein (1) said anti-inflammatory corticosteroid is a member independently selected from the group consisting essentially of alclometasone dipropionate; amcinonide; beclomethasone dipropionate; betamethasone; betamethasone benzoate; betamethasone dipropionate; betamethasone sodium phosphate; betamethasone sodium phosphate and acetate; betamethasone valerate; clobetasol propionate; clocortolone pivalate; cortisol; cortisol acetate; cortisol butyrate; cortisol cypionate; cortisol sodium phosphate; cortisol sodium succinate; cortisol valerate; cortisone acetate; desonide; desoximetasone; dexamethasone; dexamethasone acetate; dexamethasone sodium phosphate; diflorasone diacetate; fludrocortisone acetate; flunisolide; fluocinolone acetonide; fluocinonide; fluorometholone; flurandrenolide; halcinonide; medrysone; methylprednisolone; methylprednisolone acetate; methylprednisolone sodium succinate; mometasone furoate; paramethasone acetate; prednisolone; prednisolone acetate; prednisolone sodium phosphate; prednisolone tebutate; prednisone; triamcinolone; triamcinolone acetonide; triamcinolone diacetate; and triamcinolone hexacetonide; (2) said non-steroidal analgesic, antipyretic, and anti-inflammatory active agent comprises a member independently selected from the group consisting essentially of (i) salicylic acid derivatives consisting essentially of aspirin; sodium salicylate; methyl salicylate; choline magnesium trisalicylate; salsalate; diflunisal; salicylsalicylic acid; sulfasalazine; and olsalazine; (ii) para-aminophenol derivatives consisting essentially of acetaminophen; (iii) indole and indene acetic acids consisting essentially of indomethacin; sulindac; and etodolac; (iv) heteroaryl acetic acids consisting essentially of tolmetin; diclofenac; and ketorolac; (v) arylpropionic acids consisting essentially of ibuprofen; naproxen; flurbiprofen; ketoprofen; fenoprofen; and oxaprozin; (vi)

anthranilic acids consisting essentially of mefenamic acid; meclofenamic acid; flufenamic acid; tolafenamic acid; and etofenamic acid; (vii) enolic acids consisting essentially of meloxicam; piroxicam; and tenoxicam; (viii) pyrazolon derivatives consisting essentially of phenylbutazone; and oxyphenbutazone; (ix) alkanones consisting essentially of nabumetone; (x) apazone; (xi) tenidap; and (xii) nimesulide; (3) said potent opioid agonist analgesic comprises a member independently selected from the group consisting essentially of alfentanil hydrochloride; anileridine; anileridine hydrochloride; buprenorphine hydrochloride; carfentanil citrate; codeine; codeine phosphate; codeine sulfate; fentanyl citrate; hydromorphone hydrochloride; levomethadyl acetate; levomethadyl acetate hydrochloride; levorphanol tartrate; lofentanil oxalate; meperidine hydrochloride; methadone hydrochloride; methadyl acetate; morphine sulfate; oxycodone; oxycodone hydrochloride; oxycodone terephthalate; oxycodone hydrochloride; pentamorphine; and sufentanil citrate; (4) said proteinaceous endogenous or synthetic opioid analgesic comprising an enkephalin, endorphin, or dynorphin which is a selective or nonselective agonist or antagonist of a μ , κ , or δ opioid receptor subtype, comprises a member independently selected from the group consisting essentially of [Leu⁵] and [Met⁵]enkephalin; dynorphin A and B; α - and β -neoendorphin; [D-Ala²,MePhe⁴,Gly(ol)⁵]enkephalin (DAMGO); [D-Pen²,D-Pen⁵]enkephalin (DPDPE); [D-Ser²,Leu⁵]enkephalin-Thr⁶ (DSLET); [D-Ala²,D-Leu⁵]enkephalin (DADL); D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH₂ (SEQ ID NO:1) (CTOP); [D-Ala²,N-MePhe⁴,Met(O)⁵-ol]enkephalin (FK-33824); Tyr-D-Ala-Phe-Asp-Val-Val-Gly-NH₂ (SEQ ID NO: 2) ([D-Ala²]deltorphin I; Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH₂ (SEQ ID NO:3) ([D-Ala²,Glu⁴]deltorphin II; Tyr-Pro-Phe-Pro-NH₂ (SEQ ID NO:4) (morphiceptin); Tyr-Pro-MePhe-D-Pro-NH₂ (SEQ ID NO:5) (PL-017); and [D-Ala²,Leu⁵,Cys⁶]enkephalin; (5) said

leukotriene antagonist comprises a member independently selected from the group consisting essentially of ablukast; ablukast sodium; cinalukast; iralukast; montelukast sodium; ontazolast; pobilukast edamine; pranlukast; ritolukast; sulukast; tomelukast; verlukast; and zafirlukast; (6) said leukotriene biosynthesis (5-lipoxygenase) inhibitor comprises a member independently selected from the group consisting essentially of docebenone; enazadrem phosphate; and zileuton; (7) said thromboxane receptor antagonist comprises a member independently selected from the group consisting essentially of seratrodast; (8) said anticholinergic agent comprises a member independently selected from the group consisting essentially of ipratropium bromide; (9) said autocoid having agonist and antagonist activity useful for the treatment of pain and chronic inflammatory conditions, comprises a member independently selected from the group consisting essentially of bradykinin and kallidin; and their analogous derivatives independently selected from Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (SEQ ID NO:6) (bradykinin); Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (SEQ ID NO:7) (kallidin); Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (des-Arg⁹-bradykinin) (SEQ ID NO:8); Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe (des-Arg¹⁰-kallidin) (SEQ ID NO:9); Arg-Pro-Pro-Gly-Phe-Ser-Pro-Leu (des-Arg⁹-[Leu⁸]-bradykinin) (SEQ ID NO:10); Arg-Pro-Pro-Gly-Phe-Ser-[D-Phe]-Phe-Arg ([D-Phe⁷]-bradykinin) (SEQ ID NO:11); and [D-Arg]-Arg-Pro-Hyp-Gly-Thi-Ser-Tic-Oic-Arg (SEQ ID NO:12) (HOE 140), where Hyp is *trans*-4-hydroxy-Pro; Thi is β -(2-thienyl)-Ala; Tic is [D]-1,2,3,4-tetrahydroquinolin-3-yl-carbonyl; and Oic is (3*as*,7*as*)-octahydroindol-2-yl-carbonyl; and (10) said cytokine is a member independently selected from the group consisting essentially of granulocyte colony-stimulating factor (G-CSF); granulocyte macrophage colony-stimulating factor (GM-CSF); and interleukin-1 (IL-1) through interleukin-12 (IL-12).

30. (Cancelled):

31. (Presently Amended): A pharmaceutical composition according to Claim ~~30~~ 44 wherein said patient is a human.

32. (Withdrawn): A pharmaceutical composition according to Claim 31 wherein R_a^2 and R_b^2 are as defined under (- IV -) in Claim 1.

33. (Withdrawn): A pharmaceutical composition according to Claim 32 wherein R^1 is ethyl and R is cyclopentyl, cyclohexyl, or (C₆-C₁₀) aryl.

34. (Withdrawn): A pharmaceutical composition according to Claim 31 wherein R^{473} is $-(CH_2)_n(C_6-C_{10})$ aryl or $-(CH_2)_n(5\text{- to }10\text{-membered heteroaryl})$, where n is an integer selected from 0, 1, 2, and 3.

35. (Withdrawn): A pharmaceutical composition according to Claim 34 wherein R^{473} is phenyl or pyridin-4-yl.

36. (Presently Amended): A pharmaceutical composition according to Claim 31 wherein R_a^2 and R_b^2 are as defined under (- I -) ~~in Claim 1.~~

37. (Original): A pharmaceutical composition according to Claim 36 wherein R is cyclopentyl or cyclohexyl; R¹ is (C₁-C₂) alkyl; one of R²_a and R²_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, m is 0, R¹¹³ and R¹¹⁴ are in a *cis* relationship to each other, R¹¹³ is cyano, R¹¹⁵ is hydrogen, and R¹¹⁴ is carboxy, -CH₂OH, or -CH₂C(=O)NH₂.

38. (Original): A pharmaceutical composition according to Claim 36 wherein R is phenyl substituted by fluoro; R¹ is (C₁-C₂) alkyl; one of R²_a and R²_b is hydrogen and the other is a substituent of partial Formula (1.0.0) where the dashed line represents a single bond, R¹¹³ is cyano, and R¹¹⁵ and R¹¹⁴ are both hydrogen.

39. (Presently Amended): A pharmaceutical composition according to Claim ~~39~~ 44 wherein said compound of Formula (IA) or (IB) ~~as defined in Claim 1~~ is a member ~~independently~~ selected from the group consisting ~~essentially~~ of:

1-(1-Cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-oxocyclohexanecarbonitrile;

Trans-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid
methyl ester;

Cis-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl
ester;

Trans-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Cis-4-cyano-4-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

1-(1-Cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-oxocyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl ester;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid methyl ester;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazole-6-yl)-4-hydroxymethylcyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid amide;

Trans-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid amide;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-(1-hydroxy-1-methylethyl)cyclohexanecarbonitrile;

Cis-1-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarbonitrile;

Cis-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxy-4-methylcyclohexanecarbonitrile;

Trans-1-(1-cyclopentyl-3-ethyl-1H-indazol-6-yl)-4-hydroxy-4-methylcyclohexanecarbonitrile;

Cis-4-cyano-4-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

Trans-4-cyano-4-(1-cyclobutyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid;

6-Bromo-3-ethyl-1-(4-fluorophenyl)-1H-indazole;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]-4-hydroxycyclohexanecarboxylic acid
ethyl ester;

4-Cyano-4-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohexanecarboxylic acid ethyl
ester;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohex-3-enecarboxylic acid ethyl ester;

4-Cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)-cyclohexanecarboxylic acid ethyl ester;

Cis-4-Cyano-4-[3-ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohexanecarboxylic acid;

4-[3-Ethyl-1-(4-fluorophenyl)-1H-indazol-6-yl]cyclohex-3-enecarboxylic acid; and


4-(1-Cyclohexyl-3-ethyl-1H-indazol-6-yl)-4-hydroxycyclohexanecarboxylic acid.

40. (Cancelled).


41. (Cancelled).

42. (New): A method of treating or preventing a gastric or gastrointestinal disorder in a mammalian patient in need of such treatment, wherein said gastric or gastrointestinal disorder is characterized by one or more symptoms selected from a group consisting of pain, nausea,

vomiting, heartburn, postprandial discomfort, indigestion and gastroesophageal reflux comprising administering to said patient a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to treat or prevent said gastric or gastrointestinal disorder in said patient wherein said PDE4 inhibitor comprises a compound of Formula (IA) (IB):



(IA)



(IB)

and to pharmaceutically acceptable salts thereof, wherein:

-R is a member independently selected from the group consisting of hydrogen, (C₁-C₉) alkyl; -(CH₂)_n(C₃-C₁₀) cycloalkyl wherein n is 0, 1, or 2; (C₁-C₆) alkoxy(C₁-C₆) alkyl; (C₂-C₆) alkenyl; -(CH₂)_n(C₃-C₉) heterocyclyl wherein n is 0, 1, or 2; and -(Z¹)_b(Z²)_c(C₆-C₁₀) aryl wherein b and c are independently 0 or 1, Z¹ is (C₁-C₆) alkylene or (C₂-C₆) alkenylene, and Z² is O, S, SO₂, or NR¹¹⁹; and further wherein said heterocyclyl is a member independently selected from the group consisting of acridinyl; benzimidazolyl; benzodioxolane; 1,3-benzodioxol-5-yl; benzo[b]furanyl; benzo[b]thiophenyl; benzoxazolyl; benzthiazolyl; carbazolyl; cinnolinyl; 2,3-dihydrobenzofuranyl; 1,3-dioxane; 1,3-dioxolane; 1,3-dithiane; 1,3-dithiolane; furanyl; imidazolidinyl; imidazolinyl; imidazolyl; 1H-indazolyl; indolinyl; indolyl; 3H-indolyl; isoindolyl; isoquinolinyl; isothiazolyl; isoxazolyl; morpholinyl; 1,8-naphthyridinyl; oxadiazolyl; 1,3-oxathiolane; oxazolidinyl; oxazolyl; oxiranyl; parathiazinyl; phenazinyl; phenothiazinyl; phenoxazinyl; phthalazinyl; piperazinyl; piperidinyl; pteridinyl; pyranyl; pyrazinyl; pyrazolidinyl; pyrazolinyl; pyrazolo[1,5-


c]triazinyl; pyrazolyl; pyridazinyl; pyridyl; pyrimidinyl; pyrimidyl; pyrrolyl; pyrrolidinyl; purinyl; quinazolinyl; quinolinyl; 4H-quinolizinyl; quinoxalinyl; tetrazolidinyl; tetrazolyl; thiadiazolyl; thiazolidinyl; thiazolyl; thienyl; thiomorpholinyl; triazinyl; and triazolyl; wherein said aryl is a carbocyclic moiety which is a member independently selected from the group consisting of benzyl; *cis*- and *trans*-decahydronaphthalenyl; 2,3-1H-dihydroindenyl (indanyl); indenyl; 1-naphthalenyl; 2-naphthalenyl; phenyl; and 1,2,3,4-tetrahydronaphthalenyl; wherein said alkyl, alkenyl, alkoxyalkyl, heterocyclyl, and aryl moieties defining said R groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of bromo, chloro, or fluoro; hydroxy; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; (C₁-C₅) alkoxy; (C₃-C₆) cycloalkoxy; mono-, di-, and tri-fluoromethyl; nitro; -C(=O)OR¹¹⁹, -C(=O)NR¹¹⁹R¹²⁰, -NR¹¹⁹R¹²⁰ and -S(=O)₂NR¹¹⁹R¹²⁰;

-R¹ is a member independently selected from the group consisting of hydrogen; (C₁-C₉) alkyl; (C₂-C₃) alkenyl; phenyl; (C₃-C₇) cycloalkyl; and (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; wherein said alkyl, alkenyl and phenyl moieties defining said R¹ groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of methyl; ethyl; mono-, di-, and tri-fluoromethyl; bromo; chloro; and fluoro; and


-R²_a and R²_b are independently selected from the group consisting of hydrogen and hereinafter recited substituents, provided that one, but not both of R²_a and R²_b must be independently selected as hydrogen, wherein said substituents comprise moieties of the groups (- I -) through (- V -):

--(- I -)


--a moiety of partial Formulas (1.0.0), (1.0.1), (1.0.2), and (1.0.3):




(1.0.0)



(1.0.1)



(1.0.2)



(1.0.3)

---wherein the dashed lines in partial Formulas (1.0.0) and (1.0.1) independently and optionally represent a single or double bond, provided that in formula (1.0.0) both dashed lines cannot both represent double bonds at the same time;

---m is 0, 1, 2, 3, or 4, and when 2, may apply to a single carbon atom on the ring;

---R¹¹³ is a member selected from the group consisting of H; bromo; chloro; fluoro; cyano; (C₂-C₄) alkynyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting of phenyl, pyridyl and pyrimidinyl; (C₁-C₄) alkyl substituted by 0 to 6 bromo, chloro, or fluoro; -CH₂NHC(=O)C(=O)NH₂; cyclopropyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting of R¹²¹; R¹²⁷; CH₂OR¹¹⁹; NR¹¹⁹R¹²⁰; CH₂NR¹¹⁹R¹²⁰; C(=O)OR¹¹⁹; C(=O)NR¹¹⁹R¹²⁰; C≡CR₁₁; C(Z)H; and -CH=CR¹²¹R¹²¹; provided that R¹¹³ is H in Formula (1.0.0) when the dashed line for the ring carbon of R¹¹³ attachment represents a double bond;

---R¹¹⁴ is a member selected from the group consisting of H; R¹¹⁶; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰;

$C(NCN)NR^{127}R^{124}$, $C(NCN)S(C_1-C_4)$ alkyl; $CR^{119}R^{120}OR^{124}$, $CR^{119}R^{120}SR^{124}$,
 $CR^{119}R^{120}S(O)_nR^{125}$ where n is 0, 1, or 2; $CR^{119}R^{120}NR^{124}R^{127}$; $CR^{119}R^{120}NR^{127}S(=O)_2R^{15}$;
 $CR^{119}R^{120}NR^{127}C(Y)R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)OR^{125}$; $CR^{119}R^{120}NR^{127}C(Y)NR^{127}R^{124}$;
 $CR^{119}R^{120}NR^{127}C(NCN)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(CR^{119}NO_2)S(C_1-C_4)$ alkyl;
 $CR^{119}R^{120}C(=O)OR^{125}$; $CR^{119}R^{120}C(Y)NR^{127}R^{124}$; $CR^{119}R^{120}C(NR^{127})NR^{127}R^{124}$;
 $CR^{119}R^{120}CN$; $CR^{119}R^{120}C(NOR^{120})R^{124}$; $CR^{119}R^{120}C(NOR^{124})R^{120}$;
 $CR^{119}R^{120}NR^{127}C(NR^{127})S(C_1-C_4)$ alkyl; $CR^{119}R^{120}NR^{127}C(NR^{127})NR^{127}R^{124}$;
 $CR^{119}R^{120}NR^{127}C(=O)C(=O)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)C(=O)OR^{124}$; tetrazolyl;
thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl;
triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; $CR^{119}R^{120}$ (tetrazolyl); $CR^{119}R^{120}$ (thiazolyl);
 $CR^{119}R^{120}$ (imidazolyl); $CR^{119}R^{120}$ (imidazolidinyl); $CR^{119}R^{120}$ (pyrazolyl);
 $CR^{119}R^{120}$ (thiazolidinyl); $CR^{119}R^{120}$ (oxazolyl); $CR^{119}R^{120}$ (oxazolidinyl); $CR^{119}R^{120}$ (triazolyl);
 $CR^{119}R^{120}$ (isoxazolyl); $CR^{119}R^{120}$ (oxadiazolyl); $CR^{119}R^{120}$ (thiadiazolyl);
 $CR^{119}R^{120}$ (morpholinyl); $CR^{119}R^{120}$ (piperidinyl); $CR^{119}R^{120}$ (piperazinyl); and
 $CR^{119}R^{120}$ (pyrrolyl); said heterocyclic groups being substituted by 0 to 3 substituents R^{124} ;
--- R^{115} is a member selected from the group consisting of R^{119} ; OR^{119} ; $-CH_2OR^{119}$; cyano;
 $C(=O)R^{119}$; $C(=O)OR^{119}$; $C(=O)NR^{119}R^{120}$; and $NR^{119}R^{120}$; provided that R^{115} is absent when
the dashed line in partial Formula (1.0.0) represents a double bond; or
--- R^{114} and R^{115} are taken together to form $=O$ or $=R^{118}$; or
--- R^{115} is hydrogen and R^{114} is OR^{124} ; SR^{124} ; $S(O)_nR^{125}$, where n is 0, 1, or 2; $S(=O)_2NR^{127}R^{124}$;
 $NR^{127}R^{124}$; $NR^{124}C(=O)R^{119}$; $NR^{127}C(Y)R^{124}$; $NR^{127}C(=O)OR^{125}$; $NR^{127}C(Y)NR^{127}R^{124}$;
 $NR^{127}S(=O)_2NR^{127}R^{124}$; $NR^{127}C(NCN)NR^{127}R^{124}$; $NR^{127}S(=O)_2R^{125}$;
 $NR^{127}C(CR^{119}NO_2)NR^{127}R^{124}$; $NR^{127}C(NCN)S(C_1-C_4)$ alkyl;

$\text{NR}^{127}\text{C}(\text{CR}^{119}\text{NO}_2)\text{S}(\text{C}_1\text{-C}_4)\text{ alkyl}$; $\text{NR}^{127}\text{C}(\text{NR}^{127})\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{NR}^{127}\text{R}^{124}$,
or $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{OR}^{124}$;

--- R^{116} is a member independently selected from the group consisting of methyl and ethyl substituted by 0 to 5 bromo, chloro, or fluoro, wherein m may be 2 with respect to a single ring carbon atom to which R^{116} is attached;

--- R^{117} is a member independently selected from the group consisting of OR^{124} ; SR^{124} ;
 $\text{SO}_2\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{124}\text{C}(=\text{O})\text{R}^{119}$; $\text{NR}^{127}\text{C}(\text{Y})\text{R}^{124}$; $\text{NR}^{127}\text{C}(=\text{O})\text{OR}^{125}$; $\text{S}(\text{O})_n\text{R}_{12}$
where n is 0, 1, or 2; $\text{OS}(=\text{O})_2\text{R}^{122}$; OR^{122} ; $\text{OC}(=\text{O})\text{NR}^{123}\text{R}^{122}$; $\text{OC}(=\text{O})\text{R}^{123}$; $\text{OC}(=\text{O})\text{OR}^{123}$;
 $\text{O}(\text{CR}^{122}\text{R}^{123})_m\text{OR}^{122}$ where m is 0, 1, or 2; $\text{CR}^{119}\text{R}^{120}\text{OR}^{124}$; $\text{CR}^{119}\text{R}^{120}\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{Y})\text{R}^{124}$;
 $\text{C}(=\text{O})\text{OR}^{124}$; $\text{C}(\text{Y})\text{NR}^{127}\text{R}^{124}$; CN ; $\text{C}(\text{NR}^{127})\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NOR}^{119})\text{R}^{124}$;
 $\text{C}(=\text{O})\text{NR}^{119}\text{NR}^{119}\text{C}(=\text{O})\text{R}^{119}$; $\text{C}(=\text{O})\text{NR}^{119}\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NOR}^{124})\text{R}^{119}$; $\text{C}(\text{NR}^{119})\text{NR}^{127}\text{R}^{124}$;
 $\text{C}(\text{NR}^{124})\text{NR}^{119}\text{R}^{120}$; $\text{C}(\text{NCN})\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NCN})\text{S}(\text{C}_1\text{-C}_4)\text{ alkyl}$; tetrazolyl; thiazolyl;
imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl;
isoxazolyl; oxadiazolyl; and thiadiazolyl; where the recited heterocyclic groups are
substituted by 0 to 3 substituents where said substituent is R^{124} ;

---- R^{118} is a member independently selected from the group consisting of $-\text{NR}^{125}$;
 $-\text{NCR}^{119}\text{R}^{120}(\text{C}_2\text{-C}_6)\text{ alkenyl}$; $-\text{NOR}^{124}$; $-\text{NOR}^{129}$; $-\text{NOCR}^{119}\text{R}^{120}(\text{C}_2\text{-C}_6)\text{ alkenyl}$;
 $-\text{NNR}^{119}\text{R}^{124}$; $-\text{NNR}^{119}\text{R}^{129}$; $-\text{NCN}$; $-\text{NNR}^{119}\text{C}(\text{Y})\text{NR}^{119}\text{R}^{124}$; $-\text{C}(\text{CN})_2$; $-\text{CR}^{124}\text{CN}$;
 $-\text{CR}^{124}\text{C}(=\text{O})\text{OR}^{119}$; $-\text{CR}^{124}\text{C}(=\text{O})\text{NR}^{119}\text{R}^{124}$; $-\text{C}(\text{CN})\text{NO}_2$; $-\text{C}(\text{CN})\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4)\text{ alkyl}$;
 $-\text{C}(\text{CN})\text{OC}(=\text{O})\text{O}(\text{C}_1\text{-C}_4)\text{ alkyl}$; $-\text{C}(\text{CN})(\text{C}_1\text{-C}_4)\text{ alkyl}$; $-\text{C}(\text{CN})\text{C}(=\text{O})\text{NR}^{119}\text{R}^{124}$; 2-(1,3-
dithiane), 2-(1,3-dithiolane), dimethylthio ketal, diethylthio ketal, 2-(1,3-dioxolane), 2-(1,3-
dioxane), 2-(1,3-oxathiolane); dimethyl ketal and diethyl ketal;

----R¹¹⁹ and R¹²⁰ are each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl substituted by 0 to 3 fluorine atoms;

----R¹²¹ is a member independently selected from the group consisting of fluoro and R¹²⁰;

----R¹²² is a member independently selected from the group consisting of (C₁-C₆) alkyl; (C₂-C₃) alkenyl; (C₃-C₇) cycloalkyl; (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; (C₆-C₁₀) aryl; and (C₃-C₉) heterocyclyl; where said aryl and heterocyclyl are as defined under R above; and where said R¹²² groups are substituted with 0 to 3 substituents independently selected from the group consisting essentially of methyl; ethyl; mono-, di-, and tri-fluoromethyl; and bromo, chloro, or fluoro;

----R¹²³ is a member independently selected from the group consisting of hydrogen and R¹²²;

----R¹²⁴ is a member independently selected from the group consisting of hydrogen and R¹²⁵; or when R¹²⁴ and R¹²⁷ appear together as NR¹²⁷R¹²⁴ then R¹²⁷ and R¹²⁴ may be taken together with the nitrogen to which they are attached to form a 5- to 7-membered ring optionally containing one additional heteroatom selected from O, N and S;

----R¹²⁵ is a member independently selected from the group consisting of (C₁-C₆) alkyl and -(CR¹¹⁹R¹²⁰)_nR¹²⁶, where n is 0, 1, or 2 and R¹²⁶ and said (C₁-C₆) alkyl are substituted by 0 to 3 substituents where each said substituent is a member independently selected from the group consisting of bromo; chloro; fluoro; nitro; cyano; NR¹²⁰R¹²⁷; C(=O)R¹¹⁹; OR¹¹⁹; C(=O)NR¹²⁰R¹²⁷; OC(=O)NR¹²⁰R¹²⁷; NR¹²⁷C(=O)NR¹²⁷R¹²⁰; NR¹²⁷C(=O)R¹²⁰; NR₁₇C(=O)O(C₁-C₄) alkyl; C(NR¹²⁷)NR¹²⁷R¹²⁰; C(NCN)NR¹²⁷R¹²⁰; C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)NR¹²⁷R¹²⁰; NR¹²⁷S(=O)₂(C₁-C₄) alkyl; S(O)_n(C₁-C₄) alkyl; where n is 0, 1, or 2;

$\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{NR}^{127}\text{R}^{120}$, $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{R}^{127}$; thiazolyl; imidazolyl; oxazolyl; pyrazolyl; triazolyl; tetrazolyl; and (C₁-C₂) alkyl substituted with 0 to 3 fluorine atoms;

----R¹²⁶ is a member independently selected from the group consisting of (C₃-C₇) cycloalkyl; pyridyl; pyrimidyl; pyrazolyl; imidazolyl; triazolyl; pyrrolyl; piperazinyl; piperidinyl; morpholinyl; furanyl; thienyl; thiazolyl; quinolinyl; naphthyl; and phenyl;

----R¹²⁷ is a member independently selected from the group consisting of OR¹¹⁹ and R¹²⁰;

----R¹²⁸ is a member independently selected from the group consisting of H; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰SR¹²⁴; CR¹¹⁹R¹²⁰S(O)_nR¹²⁵, where n is 0, 1, or 2; CR¹¹⁹R¹²⁰NR¹²⁴R¹²⁷; CR¹¹⁹R¹²⁰NR¹²⁷S(=O)₂R¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)OR¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(CR₉NO₂)S(C₁-C₄) alkyl; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; wherein said recited heterocyclic groups are substituted by 0 to 3 substituents where each said substituent is independently selected from the group consisting essentially of R¹²⁴;

----R¹²⁹ is a member independently selected from the group consisting of -C(=O)R¹²; -C(=O)NR¹¹⁹R¹²⁴; -S(=O)₂R¹²⁵; and -S(=O)₂NR¹¹⁹R¹²⁴;

----Y is O or S; and,

---Z is O; NR¹²⁷; NCN; C(-CN)₂; CR¹¹⁹CN; CR¹¹⁹NO₂; CR¹¹⁹C(=O)OR¹¹⁹;
 CR¹¹⁹C(=O)NR¹¹⁹R¹²⁰; C(-CN)C(=O)O(C₁-C₄) alkyl); and C(-CN)C(=O)NR¹¹⁹R¹²⁰;

- or, said substituents defining R²_a and R²_b comprise: -

--(- II -)

--a member selected from the group consisting of R²²⁹;

-C(=O)NR²²²(CHR²²²)_mC(=O)NR²²²O(CH₂)_q(C₆-C₁₀) aryl);

-C(=NR²⁴²)NH(CH₂)_p(C₆-C₁₀) aryl; -C(=O)NR²¹⁸(CHR²²²)_mC(=O)NR²²²(CH₂)_pOR²²²;

-C(=O)NR²²²(CHR²²²)_mS(C₁-C₄) alkyl; -C[=NOC(=O)R²³⁵]R²³⁶;


-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹SO₂(CH₂)_pA;


-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹P(=O)(OR²²²)C(=O)(C₁-C₄) alkyl;

-CR²²⁷R²³⁸CHR²³⁸NR²¹⁹P(=O)[(C₁-C₄) alkoxy]₂, -Z³-R²¹⁷; and

-(CR²²⁷R²²⁸)_mNR²¹⁹(C(O))_qR²²⁰ wherein p is 0, 1, or 2; m is 1, 2, 3, 4, 5, or 6; and q is an integer of 1 or 2;

- or, said substituents defining R²_a and R²_b comprise a moiety of
 partial Formulas (2.0.0) through (2.0.8), inclusive: -





---wherein in said partial Formulas (2.0.0)-(2.0.8), the structures of partial Formulas (2.0.5) and (2.0.6) are attached to the nucleus of Formula (IA) or (IB) at carbons 5, 6, or 7 of said partial Formulas (2.0.5) and (2.0.6); the dashed line in partial Formulas (2.0.2) and (2.0.3) indicates a single bond or double bond, except that R²¹⁶ is absent in partial Formulas (2.0.2) and (2.0.3) where said dashed line indicates a double bond; n is 0 or an integer of 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and m is 0 or 1;

---R²¹³ is a member independently selected from the group consisting of -C(=O)N(CH₃)(OCH₃) and -(CH₂)_nOH, where n is 0, 1, 2, 3, or 4;

---R²¹⁴ and R²¹⁵ are independently selected from the group consisting of H; ethyl; -CO₂H; and -C(=O)NHOH;

---R²¹⁶ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₆) alkyl; (C₁-C₆) alkoxy; -OC(=O)(C₁-C₆) alkyl and -OC(=O)(C₆-C₁₀) aryl;

---R²¹⁷ is a member independently selected from the group consisting of (C₆-C₁₀) aryl and a 5- to 10-membered heterocyclyl, wherein said R²¹⁷ groups are substituted by 0 to 3 substituents independently selected from the group consisting of bromo, chloro, or fluoro; trifluoromethyl; cyano; nitro; -CO₂R²²², (C₁-C₄) alkoxy; -OC(=O)(C₁-C₄) alkyl;

$-\text{NR}^{222}\text{C}(=\text{O})(\text{C}_1\text{-C}_4)$ alkyl; $-\text{C}(=\text{O})\text{NH}_2$; $-\text{C}(=\text{O})\text{NHOH}$; $-\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4)$ alkyl;
 $(\text{C}_1\text{-C}_4)$ alkyl; $-\text{S}(\text{O})_n\text{R}^{222}$ where n is 0, 1, or 2; benzoyl; $-\text{NR}^{222}\text{R}^{223}$, $-\text{OR}^{222}$,
 $(\text{C}_1\text{-C}_6)$ alkanoyl; $-\text{Y}^1\text{-(C}_6\text{-C}_{10})$ aryl; $-\text{C}(=\text{O})\text{O}(\text{C}_6\text{-C}_{10})$ aryl; $-\text{NH}(\text{C}_6\text{-C}_{10})$ aryl;
 $-\text{C}(=\text{O})\text{NH}(\text{C}_6\text{-C}_{10})$ aryl; $-\text{C}(=\text{O})\text{NR}^{222}\text{O}(\text{CH}_2)_n(\text{C}_6\text{-C}_{10})$ aryl, where n is 1, 2, or 3; and
 $-\text{SO}_2\text{NH}(\text{C}_6\text{-C}_{10})$ aryl;

$---\text{R}^{218}$ is a member independently selected from the group consisting of H; $(\text{C}_1\text{-C}_6)$ alkyl; and
 $-(\text{CH}_2)_n(\text{C}_6\text{-C}_{10})$ aryl, where n is 0, 1, 2, 3, or 4;

$----\text{R}^{219}$ is a member independently selected from the group consisting of H; $-\text{OR}^{222}$; $-(\text{CH}_2)_m\text{A}$; and
 $-\text{CH}_2\text{O}(\text{CH}_2)_m\text{A}$, where m is 0, 1, or 2;

$----\text{R}^{220}$ is a member independently selected from the group consisting of $(\text{C}_1\text{-C}_4)$ alkyl; $-\text{OR}^{222}$,
 $-\text{CR}^{222}\text{R}^{223}\text{OR}^{222}$, $-\text{CR}^{222}\text{R}^{223}\text{NR}^{222}\text{R}^{223}$; $-\text{CR}^{222}(\text{OR}^{223})\text{CR}^{222}\text{R}^{223}\text{OR}^{222}$,
 $2,2\text{-dimethyl-1,3-dioxolan-4-yl}$; $-\text{NR}^{222}\text{C}(=\text{O})\text{NR}^{222}\text{R}^{223}$, $-\text{S}(\text{CR}^{222}\text{R}^{223})_n\text{CH}_3$ where n is 0, 1,
2, 3, 4, or 5; $-\text{NR}^{222}(\text{CH}_2)_q(\text{pyridyl})$ where q is 0 or 1; $-\text{P}(=\text{O})[(\text{C}_1\text{-C}_4)\text{alkoxy}]_2$; $-\text{NR}^{222}\text{R}^{223}$,
 $-\text{NR}^{222}\text{OR}^{223}$; $-\text{NR}^{222}\text{NR}^{223}\text{R}^{221}$, $-\text{NR}^{222}\text{CH}_2\text{R}^{224}$; $-\text{OCH}_2\text{NR}^{222}\text{C}(=\text{O})\text{R}^{224}$,
 $-\text{OCH}_2\text{C}(=\text{O})\text{NR}^{225}\text{R}^{226}$, $-\text{OCHR}^{222}\text{OC}(=\text{O})(\text{C}_1\text{-C}_4)$ alkyl; $-\text{OCHR}^{222}\text{C}(=\text{O})(\text{C}_1\text{-C}_3)$ alkoxy;
 $-\text{O}(\text{CH}_2)_m\text{R}^{221}$; and $-\text{NR}^{222}(\text{CH}_2)_m\text{R}^{221}$ where m is 0, 1, or 2;

$----\text{R}^{221}$ is a member independently selected from the group consisting of H and A;

$---\text{R}^{222}$ and R^{223} are each a member independently selected from the group consisting of H and
 $(\text{C}_1\text{-C}_4)$ alkyl;

$----\text{R}^{224}$ is a member independently selected from the group consisting of methyl and phenyl;

$----\text{R}^{225}$ is a member independently selected from the group consisting of H; methyl; ethyl; and
 $-\text{CH}_2\text{CH}_2\text{OH}$;

---R²²⁶ is a member independently selected from the group consisting of H; methyl; ethyl;
-CH₂C(=O)NH₂; and -CH₂CH₂OH;


---R²²⁷ is each a member independently selected from the group consisting of H; hydroxy;
cyano; halo; (C₁-C₃) alkyl; (C₁-C₃) alkoxy; -NR²²²R²²³; -C(=O)OR²²²; -C(=O)R²²²;
-CH=CR²²²R²²³; -C≡CR²²²; -CH₂NR²²²R²²³; -CH₂OR²²²; -C(=O)NR²²²R²²³; -C(Y⁵)H; and
-CH₂NR₁₂C(=O)C(=O)NR²²²R²²³; provided that when R²²⁷ is hydroxy then R²²⁸ is H or
(C₁-C₄) alkyl;

---R²²⁸ is each a member independently selected from the group consisting of H; fluoro; cyano;
and (C₁-C₄) alkyl; where said methyl is substituted by 0 to 3 substituents each comprising a
fluorine atom; or

---R²²⁷ and R²²⁸ are taken together to form an oxo (=O) moiety;

---R²²⁹ is a member independently selected from the group consisting of phenyl; naphthyl;
pyrrolyl; furanyl; thienyl; oxazolyl; pyridinyl; pyrimidinyl; pyridazinyl; quinolinyl;
isoquinolinyl; 5,6,7,8-tetrahydroquinolinyl; and 5,6,7,8-tetrahydroisoquinolinyl, where said
R²²⁹ groups, except said phenyl, are substituted by 0 to 3 substituents R²³³, and wherein said
phenyl R²²⁹ group is substituted by 0 to 3 substituents independently selected from the group
consisting of R²³³ and R²³⁴;

---R²³⁰ is a member independently selected from the group consisting of -C(=O)R²³¹;
-C(=O)C(=O)R²³¹, -C(=O)C(Y²)C(=O)R²³¹ and a moiety of partial Formula (2.0.9):



(2.0.9)

wherein:

----R²³¹ is a member independently selected from the group consisting of H; -OR²³²; -NHR²³²; -NHOH; -NHNH₂; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is 0, 1, 2, 3, or 4;

-----R²³² is a member independently selected from the group consisting of H; (C₁-C₈) alkyl; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is 0, 1, 2, 3, or 4;

-----R²³³ is each a member independently selected from the group consisting of bromo; chloro; fluoro; (C₁-C₆) alkyl; (C₁-C₇) alkoxy; (C₂-C₆) alkylenedioxy; trifluoromethyl; -NR²²²R²²³; nitro; -C(NR²²²)NR²²²R²²³; -C(=O)NR²²²R²²³C(=O)R²²²; -C(NOR²²²)R²²³; -C(NCN)NR²²²R²²³; -C(NCN)SR²²²; -(CH₂)_m(CN) where m is 0, 1, 2, or 3; hydroxy; -C(=O)R²²²; -C(=O)NR²²²OR²²³; -C(=O)NR²²²NR²²²R²²³; -OC(=O)NR²²²R²²³; -NR²²²C(=O)R²²²; -C(=O)C(=O)NR²²²R²²³; -CO₂R²²²; -SO₂R²²²; -SO₂NR²²²R²²³; -C(=O)NR²²²R²²³; -NR²²²SO₂R²²³; and -NR²²²C(=O)NR²²²R²²³;

-----R²³⁴ is each a member independently selected from the group consisting of imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl, where each of said foregoing R²³⁴ substituents is substituted by 0 to 3 substituents R²³³;

-----R²³⁵ is a member independently selected from the group consisting of -NR²²²R²²³; -NH(C₆-C₁₀) aryl; (C₁-C₆) alkoxy; and (C₆-C₁₀) aryloxy;

-----R²³⁶ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl and -(CH₂)_mY⁴(phenyl) where m is 0, 1, 2, 3, or 4 and the phenyl moiety of said -(CH₂)_mY⁴(phenyl)R²³⁶ group is substituted by 0 to 3 substituents independently selected

from the group consisting of bromo, chloro, and fluoro; $-OR^{222}$; (C_1-C_6) alkanoyloxy; (C_6-C_{10}) aryloxy; $-NR^{222}R^{223}$; $-NH(C_6-C_{10})$ aryl; and $-NHC(=O)(C_1-C_4)$ alkyl;

----- R^{237} is each a member independently selected from the group consisting of bromo; chloro; fluoro; $-(CH_2)_pNR^{222}C(=O)CH_3$ where p is 1, 2, 3, or 4, and; (C_1-C_4) alkoxy; nitro; cyano; $-NR^{222}R^{223}$; $-CO_2R^{222}$; $-OR^{222}$; $-C(Y^1)NR^{222}R^{223}$; $-NR^{222}C(NCN)S(C_1-C_3)$ alkyl; $-NR^{222}C(NCN)NR^{222}R^{223}$; $-NR^{222}C(=O)NR^{222}R^{223}$; $-NR^{222}C(=O)C(=O)NR^{222}R^{223}$; $-C(=NR^{222})NR^{222}R^{223}$; $-S(O)_mCH_3$ where m is 0, 1, or 2; $-C(=NR^{222})S(C_1-C_3)$ alkyl; $-NR^{222}SO_2(C_1-C_3)$ alkyl; $-OC(=O)R^{222}$; $-OC(=O)NR^{222}R^{223}$; $-NR^{222}SO_2CF_3$; $-NR^{222}C(=O)C(=O)OR^{222}$; $-NR^{222}C(=O)R^{222}$; $-NR^{222}C(=O)OR^{222}$; imidazolyl; thiazolyl; oxazolyl; pyrazolyl; triazolyl; and tetrazolyl;

----- R^{238} is a member independently selected from the group consisting of H; fluoro; cyano; and (C_1-C_2) alkyl, where said alkyl is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; $-C(=O)NR^{222}R^{223}$; and $-C(=O)OR^{222}$;

----- R^{239} is a member independently selected from the group consisting of phenyl substituted by 0 to 2 substituents independently selected from the group consisting of $-NR^{222}R^{223}$, nitro, halo, $-OR^{222}$, $-NHR^{240}$, $-NR^{240}R^{241}$, and $-C(=O)OR^{222}$;

----- R^{240} and R^{241} are each a member independently selected from the group consisting of (C_1-C_8) alkyl and (C_2-C_8) alkenyl;

----- R^{242} is pyridin-4-yl substituted by 0 to 2 substituents independently selected from the group consisting of bromo, chloro, or fluoro; and (C_1-C_4) alkyl;

-----A is each a member independently selected from the group consisting of (C_1-C_6) alkyl; pyridyl; morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; triazolyl;

quinolinyl; phenyl; and naphthyl; wherein the foregoing A groups are substituted with 0 to 3 substituents R^{237} ; or A is $-(CH_2)_qS(C_1-C_4)$ alkyl wherein q is an integer of 1 or 2;

-----W is a member independently selected from the group consisting of O; NOH; NNH_2 ; $NOC(=O)CH_3$; and $NNHC(=O)CH_3$;

-----Y¹ is O or S;

-----Y² is O, NOH or H₂;

-----Y³ is a bond or $-CH=CH-$;

-----Y⁴ is a bond, O, S, or $-NH-$;

-----Y⁵ is a member independently selected from the group consisting of O; NR^{222} ; NOR^{222} ;

NCN ; $C(CN)_2$; $CR^{222}NO_2$; $CR^{222}C(=O)OR^{222}$; $CR^{222}C(=O)NR^{222}R^{223}$; $C(CN)NO_2$;

$C(CN)C(=O)OR^{222}$; and $C(CN)C(=O)NR^{222}R^{223}$; and

-----Z³ is a member independently selected from the group consisting of $-NR^{222}-$; $-(CH_2)_m-$; -

$CH_2C(=O)NH-$; $-NHCH_2C(=O)-$; $-CH_2C(Y^1)CH_2-$; $-CH=CH-$; $-C\equiv C-$; $-CH(Y^1H)-$;

$-C(Y^1)-$; $-CH_2C(Y^1)-$; $-C(Y^1)CH_2-$; $-C(Y_1)C(Y_1)-$; $-CH_2NR^{222}-$; $-CH_2-Y^1-$;

$-C(Y^1)NR^{218}(CHR^{222})_n-$; $-NR^{218}C(Y^1)(CHR^{222})_n-$; $-NHCH_2-$; $-Y^1-CH_2-$; $-SOCH_2-$;

$-CH_2SO-$; $-SO_2CH_2-$; $-CH_2SO_2-$; $-OC(Y^1)-$; $-N=N-$; $-NHSO_2-$; $-SO_2NH-$; $-C(Y^1)C(Y^1)NH-$;

$-NHC(=O)O-$; $-OC(=O)NH-$; and $-NHC(=O)NH-$; wherein for said Z₃ moieties n is 0, 1, 2,

3, or 4; and m is 1, 2, or 3;


- or said substituents defining R_a^2 and R_b^2 comprise: -


--(- III -)

--a member independently selected from the group consisting of 2-oxo-4-pyrrolyl; pyrazolyl; 2-oxo-3,4-dihydro-5-pyrimidyl; 2-oxo-3,4-dihydro-4-pyrimidyl; 2-oxo-tetrahydro-4-pyrimidyl; 2-oxo-tetrahydro-5-pyrimidyl; 2-oxo-4-pyrimidyl; and 2-oxo-5-pyrimidyl; wherein each of said R^2_a and R^2_b groups is substituted by 0, 1, 2, 3, or 4 R^{236} groups;


- or, said substituents defining R^2_a and R^2_b comprise a

moiety of partial Formulas (3.0.0) through (3.0.19), inclusive: -







(3.15)




(3.16)



(3.17)



(3.18)



(3.19)

----wherein in said partial Formulas (3.0.0) through (3.0.19), q is 0 or 1 in partial Formula

(3.0.1); n is 0, 1, or 2 in partial Formula (3.0.2); and the dashed lines appearing in formulas (3.0.1), (3.0.3), (3.0.6), (3.0.7), (3.0.8), (3.0.9) and (3.0.14) represent a double bond or a single bond;

----X¹ is O or S;

----X² in formula (3.0.10) and where the dashed line in formula (3.0.9) represents a double bond, is a member independently selected from the group consisting of CR³³⁵; CR³³⁶; CR³⁴⁶, and COC(=O)NR³³⁹R³⁴²; or, where the dashed line in formula (3.0.9) represents a single bond, X² is a member independently selected from the group consisting of CR³³⁵R³³⁹; CR³³⁶R³³⁹; and CR³⁴⁶R³³⁹;

----X³ is a member independently selected from the group consisting of C(=Z³); C(S); and CR³³⁶R³⁴⁰;

----X⁴ is a member independently selected from the group consisting of -(CH₂)_m- where m is 0, 1, or 2;

----X⁵ is a bond or -CH₂-;

----X⁶ is a member independently selected from the group consisting of -CH₂- and -C(=O)-;

----R³³³ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₄) alkoxy; -CHR³³⁷(O)_q(CH₂)_mA where q is 0 or 1, and m is 0, 1, or 2;

- R³³⁴ is a member independently selected from the group consisting of H; hydroxy;
(C₁-C₄) alkyl; (C₁-C₂) alkoxy; -OC(=O)CH₃; (C₂-C₃) alkenyl; and phenyl(C₁-C₂) alkyl-;
- R³³⁵ is a member independently selected from the group consisting of H; hydroxy;
-(CH₂)_mA where m is 0, 1, or 2; (C₁-C₆) alkyl; and (C₂-C₃) alkanoyl; where said alkyl group
is substituted by 0 to 3 substituents independently selected from the group consisting of
bromo; chloro; fluoro; nitro; -NR³⁴⁰R³⁴¹; -CO₂R³⁴⁰; -OR³⁴⁰; -OC(=O)R³⁴⁰; -C(=O)R³⁴⁰;
cyano; -C(=Y)NR³⁴⁰R³⁴¹; -NR³⁴⁰C(=Y)NR³⁴⁰R³⁴¹; -NR³⁴⁰C(=Y)R³⁴⁰; -NR³⁴⁰C(=O)OR³⁴⁰;
-C(NR³⁴⁰)NR³⁴⁰R³⁴¹; -C(NCN)NR³⁴⁰R³⁴¹; -C(NCN)SR³⁴⁰; -NR³⁴⁰SO₂R³⁴⁰; -S(O)_mR³⁴⁰,
where m is 0, 1, or 2; -NR³⁴⁰SO₂CF₃; -NR³⁴⁰C(=O)C(=O)NR³⁴⁰R³⁴¹;
-NR³⁴⁰C(=O)C(=O)OR³⁴⁰; imidazolyl; and 1-(NHR³⁴⁰)-2-imidazolyl;
- R³³⁶ is each a member independently selected from the group consisting of H; bromo;
chloro; fluoro; cyano; R³⁴³; cyclopropyl substituted by 0 or 1 substituent independently
selected from the group consisting of R³³⁹; -OR³⁴⁰; -CH₂OR³⁴⁰; -NR³⁴⁰R³⁴²; -CH₂NR³⁴⁰R³⁴²;
-C(=O)OR³⁴⁰; -C(=O)NR³⁴⁰R³⁴²; -CH=CR³³⁹R³³⁹; -C≡CR³³⁹; and -C(=Z³)H;
- R³³⁷ is a member independently selected from the group consisting of H; -C(=O)R³³⁸;
imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl;
thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl;
- R³³⁸ is each a member independently selected from the group consisting of -OR³⁴⁰;
-NR³⁴⁰R³⁴²; and -R³⁴³;
- R³³⁹ is each a member independently selected from the group consisting of H; bromo;
chloro; fluoro; and (C₁-C₄) alkyl substituted by 0 to 3 fluorine atoms;

- R³⁴⁰ and R³⁴¹ are each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl;
- R³⁴² is each a member independently selected from the group consisting of -OR³⁴⁰ and -R³⁴⁰;
- R³⁴³ is (C₁-C₄) alkyl;
- R³⁴⁴ is each a member independently selected from the group consisting of bromo; chloro; fluoro; nitro; cyano; -NR³⁴⁰R³⁴⁶; -NR³⁴⁶R³⁴²; -C(=Z³)R³³⁸; -S(O)_mR³⁴³ where m is 0, 1, or 2; -OR³⁴²; -OC(=O)NR³⁴⁰R³⁴²; -C(NR³⁴²)NR³⁴⁰R³⁴²; -C(NR³⁴⁰)SR³⁴³; -OC(=O)CH₃; -C(NCN)NR³⁴⁰R³⁴²; -C(S)NR³⁴⁰R³⁴²; -NR³⁴²C(=O)R³⁴⁷; -C(=O)R³⁴⁷; oxazolyl; imidazolyl; thiazolyl; pyrazolyl; triazolyl; and tetrazolyl;
- R³⁴⁵ is each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl substituted by 0, 1, 2 or 3 fluorine atoms;
- R³⁴⁶ is each a member independently selected from the group consisting of H; -R³⁴³; -C(=O)R³⁴³; -C(=O)C(=O)R³³⁸; -C(=O)NR³⁴⁰R³⁴²; -S(O)_mR³⁴³ where m is 0, 1, or 2; -C(NCN)SR³⁴³; -C(NCN)R³⁴³; -C(NR³⁴²)R³⁴³; -C(NR³⁴²)SR³⁴³; and -C(NCN)NR³⁴⁰R³⁴²;
- R³⁴⁷ is each a member independently selected from the group consisting of -R³⁴³; -C(=O)R³⁴³; oxazolidinyl; oxazolyl; thiazolyl; pyrazolyl; triazolyl; tetrazolyl; imidazolyl; imidazolidinyl; thiazolidinyl; isoxazolyl; oxadiazolyl; thiadiazolyl; morpholinyl; piperidinyl; piperazinyl; and pyrrolyl; where each of said recited R³⁴⁷ heterocyclic groups is substituted by 0 to 2 (C₁-C₂) alkyl groups;
- R³⁴⁸ is each a member independently selected from the group consisting of H; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; benzyl; and phenethyl;

- R³⁴⁹ is a member independently selected from the group consisting of H; (C₁-C₅) alkyl; (C₁-C₅) alkanoyl; and benzoyl;
- R³⁵⁰ is a member independently selected from the group consisting of H; (C₁-C₄) alkyl; carboxy; aminocarbonyl; (C₁-C₆) alkyl substituted by 0 or 1 carboxy, -(CH₂)_mC(=O)(C₁-C₆) alkoxy; or -(CH₂)_m(C₆-C₁₀) aryl; where m is 0, 1, or 2;
- R³⁵¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; -C(=Y)R³⁵²; -C(=Y)NH₂; -C(=O)OR³⁵²; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4, or 5; and X⁷ is a bond or -CH=CH-; and where said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵² is a member independently selected from the group consisting of (C₁-C₆) alkyl (C₃-C₈) cycloalkyl; -(CH₂)_m(C₆-C₁₀) aryl; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4, or 5; and X⁷ is a bond or -CH=CH-; and where said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵³ is a member independently selected from the group consisting of H; -R³⁴⁵; (C₁-C₃) alkyl substituted by 0 or 1 hydroxy, or (C₁-C₃) alkoxy(C₁-C₃) alkyl;
- R³⁵⁴ is a member independently selected from the group consisting of H; -R³⁴⁵; carboxy; (C₁-C₃) alkoxy(C₁-C₃) alkyl-; (C₃-C₇) cycloalkyl; and (C₁-C₅) alkyl substituted by 0 or 1 -NR³⁴⁰R³⁴¹; or
- R³⁵³ and R³⁵⁴ are taken together to form -CH₂OCH₂OCH₂-;
- R³⁵⁵ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₄) alkyl substituted by 0 or 1 substituent selected from the group consisting of hydroxy; -C(=O)R³⁴⁰; -NR³⁴⁰R³⁴¹; -(CH₂)_mNHC(=O)R³⁴⁰; -(CH₂)_mNHC(=O)R³⁴³;

$-(CH_2)_mCO_2R^{340}$; $-(CH_2)_mC(=O)NR^{340}R^{341}$; $-(CH_2)_mC(=O)N(OH)R^{340}$;
 $-(CH_2)_mSO_2NR^{340}R^{341}$; $-(CH_2)_mPO_3H_2$; $-(CH_2)_mSO_2NHC(=O)R^{343}$; and
 $-(CH_2)_mSO_2NHC(=O)(phenyl)$, where m is 0, 1, 2, 3, or 4;

----- R^{356} is a member independently selected from the group consisting of H; (C₁-C₄) alkyl;
 phenyl; $-NR^{340}R^{341}$; and $-NR^{340}(C_1-C_4)$ alkanoyl;

----- R^{357} is a member independently selected from the group consisting of $-R^{340}$; $-CH_2CO_2R^{343}$;
 and $-CH_2C(=O)NR^{340}R^{341}$;

----- R^{358} is a member independently selected from the group consisting of $-C(=O)R^{340}$;
 $-C(=O)(C_6-C_{10})$ aryl; $-C(=O)(C_3-C_9)$ heteroaryl; $-CO_2R^{340}$; $-C(=O)NR^{340}R^{341}$; cyano; nitro;
 $-CH_2OH$; $-NR^{340}SO_2R^{340}$; $-NHSO_2(C_6-C_{10})$ aryl; $-NHCO_2(C_1-C_4)$ alkyl; $-NR^{340}C(=O)R^{340}$;
 and $-NHCO_2(C_6-C_{10})$ aryl;

----- R^{359} is a member independently selected from the group consisting of $-R^{345}$; cyano;
 carboxy; formyl; $-C(=O)R^{340}$; and (C₁-C₄) alkanoyl;

----- R^{360} is a member independently selected from the group consisting of cyano; $-NR^{340}R^{341}$;
 $-SO_2(C_1-C_4)$ alkyl; $-SO_2(C_6-C_{10})$ aryl; $-C(=O)R^{340}$; $-C(=O)(C_6-C_{10})$ aryl;
 $-C(=O)(C_3-C_9)$ heteroaryl; $-C(=O)NR^{340}R^{341}$; and $-CO_2R^{340}$;

----- R^{361} and R^{362} are each a member independently selected from the group consisting of H;
 cyano; nitro; $-CO_2R^{340}$; $-C(=O)NR^{340}R^{341}$; $-CH_2OH$; $-C(=O)R^{340}$; $-NHCO_2R^{340}$; and
 $-NHSO_2R^{340}$;

-----A is a member independently selected from the group consisting of pyridyl; morpholinyl;
 piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; phenyl; and naphthyl; where each of
 said A groups is substituted by 0 to 2 substituents R^{344} or by 1 substituent R^{345} ;


-----Z³ is a member independently selected from the group consisting of O; -NR³⁴²; NOR³⁴⁰; N(CN); C(CN)₂; CR³⁴⁰NO₂; CR³⁴⁰C(=O)OR³⁴³; CR³⁴⁰C(=O)NR³⁴⁰R³⁴¹; C(CN)NO₂; C(CN)C(=O)OR³⁴³; and C(CN)C(=O)NR³⁴⁰R³⁴¹; and,

-----Y is O or S;

- or said substituents defining R²_a and R²_b

comprise a moiety of partial Formula (4.0.0): -

--(- IV -)



(4.0.0)

---wherein the broken line indicates a single or double bond;

---X¹ is -CR⁴⁷²R⁴⁷³- where said broken line indicates a single bond; or -CR⁴⁷³- where said broken line indicates a double bond;

---X² is -CR⁴⁷⁵R⁴⁷⁷R⁴⁷⁸- or -C(=NOR⁴⁸¹)R⁴⁸²- where said broken line indicates a single bond; or -CR⁴⁷⁷R⁴⁷⁸ where said broken line indicates a double bond;

---R⁴⁷² is a member independently selected from the group consisting of H; hydroxy; bromo, chloro, or fluoro; and -OR⁴⁷⁹;

---R⁴⁷³ is each a member independently selected from the group consisting of cyano; cyanomethyl; benzyloxy; -R⁴⁷⁵; -CO₂R⁴⁷⁵; -CO₂(CH₂)_n(C₆-C₁₀) aryl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NR⁴⁷⁵(CH₂)_n(C₆-C₁₀) aryl; -(CH₂)_n(C₆-C₁₀) aryl; and -(CH₂)_n(5- to 10-membered

heteroaryl); where n is selected from 0, 1, 2, or 3; each R^{473} group is substituted by 0 to 3 substituents R^{474} ; and each R^{473} group is substituted by 0 or 1 substituent R^{480} ;

----- R^{474} is each a member independently selected from the group consisting of bromo; chloro; fluoro; cyano; nitro; (C_1-C_6) alkyl; (C_2-C_6) alkenyl; $-OR^{475}$; (C_3-C_7) cycloalkoxy; $-NR^{475}R^{476}$; $-NR^{475}OR^{476}$; $-S(O)_mR^{475}$ where m is 0, 1, or 2; $-CO_2R^{475}$; $-C(=O)R^{475}$; $-SO_2NR^{475}R^{476}$; $-C(=O)NR^{475}R^{476}$; $-CR^{475}R^{476}SO_2NR^{475}R^{476}$; $-CR^{475}R^{476}C(=O)NR^{475}R^{476}$; $-NHSO_2R^{475}$; $-NHSO_2NR^{475}R^{476}$; $-NHC(=O)NR^{475}R^{476}$; $-NHC(=O)(C_1-C_6)$ alkyl; and $-NHC(=O)O(C_1-C_6)$ alkyl);

---- R^{475} and R^{476} are each a member independently selected from the group consisting of H; and (C_1-C_6) alkyl;

---- R^{477} is a member independently selected from the group consisting of $-R^{473}$; 2-oxo-pyridyl; 3-oxo-pyridyl; 4-oxo-pyridyl; 2-oxo-pyrrolyl; 4-oxo-thiazolyl; 4-oxo-piperidyl; 2-oxo-quinolyl; 4-oxo-quinolyl; 1-oxo-isoquinolyl; 4-oxo-oxazolyl; 5-oxo-pyrazolyl; 5-oxo-isoxazolyl; and 4-oxo-isoxazolyl; where each of said R^{477} groups is substituted by 0 to 3 substituents R^{474} ;

---- R^{478} is a member independently selected from the group consisting of $-R^{475}$; cyano; $-(CH_2)_p(C_6-C_{10})$ aryl; and $-(CH_2)_p(5- to 10-membered heteroaryl)$; where p is 1, 2, or 3; and where each said R^{478} group is substituted by 0 to 3 substituents R^{474} ;

----- R^{479} is a member independently selected from the group consisting of formyl; carbamoyl; thiocarbamyl; (C_1-C_6) alkyl; (C_2-C_6) alkenyl; (C_1-C_4) alkoxy (C_1-C_4) alkyl-; and (C_1-C_6) alkanoyl; where said alkyl moieties of each of said R^{479} groups is substituted by 0

to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; hydroxy; and (C₁-C₄) alkoxy;

-----R⁴⁸⁰ is a member independently selected from the group consisting of cyclobutyl; cyclopentyl; cyclohexyl; 2-cyclobuten-1-yl; 2-cyclopenten-1-yl; 3-cyclopenten-1-yl; 2,4-cyclopentadien-1-yl; 3,5-cyclohexadien-1-yl; pyrrolyl; pyrrolidinyl; dioxolanyl; imidazolyl; oxazolyl; imidazolidinyl; pyrazolyl; pyrazolidinyl; pyranyl; piperidinyl; 1,4-dioxanyl; morpholinyl; 1,4-dithianyl; thiomorpholinyl; piperazinyl; 1,3,5-trithianyl; oxazinyl; isoxazinyl; oxathiazinyl; and oxadiazinyl; where each of said R⁴⁸⁰ groups is substituted by 0 to 2 (C₁-C₂) alkyl;


----R⁴⁸¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₂-C₆) alkynyl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NH(C₆-C₁₀) aryl; -C(Y)(C₁-C₆) alkoxy; -C(Y)(C₆-C₁₀) aryloxy; and -C(Y)(C₁-C₆) alkyl;

----R⁴⁸² is a member independently selected from the group consisting of phenyl and pyridinyl; where each of said R⁴⁸² groups is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; (C₁-C₄) alkyl; hydroxy; (C₁-C₄) alkoxy; -NR⁴⁷⁵R⁴⁷⁶; and -S(O)_mR⁴⁷⁵, where m is 0, 1, or 2; and,


-----Y is O or S;

- or , said substituents defining R²_a and R²_b comprise a moiety of partial Formulas (5.0.0) through (5.0.13), inclusive: -


--(- V -)




(5.0.0)




(5.0.1)




(5.0.2)




(5.0.3)




(5.0.4)



(5.0.5)




(5.0.6)




(5.0.7)


(5.0.8)




(5.0.9)




(5.0.10)



(5.0.11)




(5.0.12)




(5.0.13)

43. (New): A method of treating or preventing a gastric or gastrointestinal disorder in a mammalian patient in need of such treatment, wherein said gastric or gastrointestinal disorder is, with respect to said patient, (i) a sign or concomitant of diabetic neuropathy, anorexia nervosa, achlorhydria, gastrointestinal surgery, post-surgical recovery in the period of emergence from general anesthesia; or the administration of morphine and morphine-like opioids; (ii) a secondary aspect of a primary disease or disorder in said patient which is organic, wherein said disease or disorder involves particularly a gastroenteric or gastroesophageal organ or tissue, or an organ or tissue of the central nervous system of said patient; or (iii) an adverse side effect of a different therapeutic agent administered to said patient in the course of treating another unrelated disease or disorder in said patient, comprising administering to said patient a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to treat or prevent said gastric or gastrointestinal disorder in said patient, wherein said PDE4 inhibitor comprises a compound of Formula (IA) or (IB);



(IA)



(IB)

and to pharmaceutically acceptable salts thereof, wherein:

- R is a member independently selected from the group consisting of hydrogen, (C₁-C₉) alkyl;
- (CH₂)_n(C₃-C₁₀) cycloalkyl wherein n is 0, 1, or 2; (C₁-C₆) alkoxy(C₁-C₆) alkyl;
- (C₂-C₆) alkenyl; -(CH₂)_n(C₃-C₉) heterocyclyl wherein n is 0, 1, or 2; and
- (Z¹)_b(Z²)_c(C₆-C₁₀) aryl wherein b and c are independently 0 or 1, Z¹ is (C₁-C₆) alkylene or


(C₂-C₆) alkenylene, and Z² is O, S, SO₂, or NR¹¹⁹; and further wherein said heterocyclyl is a member independently selected from the group consisting of acridinyl; benzimidazolyl; benzodioxolane; 1,3-benzodioxol-5-yl; benzo[*b*]furanyl; benzo[*b*]thiophenyl; benzoxazolyl; benzthiazolyl; carbazolyl; cinnoliny; 2,3-dihydrobenzofuranyl; 1,3-dioxane; 1,3-dioxolane; 1,3-dithiane; 1,3-dithiolane; furanyl; imidazolidinyl; imidazoliny; imidazolyl; 1H-indazolyl; indoliny; indolyl; 3H-indolyl; isoindolyl; isoquinoliny; isothiazolyl; isoxazolyl; morpholiny; 1,8-naphthyridiny; oxadiazolyl; 1,3-oxathiolane; oxazolidinyl; oxazolyl; oxiranyl; parathiaziny; phenaziny; phenothiaziny; phenoxaziny; phthalaziny; piperaziny; piperidinyl; pteridinyl; pyranyl; pyraziny; pyrazolidinyl; pyrazoliny; pyrazolo[1,5-*c*]triaziny; pyrazolyl; pyridaziny; pyridyl; pyrimidinyl; pyrimidyl; pyrroly; pyrrolidinyl; puriny; quinazoliny; quinoliny; 4H-quinoliziny; quinoxaliny; tetrazolidinyl; tetrazolyl; thiadiazolyl; thiazolidinyl; thiazolyl; thienyl; thiomorpholiny; triaziny; and triazolyl; wherein said aryl is a carbocyclic moiety which is a member independently selected from the group consisting of benzyl; *cis*- and *trans*-decahydronaphthalenyl; 2,3-1H-dihydroindenyl (indanyl); indenyl; 1-naphthalenyl; 2-naphthalenyl; phenyl; and 1,2,3,4-tetrahydronaphthalenyl; wherein said alkyl, alkenyl, alkoxyalkyl, heterocyclyl, and aryl moieties defining said R groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of bromo, chloro, or fluoro; hydroxy; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; (C₁-C₅) alkoxy; (C₃-C₆) cycloalkoxy; mono-, di-, and tri-fluoromethyl; nitro; -C(=O)OR¹¹⁹, -C(=O)NR¹¹⁹R¹²⁰, -NR¹¹⁹R¹²⁰ and -S(=O)₂NR¹¹⁹R¹²⁰;

-R¹ is a member independently selected from the group consisting of hydrogen; (C₁-C₉) alkyl; (C₂-C₃) alkenyl; phenyl; (C₃-C₇) cycloalkyl; and (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; wherein said


alkyl, alkenyl and phenyl moieties defining said R^1 groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of methyl; ethyl; mono-, di-, and tri-fluoromethyl; and bromo, chloro, or fluoro; and $-R_a^2$ and R_b^2 are independently selected from the group consisting of hydrogen and hereinafter recited substituents, provided that one, but not both of R_a^2 and R_b^2 must be independently selected as hydrogen, wherein said substituents comprise moieties of the groups (- I -) through (- V -):

--(- I -)


--a moiety of partial Formulas (1.0.0), (1.0.1), (1.0.2), and (1.0.3):




(1.0.0)



(1.0.1)



(1.0.2)



(1.0.3)

---wherein the dashed lines in partial Formulas (1.0.0) and (1.0.1) independently and optionally represent a single or double bond, provided that in formula (1.0.0) both dashed lines cannot both represent double bonds at the same time;

---m is 0, 1, 2, 3, or 4, and when 2, may apply to a single carbon atom on the ring;

--- R^{113} is a member selected from the group consisting of H; bromo, chloro, or fluoro; cyano; (C_2-C_4) alkynyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting of phenyl, pyridyl and pyrimidinyl; (C_1-C_4) alkyl substituted by 0 to 6 bromo, chloro, or fluoro; $-CH_2NHC(=O)C(=O)NH_2$; cyclopropyl substituted by 0 or 1

substituent where said substituent is a member selected from the group consisting of R^{121} ; R^{127} ; CH_2OR^{119} ; $NR^{119}R^{120}$; $CH_2NR^{119}R^{120}$; $C(=O)OR^{119}$; $C(=O)NR^{119}R^{120}$; $C\equiv CR_{11}$; $C(Z)H$; and $-CH=CR^{121}R^{121}$; provided that R^{113} is H in Formula (1.0.0) when the dashed line for the ring carbon of R^{113} attachment represents a double bond;

--- R^{114} is a member selected from the group consisting of H; R^{116} ; $C(Y)R^{124}$; $C(=O)OR^{124}$; $C(Y)NR^{127}R^{124}$; CN; $C(NR^{127})NR^{127}R^{124}$; $C(NOR^{119})R^{124}$; $C(=O)NR^{119}NR^{119}C(=O)R^{119}$; $C(=O)NR^{119}NR^{127}R^{124}$; $C(NOR^{124})R^{119}$; $C(NR^{119})NR^{127}R^{124}$; $C(NR^{124})NR^{119}R^{120}$; $C(NCN)NR^{127}R^{124}$; $C(NCN)S(C_1-C_4)$ alkyl; $CR^{119}R^{120}OR^{124}$; $CR^{119}R^{120}SR^{124}$; $CR^{119}R^{120}S(O)_nR^{125}$ where n is 0, 1, or 2; $CR^{119}R^{120}NR^{124}R^{127}$; $CR^{119}R^{120}NR^{127}S(=O)_2R_{15}$; $CR^{119}R^{120}NR^{127}C(Y)R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)OR^{125}$; $CR^{119}R^{120}NR^{127}C(Y)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(NCN)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(CR^{119}NO_2)S(C_1-C_4)$ alkyl; $CR^{119}R^{120}C(=O)OR^{125}$; $CR^{119}R^{120}C(Y)NR^{127}R^{124}$; $CR^{119}R^{120}C(NR^{127})NR^{127}R^{124}$; $CR^{119}R^{120}CN$; $CR^{119}R^{120}C(NOR^{120})R^{124}$; $CR^{119}R^{120}C(NOR^{124})R^{120}$; $CR^{119}R^{120}NR^{127}C(NR^{127})S(C_1-C_4)$ alkyl; $CR^{119}R^{120}NR^{127}C(NR^{127})NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)C(=O)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)C(=O)OR^{124}$; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; $CR^{119}R^{120}$ (tetrazolyl); $CR^{119}R^{120}$ (thiazolyl); $CR^{119}R^{120}$ (imidazolyl); $CR^{119}R^{120}$ (imidazolidinyl); $CR^{119}R^{120}$ (pyrazolyl); $CR^{119}R^{120}$ (thiazolidinyl); $CR^{119}R^{120}$ (oxazolyl); $CR^{119}R^{120}$ (oxazolidinyl); $CR^{119}R^{120}$ (triazolyl); $CR^{119}R^{120}$ (isoxazolyl); $CR^{119}R^{120}$ (oxadiazolyl); $CR^{119}R^{120}$ (thiadiazolyl); $CR^{119}R^{120}$ (morpholinyl); $CR^{119}R^{120}$ (piperidinyl); $CR^{119}R^{120}$ (piperazinyl); and $CR^{119}R^{120}$ (pyrrolyl); said heterocyclic groups being substituted by 0 to 3 substituents R^{124} ;

---R¹¹⁵ is a member selected from the group consisting of R¹¹⁹; OR¹¹⁹; -CH₂OR¹¹⁹; cyano; C(=O)R¹¹⁹; C(=O)OR¹¹⁹; C(=O)NR¹¹⁹R¹²⁰; and NR¹¹⁹R¹²⁰; provided that R¹¹⁵ is absent when the dashed line in partial Formula (1.0.0) represents a double bond; or

---R¹¹⁴ and R¹¹⁵ are taken together to form =O or =R¹¹⁸; or

---R¹¹⁵ is hydrogen and R¹¹⁴ is OR¹²⁴; SR¹²⁴; S(O)_nR¹²⁵, where n is 0, 1, or 2; S(=O)₂NR¹²⁷R¹²⁴; NR¹²⁷R¹²⁴; NR¹²⁴C(=O)R¹¹⁹; NR¹²⁷C(Y)R¹²⁴; NR¹²⁷C(=O)OR¹²⁵; NR¹²⁷C(Y)NR¹²⁷R¹²⁴; NR¹²⁷S(=O)₂NR¹²⁷R¹²⁴; NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; NR¹²⁷S(=O)₂R¹²⁵; NR¹²⁷C(CR¹¹⁹NO₂)NR¹²⁷R¹²⁴; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(CR¹¹⁹NO₂)S(C₁-C₄) alkyl; NR¹²⁷C(NR¹²⁷)NR¹²⁷R¹²⁴; NR¹²⁷C(=O)C(=O)NR¹²⁷R¹²⁴; or NR¹²⁷C(=O)C(=O)OR¹²⁴;

---R¹¹⁶ is a member independently selected from the group consisting of methyl and ethyl substituted by 0 to 5 bromo, chloro, or fluoro, wherein m may be 2 with respect to a single ring carbon atom to which R¹¹⁶ is attached;

---R¹¹⁷ is a member independently selected from the group consisting of OR¹²⁴; SR¹²⁴; SO₂NR¹²⁷R¹²⁴; NR¹²⁷R¹²⁴; NR¹²⁴C(=O)R¹¹⁹; NR¹²⁷C(Y)R¹²⁴; NR¹²⁷C(=O)OR¹²⁵; S(O)_nR₁₂ where n is 0, 1, or 2; OS(=O)₂R¹²²; OR¹²²; OC(=O)NR¹²³R¹²²; OC(=O)R¹²³; OC(=O)OR¹²³; O(CR¹²²R¹²³)_mOR¹²² where m is 0, 1, or 2; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷R¹²⁴; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; and thiadiazolyl; where the recited heterocyclic groups are substituted by 0 to 3 substituents where said substituent is R¹²⁴;

----R¹¹⁸ is a member independently selected from the group consisting of -NR¹²⁵;
 -NCR¹¹⁹R¹²⁰(C₂-C₆) alkenyl; -NOR¹²⁴; -NOR¹²⁹; -NOCR¹¹⁹R¹²⁰(C₂-C₆) alkenyl;
 -NNR¹¹⁹R¹²⁴; -NNR¹¹⁹R¹²⁹; -NCN; -NNR¹¹⁹C(Y)NR¹¹⁹R¹²⁴; -C(CN)₂; -CR¹²⁴CN;
 -CR¹²⁴C(=O)OR¹¹⁹; -CR¹²⁴C(=O)NR¹¹⁹R¹²⁴; -C(CN)NO₂; -C(CN)C(=O)O(C₁-C₄) alkyl;
 -C(CN)OC(=O)O(C₁-C₄) alkyl; -C(CN)(C₁-C₄) alkyl; -C(CN)C(=O)NR¹¹⁹R¹²⁴; 2-(1,3-
 dithiane), 2-(1,3-dithiolane), dimethylthio ketal, diethylthio ketal, 2-(1,3-dioxolane), 2-(1,3-
 dioxane), 2-(1,3-oxathiolane); dimethyl ketal and diethyl ketal;

----R¹¹⁹ and R¹²⁰ are each a member independently selected from the group consisting of
 hydrogen and (C₁-C₄) alkyl substituted by 0 to 3 fluorine atoms;

----R¹²¹ is a member independently selected from the group consisting of fluoro and R¹²⁰;

----R¹²² is a member independently selected from the group consisting of (C₁-C₆) alkyl;
 (C₂-C₃) alkenyl; (C₃-C₇) cycloalkyl; (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; (C₆-C₁₀) aryl; and
 (C₃-C₉) heterocyclyl; where said aryl and heterocyclyl are as defined under R above; and
 where said R¹²² groups are substituted with 0 to 3 substituents independently selected from
 the group consisting essentially of methyl; ethyl; mono-, di-, and tri-fluoromethyl; and
 bromo, chloro, or fluoro;

----R¹²³ is a member independently selected from the group consisting of hydrogen and R¹²²;

----R¹²⁴ is a member independently selected from the group consisting of hydrogen and R¹²⁵; or
 when R¹²⁴ and R¹²⁷ appear together as NR¹²⁷R¹²⁴ then R¹²⁷ and R¹²⁴ may be taken together
 with the nitrogen to which they are attached to form a 5- to 7-membered ring optionally
 containing one additional heteroatom selected from O, N and S;

----R¹²⁵ is a member independently selected from the group consisting of (C₁-C₆) alkyl and -(CR¹¹⁹R¹²⁰)_nR¹²⁶, where n is 0, 1, or 2 and R¹²⁶ and said (C₁-C₆) alkyl are substituted by 0 to 3 substituents where each said substituent is a member independently selected from the group consisting of bromo, chloro, or fluoro; nitro; cyano; NR¹²⁰R¹²⁷; C(=O)R¹¹⁹; OR¹¹⁹; C(=O)NR¹²⁰R¹²⁷; OC(=O)NR¹²⁰R¹²⁷; NR¹²⁷C(=O)NR¹²⁷R¹²⁰; NR¹²⁷C(=O)R¹²⁰; NR₁₇C(=O)O(C₁-C₄) alkyl; C(NR¹²⁷)NR¹²⁷R¹²⁰; C(NCN)NR¹²⁷R¹²⁰; C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)NR¹²⁷R¹²⁰; NR¹²⁷S(=O)₂(C₁-C₄) alkyl; S(O)_n(C₁-C₄) alkyl; where n is 0, 1, or 2; NR¹²⁷C(=O)C(=O)NR¹²⁷R¹²⁰; NR¹²⁷C(=O)C(=O)R¹²⁷; thiazolyl; imidazolyl; oxazolyl; pyrazolyl; triazolyl; tetrazolyl; and (C₁-C₂) alkyl substituted with 0 to 3 fluorine atoms;

----R¹²⁶ is a member independently selected from the group consisting of (C₃-C₇) cycloalkyl; pyridyl; pyrimidyl; pyrazolyl; imidazolyl; triazolyl; pyrrolyl; piperazinyl; piperidinyl; morpholinyl; furanyl; thienyl; thiazolyl; quinolinyl; naphthyl; and phenyl;

----R¹²⁷ is a member independently selected from the group consisting of OR¹¹⁹ and R¹²⁰;

----R¹²⁸ is a member independently selected from the group consisting of H; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰SR¹²⁴; CR¹¹⁹R¹²⁰S(O)_nR¹²⁵, where n is 0, 1, or 2; CR¹¹⁹R¹²⁰NR¹²⁴R¹²⁷; CR¹¹⁹R¹²⁰NR¹²⁷S(=O)₂R¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)OR¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(CR₉NO₂)S(C₁-C₄) alkyl; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl;

thiadiazolyl; wherein said recited heterocyclic groups are substituted by 0 to 3 substituents where each said substituent is independently selected from the group consisting essentially of R¹²⁴;

---R¹²⁹ is a member independently selected from the group consisting of -C(=O)R¹²;

-C(=O)NR¹¹⁹R¹²⁴; -S(=O)₂R¹²⁵; and -S(=O)₂NR¹¹⁹R¹²⁴;

---Y is O or S; and,

---Z is O; NR¹²⁷; NCN; C(-CN)₂; CR¹¹⁹CN; CR¹¹⁹NO₂; CR¹¹⁹C(=O)OR¹¹⁹;

CR¹¹⁹C(=O)NR¹¹⁹R¹²⁰; C(-CN)C(=O)O(C₁-C₄) alkyl; and C(-CN)C(=O)NR¹¹⁹R¹²⁰;

- or, said substituents defining R^{2_a} and R^{2_b} comprise: -

--(- II -)

--a member selected from the group consisting of R²²⁹;

-C(=O)NR²²²(CHR²²²)_mC(=O)NR²²²O(CH₂)_q(C₆-C₁₀) aryl);

-C(=NR²⁴²)NH(CH₂)_p(C₆-C₁₀) aryl; -C(=O)NR²¹⁸(CHR²²²)_mC(=O)NR²²²(CH₂)_pOR²²²;

-C(=O)NR²²²(CHR²²²)_mS(C₁-C₄) alkyl; -C[=NOC(=O)R²³⁵]R²³⁶;

-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹SO₂(CH₂)_pA;


-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹P(=O)(OR²²²)C(=O)(C₁-C₄) alkyl;

-CR²²⁷R²³⁸CHR²³⁸NR²¹⁹P(=O)[(C₁-C₄) alkoxy]₂, -Z³-R²¹⁷; and

-(CR²²⁷R²²⁸)_mNR²¹⁹(C(O))_qR²²⁰ wherein p is 0, 1, or 2; m is an integer of 1, 2, 3, 4, 5, or 6;

and q is an integer of 1 or 2;

- or, said substituents defining R_a^2 and R_b^2 comprise a moiety of partial Formulas (2.0.0) through (2.0.8), inclusive: -



---wherein in said partial Formulas (2.0.0)-(2.0.8), the structures of partial Formulas (2.0.5) and (2.0.6) are attached to the nucleus of Formula (IA) or (IB) at carbons 5, 6, or 7 of said partial Formulas (2.0.5) and (2.0.6); the dashed line in partial Formulas (2.0.2) and (2.0.3) indicates a single bond or double bond, except that R^{216} is absent in partial Formulas (2.0.2) and (2.0.3) where said dashed line indicates a double bond; n is 0 or an integer of 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and m is 0 or 1;

--- R^{213} is a member independently selected from the group consisting of $-C(=O)N(CH_3)(OCH_3)$ and $-(CH_2)_nOH$, where n is 0, 1, 2, 3, or 4;

--- R^{214} and R^{215} are independently selected from the group consisting of H; ethyl; $-CO_2H$; and $-C(=O)NHOH$;

---R²¹⁶ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₆) alkyl; (C₁-C₆) alkoxy; -OC(=O)(C₁-C₆) alkyl and -OC(=O)(C₆-C₁₀) aryl;

----R²¹⁷ is a member independently selected from the group consisting of (C₆-C₁₀) aryl and a 5- to 10-membered heterocyclyl, wherein said R²¹⁷ groups are substituted by 0 to 3 substituents independently selected from the group consisting of bromo, chloro, or fluoro; trifluoromethyl; cyano; nitro; -CO₂R²²², (C₁-C₄) alkoxy; -OC(=O)(C₁-C₄) alkyl; -NR²²²C(=O)(C₁-C₄) alkyl; -C(=O)NH₂; -C(=O)NHOH; -C(=O)O(C₁-C₄) alkyl; (C₁-C₄) alkyl; -S(O)_nR²²² where n is 0, 1, or 2; benzoyl; -NR²²²R²²³, -OR²²², (C₁-C₆) alkanoyl; -Y¹-(C₆-C₁₀) aryl; -C(=O)O(C₆-C₁₀) aryl; -NH(C₆-C₁₀) aryl; -C(=O)NH(C₆-C₁₀) aryl; -C(=O)NR²²²O(CH₂)_n(C₆-C₁₀) aryl, where n is 1, 2, or 3; and -SO₂NH(C₆-C₁₀) aryl;

----R²¹⁸ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; and -(CH₂)_n(C₆-C₁₀) aryl, where n is 0, 1, 2, 3, or 4;

----R²¹⁹ is a member independently selected from the group consisting of H; -OR²²²; -(CH₂)_mA; and -CH₂O(CH₂)_mA, where m is 0, 1, or 2;

----R²²⁰ is a member independently selected from the group consisting of (C₁-C₄) alkyl; -OR²²², -CR²²²R²²³OR²²²; -CR²²²R²²³NR²²²R²²³; -CR²²²(OR²²³)CR²²²R²²³OR²²²; 2,2-dimethyl-1,3-dioxolan-4-yl; -NR²²²C(=O)NR²²²R²²³, -S(CR²²²R²²³)_nCH₃ where n is 0, 1, 2, 3, 4, or 5; -NR²²²(CH₂)_q(pyridyl) where q is 0 or 1; -P(=O)[(C₁-C₄) alkoxy]₂; -NR²²²R²²³; -NR²²²OR²²³; -NR²²²NR²²³R²²¹, -NR²²²CH₂R²²⁴; -OCH₂NR²²²C(=O)R²²⁴; -OCH₂C(=O)NR²²⁵R²²⁶, -OCHR²²²OC(=O)(C₁-C₄) alkyl; -OCHR²²²C(=O)(C₁-C₃) alkoxy; -O(CH₂)_mR²²¹; and -NR²²²(CH₂)_mR²²¹ where m is 0, 1, or 2;

----R²²¹ is a member independently selected from the group consisting of H and A;

---R²²² and R²²³ are each a member independently selected from the group consisting of H and (C₁-C₄) alkyl;

----R²²⁴ is a member independently selected from the group consisting of methyl and phenyl;

----R²²⁵ is a member independently selected from the group consisting of H; methyl; ethyl; and -CH₂CH₂OH;

----R²²⁶ is a member independently selected from the group consisting of H; methyl; ethyl; -CH₂C(=O)NH₂; and -CH₂CH₂OH;

----R²²⁷ is each a member independently selected from the group consisting of H; hydroxy; cyano; halo; (C₁-C₃) alkyl; (C₁-C₃) alkoxy; -NR²²²R²²³; -C(=O)OR²²²; -C(=O)R²²²; -CH=CR²²²R²²³; -C≡CR²²²; -CH₂NR²²²R²²³; -CH₂OR²²²; -C(=O)NR²²²R²²³; -C(Y⁵)H; and -CH₂NR₁₂C(=O)C(=O)NR²²²R²²³; provided that when R²²⁷ is hydroxy then R²²⁸ is H or (C₁-C₄) alkyl;


----R²²⁸ is each a member independently selected from the group consisting of H; fluoro; cyano; and (C₁-C₄) alkyl; where said methyl is substituted by 0 to 3 substituents each comprising a fluorine atom; or

----R²²⁷ and R²²⁸ are taken together to form an oxo (=O) moiety;

---R²²⁹ is a member independently selected from the group consisting of phenyl; naphthyl; pyrrolyl; furanyl; thienyl; oxazolyl; pyridinyl; pyrimidinyl; pyridazinyl; quinolinyl; isoquinolinyl; 5,6,7,8-tetrahydroquinolinyl; and 5,6,7,8-tetrahydroisoquinolinyl, where said R²²⁹ groups, except said phenyl, are substituted by 0 to 3 substituents R²³³, and wherein said

phenyl R^{229} group is substituted by 0 to 3 substituents independently selected from the group consisting of R^{233} and R^{234} ;

--- R^{230} is a member independently selected from the group consisting of $-C(=O)R^{231}$;
 $-C(=O)C(=O)R^{231}$, $-C(=O)C(Y^2)C(=O)R^{231}$ and a moiety of partial Formula (2.0.9):



(2.0.9)

wherein:

---- R^{231} is a member independently selected from the group consisting of H; $-OR^{232}$; $-NHR^{232}$;
 $-NHOH$; $-NHNH_2$; $-(CH_2)_nY^3$ (phenyl) and $-(CH_2)_nY^3$ (pyridyl) where n is 0, 1, 2, 3, or 4;

----- R^{232} is a member independently selected from the group consisting of H; (C_1-C_8) alkyl;
 $-(CH_2)_nY^3$ (phenyl) and $-(CH_2)_nY^3$ (pyridyl) where n is 0, 1, 2, 3, or 4;

----- R^{233} is each a member independently selected from the group consisting of bromo, chloro,
or fluoro; (C_1-C_6) alkyl; (C_1-C_7) alkoxy; (C_2-C_6) alkylenedioxy; trifluoromethyl;
 $-NR^{222}R^{223}$; nitro; $-C(NR^{222})NR^{222}R^{223}$; $-C(=O)NR^{222}R^{223}C(=O)R^{222}$; $-C(NOR^{222})R^{223}$;
 $-C(NCN)NR^{222}R^{223}$; $-C(NCN)SR^{222}$; $-(CH_2)_m(CN)$ where m is 0, 1, 2, or 3; hydroxy;
 $-C(=O)R^{222}$; $-C(=O)NR^{222}OR^{223}$; $-C(=O)NR^{222}NR^{222}R^{223}$; $-OC(=O)NR^{222}R^{223}$;
 $-NR^{222}C(=O)R^{222}$; $-C(=O)C(=O)NR^{222}R^{223}$; $-CO_2R^{222}$; $-SO_2R^{222}$; $-SO_2NR^{222}R^{223}$;
 $-C(=O)NR^{222}R^{223}$; $-NR^{222}SO_2R^{223}$; and $-NR^{222}C(=O)NR^{222}R^{223}$;

----- R^{234} is each a member independently selected from the group consisting of imidazolyl;
pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; thiazolyl;

oxazolidinyl; thiazolidinyl; and imidazolidinyl, where each of said foregoing R^{234} substituents is substituted by 0 to 3 substituents R^{233} ;

----- R^{235} is a member independently selected from the group consisting of $-NR^{222}R^{223}$; $-NH(C_6-C_{10})$ aryl; (C_1-C_6) alkoxy; and (C_6-C_{10}) aryloxy;

----- R^{236} is a member independently selected from the group consisting of H; (C_1-C_6) alkyl and $-(CH_2)_mY^4$ (phenyl) where m is 0, 1, 2, 3, or 4 and the phenyl moiety of said $-(CH_2)_mY^4$ (phenyl) R^{236} group is substituted by 0 to 3 substituents independently selected from the group consisting of bromo, chloro, and fluoro; $-OR^{222}$; (C_1-C_6) alkanoyloxy; (C_6-C_{10}) aryloxy; $-NR^{222}R^{223}$; $-NH(C_6-C_{10})$ aryl; and $-NHC(=O)(C_1-C_4)$ alkyl;

----- R^{237} is each a member independently selected from the group consisting of bromo; chloro; fluoro; $-(CH_2)_pNR^{222}C(=O)CH_3$ where p is an integer of 1, 2, 3, or 4, and; (C_1-C_4) alkoxy; nitro; cyano; $-NR^{222}R^{223}$; $-CO_2R^{222}$; $-OR^{222}$; $-C(Y^1)NR^{222}R^{223}$; $-NR^{222}C(NCN)S(C_1-C_3)$ alkyl; $-NR^{222}C(NCN)NR^{222}R^{223}$; $-NR^{222}C(=O)NR^{222}R^{223}$; $-NR^{222}C(=O)C(=O)NR^{222}R^{223}$; $-C(=NR^{222})NR^{222}R^{223}$; $-S(O)_mCH_3$ where m is 0, 1, or 2; $-C(=NR^{222})S(C_1-C_3)$ alkyl; $-NR^{222}SO_2(C_1-C_3)$ alkyl; $-OC(=O)R^{222}$; $-OC(=O)NR^{222}R^{223}$; $-NR^{222}SO_2CF_3$; $-NR^{222}C(=O)C(=O)OR^{222}$; $-NR^{222}C(=O)R^{222}$; $-NR^{222}C(=O)OR^{222}$; imidazolyl; thiazolyl; oxazolyl; pyrazolyl; triazolyl; and tetrazolyl;

----- R^{238} is a member independently selected from the group consisting of H; fluoro; cyano; and (C_1-C_2) alkyl, where said alkyl is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; $-C(=O)NR^{222}R^{223}$; and $-C(=O)OR^{222}$;

-----R²³⁹ is a member independently selected from the group consisting of phenyl substituted by 0 to 2 substituents independently selected from the group consisting of -NR²²²R²²³, nitro, halo, -OR²²², -NHR²⁴⁰, -NR²⁴⁰R²⁴¹, and -C(=O)OR²²²;

-----R²⁴⁰ and R²⁴¹ are each a member independently selected from the group consisting of (C₁-C₈) alkyl and (C₂-C₈) alkenyl;

-----R²⁴² is pyridin-4-yl substituted by 0 to 2 substituents independently selected from the group consisting of bromo, chloro, or fluoro; and (C₁-C₄) alkyl;

-----A is each a member independently selected from the group consisting of (C₁-C₆) alkyl; pyridyl; morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; triazolyl; quinolinyl; phenyl; and naphthyl; wherein the foregoing A groups are substituted with 0 to 3 substituents R²³⁷; or A is -(CH₂)_qS(C₁-C₄) alkyl wherein q is an integer of 1 or 2;

-----W is a member independently selected from the group consisting of O; NOH; NNH₂; NOC(=O)CH₃; and NNHC(=O)CH₃;

-----Y¹ is O or S;

-----Y² is O, NOH or H₂;

-----Y³ is a bond or -CH=CH-;

-----Y⁴ is a bond, O, S, or -NH-;

-----Y⁵ is a member independently selected from the group consisting of O; NR²²²; NOR²²²; NCN; C(CN)₂; CR²²²NO₂; CR²²²C(=O)OR²²²; CR²²²C(=O)NR²²²R²²³; C(CN)NO₂; C(CN)C(=O)OR²²²; and C(CN)C(=O)NR²²²R²²³; and

-----Z³ is a member independently selected from the group consisting of -NR²²²-; -(CH₂)_m-; -

CH₂C(=O)NH-; -NHCH₂C(=O)-; -CH₂C(Y¹)CH₂-; -CH=CH-; -C≡C-; -CH(Y¹H)-;

-C(Y¹)-; -CH₂C(Y¹)-; -C(Y¹)CH₂-; -C(Y₁)C(Y₁)-; -CH₂NR²²²-; -CH₂-Y¹-;

-C(Y¹)NR²¹⁸(CHR²²²)_n-; -NR²¹⁸C(Y¹)(CHR²²²)_n-; -NHCH₂-; -Y¹-CH₂-; -SOCH₂-;

-CH₂SO-; -SO₂CH₂-; -CH₂SO₂-; -OC(Y¹)-; -N=N-; -NHSO₂-; -SO₂NH-; -C(Y¹)C(Y¹)NH-;

-NHC(=O)O-; -OC(=O)NH-; and -NHC(=O)NH-; wherein for said Z₃ moieties n is 0, 1, 2,

3, or 4; and m is 1, 2, or 3;

- or said substituents defining R²_a and R²_b comprise: -

--(- III -)

--a member independently selected from the group consisting of 2-oxo-4-pyrrolyl; pyrazolyl; 2-


oxo-3,4-dihydro-5-pyrimidyl; 2-oxo-3,4-dihydro-4-pyrimidyl; 2-oxo-tetrahydro-4-pyrimidyl;

2-oxo-tetrahydro-5-pyrimidyl; 2-oxo-4-pyrimidyl; and 2-oxo-5-pyrimidyl; wherein each of said


R²_a and R²_b groups is substituted by 0, 1, 2, 3, or 4 R²³⁶ groups;

- or, said substituents defining R²_a and R²_b comprise a


moiety of partial Formulas (3.0.0) through (3.0.19), inclusive: -




(3.0.0)




(3.0.1)




(3.0.2)




(3.0.3)




(3.0.4)




(3.0.5)




(3.0.6)




(3.0.7)




(3.0.8)




(3.0.9)




(3.10)




(3.11)




(3.12)




(3.13)




(3.14)




(3.15)




(3.16)



(3.17)



(3.18)



(3.19)

----wherein in said partial Formulas (3.0.0) through (3.0.19), q is 0 or 1 in partial Formula

(3.0.1); n is 0, 1, or 2 in partial Formula (3.0.2); and the dashed lines appearing in formulas (3.0.1), (3.0.3), (3.0.6), (3.0.7), (3.0.8), (3.0.9) and (3.0.14) represent a double bond or a single bond;

-----X¹ is O or S;

-----X² in formula (3.0.10) and where the dashed line in formula (3.0.9) represents a double bond, is a member independently selected from the group consisting of CR³³⁵; CR³³⁶; CR³⁴⁶, and COC(=O)NR³³⁹R³⁴²; or, where the dashed line in formula (3.0.9) represents a single

bond, X^2 is a member independently selected from the group consisting of $CR^{335}R^{339}$, $CR^{336}R^{339}$; and $CR^{346}R^{339}$;

----- X^3 is a member independently selected from the group consisting of $C(=Z^3)$; $C(S)$; and $CR^{336}R^{340}$;

----- X^4 is a member independently selected from the group consisting of $-(CH_2)_m$ - where m is 0, 1, or 2;

----- X^5 is a bond or $-CH_2-$;

----- X^6 is a member independently selected from the group consisting of $-CH_2-$ and $-C(=O)-$;

----- R^{333} is a member independently selected from the group consisting of H; hydroxy; (C_1-C_4) alkoxy; $-CHR^{337}(O)_q(CH_2)_mA$ where q is 0 or 1, and m is 0, 1, or 2;

----- R^{334} is a member independently selected from the group consisting of H; hydroxy; (C_1-C_4) alkyl; (C_1-C_2) alkoxy; $-OC(=O)CH_3$; (C_2-C_3) alkenyl; and phenyl (C_1-C_2) alkyl-;

----- R^{335} is a member independently selected from the group consisting of H; hydroxy; $-(CH_2)_mA$ where m is 0, 1, or 2; (C_1-C_6) alkyl; and (C_2-C_3) alkanoyl; where said alkyl group is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; nitro; $-NR^{340}R^{341}$; $-CO_2R^{340}$; $-OR^{340}$; $-OC(=O)R^{340}$; $-C(=O)R^{340}$; cyano; $-C(=Y)NR^{340}R^{341}$; $-NR^{340}C(=Y)NR^{340}R^{341}$; $-NR^{340}C(=Y)R^{340}$; $-NR^{340}C(=O)OR^{340}$; $-C(NR^{340})NR^{340}R^{341}$; $-C(NCN)NR^{340}R^{341}$; $-C(NCN)SR^{340}$; $-NR^{340}SO_2R^{340}$; $-S(O)_mR^{340}$, where m is 0, 1, or 2; $-NR^{340}SO_2CF_3$; $-NR^{340}C(=O)C(=O)NR^{340}R^{341}$; $-NR^{340}C(=O)C(=O)OR^{340}$; imidazolyl; and 1-(NHR^{340})-2-imidazolyl;

----- R^{336} is each a member independently selected from the group consisting of H; bromo; chloro; fluoro; cyano; R^{343} ; cyclopropyl substituted by 0 or 1 substituent independently

selected from the group consisting of R^{339} ; $-OR^{340}$; $-CH_2OR^{340}$; $-NR^{340}R^{342}$; $-CH_2NR^{340}R^{342}$; $-C(=O)OR^{340}$; $-C(=O)NR^{340}R^{342}$; $-CH=CR^{339}R^{339}$; $-C\equiv CR^{339}$; and $-C(=Z^3)H$;

----- R^{337} is a member independently selected from the group consisting of H; $-C(=O)R^{338}$; imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl;

----- R^{338} is each a member independently selected from the group consisting of $-OR^{340}$; $-NR^{340}R^{342}$; and $-R^{343}$;

----- R^{339} is each a member independently selected from the group consisting of H; bromo; chloro; fluoro; and (C_1-C_4) alkyl substituted by 0 to 3 fluorine atoms;

----- R^{340} and R^{341} are each a member independently selected from the group consisting of hydrogen and (C_1-C_4) alkyl;

----- R^{342} is each a member independently selected from the group consisting of $-OR^{340}$ and $-R^{340}$;

----- R^{343} is (C_1-C_4) alkyl;

----- R^{344} is each a member independently selected from the group consisting of bromo; chloro; fluoro; nitro; cyano; $-NR^{340}R^{346}$; $-NR^{346}R^{342}$; $-C(=Z^3)R^{338}$; $-S(O)_mR^{343}$ where m is 0, 1, or 2; $-OR^{342}$; $-OC(=O)NR^{340}R^{342}$; $-C(NR^{342})NR^{340}R^{342}$; $-C(NR^{340})SR^{343}$; $-OC(=O)CH_3$; $-C(NCN)NR^{340}R^{342}$; $-C(S)NR^{340}R^{342}$; $-NR^{342}C(=O)R^{347}$; $-C(=O)R^{347}$; oxazolyl; imidazolyl; thiazolyl; pyrazolyl; triazolyl; and tetrazolyl;

----- R^{345} is each a member independently selected from the group consisting of hydrogen and (C_1-C_4) alkyl substituted by 0, 1, 2 or 3 fluorine atoms;

- R³⁴⁶ is each a member independently selected from the group consisting of H; -R³⁴³;
 -C(=O)R³⁴³; -C(=O)C(=O)R³³⁸; -C(=O)NR³⁴⁰R³⁴²; -S(O)_mR³⁴³ where m is 0, 1, or 2;
 -C(NCN)SR³⁴³; -C(NCN)R³⁴³; -C(NR³⁴²)R³⁴³; -C(NR³⁴²)SR³⁴³; and -C(NCN)NR³⁴⁰R³⁴²;
- R³⁴⁷ is each a member independently selected from the group consisting of -R³⁴³;
 -C(=O)R³⁴³; oxazolidinyl; oxazolyl; thiazolyl; pyrazolyl; triazolyl; tetrazolyl; imidazolyl;
 imidazolidinyl; thiazolidinyl; isoxazolyl; oxadiazolyl; thiadiazolyl; morpholinyl;
 piperidinyl; piperazinyl; and pyrrolyl; where each of said recited R³⁴⁷ heterocyclic groups
 is substituted by 0 to 2 (C₁-C₂) alkyl groups;
- R³⁴⁸ is each a member independently selected from the group consisting of H; (C₁-C₅) alkyl;
 (C₂-C₅) alkenyl; benzyl; and phenethyl;
- R³⁴⁹ is a member independently selected from the group consisting of H; (C₁-C₅) alkyl;
 (C₁-C₅) alkanoyl; and benzoyl;
- R³⁵⁰ is a member independently selected from the group consisting of H; (C₁-C₄) alkyl;
 carboxy; aminocarbonyl; (C₁-C₆) alkyl substituted by 0 or 1 carboxy,
 -(CH₂)_mC(=O)(C₁-C₆) alkoxy; or -(CH₂)_m(C₆-C₁₀) aryl; where m is 0, 1, or 2;
- R³⁵¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl;
 -C(=Y)R³⁵²; -C(=Y)NH₂; -C(=O)OR³⁵²; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4,
 or 5; and X⁷ is a bond or -CH=CH-; and where said pyridyl moiety is substituted by 0 or 1
 bromo, chloro, or fluoro;
- R³⁵² is a member independently selected from the group consisting of (C₁-C₆) alkyl
 (C₃-C₈) cycloalkyl; -(CH₂)_m(C₆-C₁₀) aryl; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4, or

5; and X^7 is a bond or $-\text{CH}=\text{CH}-$; and where said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;

----- R^{353} is a member independently selected from the group consisting of H; $-R^{345}$;
(C_1 - C_3) alkyl substituted by 0 or 1 hydroxy, or (C_1 - C_3) alkoxy(C_1 - C_3) alkyl;

----- R^{354} is a member independently selected from the group consisting of H; $-R^{345}$; carboxy;
(C_1 - C_3) alkoxy(C_1 - C_3) alkyl-; (C_3 - C_7) cycloalkyl; and (C_1 - C_5) alkyl substituted by 0 or 1
 $-\text{NR}^{340}\text{R}^{341}$; or

----- R^{353} and R^{354} are taken together to form $-\text{CH}_2\text{OCH}_2\text{OCH}_2-$;

----- R^{355} is a member independently selected from the group consisting of H; hydroxy;
(C_1 - C_4) alkyl substituted by 0 or 1 substituent selected from the group consisting of
hydroxy; $-\text{C}(=\text{O})\text{R}^{340}$; $-\text{NR}^{340}\text{R}^{341}$; $-(\text{CH}_2)_m\text{NHC}(=\text{O})\text{R}^{340}$; $-(\text{CH}_2)_m\text{NHC}(=\text{O})\text{R}^{343}$;
 $-(\text{CH}_2)_m\text{CO}_2\text{R}^{340}$; $-(\text{CH}_2)_m\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$; $-(\text{CH}_2)_m\text{C}(=\text{O})\text{N}(\text{OH})\text{R}^{340}$;
 $-(\text{CH}_2)_m\text{SO}_2\text{NR}^{340}\text{R}^{341}$; $-(\text{CH}_2)_m\text{PO}_3\text{H}_2$; $-(\text{CH}_2)_m\text{SO}_2\text{NHC}(=\text{O})\text{R}^{343}$; and
 $-(\text{CH}_2)_m\text{SO}_2\text{NHC}(=\text{O})(\text{phenyl})$, where m is 0, 1, 2, 3, or 4;

----- R^{356} is a member independently selected from the group consisting of H; (C_1 - C_4) alkyl;
phenyl; $-\text{NR}^{340}\text{R}^{341}$; and $-\text{NR}^{340}(\text{C}_1\text{-C}_4)$ alkanoyl;

----- R^{357} is a member independently selected from the group consisting of $-R^{340}$; $-\text{CH}_2\text{CO}_2\text{R}^{343}$;
and $-\text{CH}_2\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$;

----- R^{358} is a member independently selected from the group consisting of $-\text{C}(=\text{O})\text{R}^{340}$;
 $-\text{C}(=\text{O})(\text{C}_6\text{-C}_{10})$ aryl; $-\text{C}(=\text{O})(\text{C}_3\text{-C}_9)$ heteroaryl; $-\text{CO}_2\text{R}^{340}$; $-\text{C}(=\text{O})\text{NR}^{340}\text{R}^{341}$; cyano; nitro;
 $-\text{CH}_2\text{OH}$; $-\text{NR}^{340}\text{SO}_2\text{R}^{340}$; $-\text{NHSO}_2(\text{C}_6\text{-C}_{10})$ aryl; $-\text{NHCO}_2(\text{C}_1\text{-C}_4)$ alkyl; $-\text{NR}^{340}\text{C}(=\text{O})\text{R}^{340}$;
and $-\text{NHCO}_2(\text{C}_6\text{-C}_{10})$ aryl;

-----R³⁵⁹ is a member independently selected from the group consisting of -R³⁴⁵; cyano; carboxy; formyl; -C(=O)R³⁴⁰; and (C₁-C₄) alkanoyl;

-----R³⁶⁰ is a member independently selected from the group consisting of cyano; -NR³⁴⁰R³⁴¹; -SO₂(C₁-C₄) alkyl; -SO₂(C₆-C₁₀) aryl; -C(=O)R³⁴⁰; -C(=O)(C₆-C₁₀) aryl; -C(=O)(C₃-C₉) heteroaryl; -C(=O)NR³⁴⁰R³⁴¹; and -CO₂R³⁴⁰;

-----R³⁶¹ and R³⁶² are each a member independently selected from the group consisting of H; cyano; nitro; -CO₂R³⁴⁰; -C(=O)NR³⁴⁰R³⁴¹; -CH₂OH; -C(=O)R³⁴⁰; -NHCO₂R³⁴⁰; and -NHSO₂R³⁴⁰;

-----A is a member independently selected from the group consisting of pyridyl; morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; phenyl; and naphthyl; where each of said A groups is substituted by 0 to 2 substituents R³⁴⁴ or by 1 substituent R³⁴⁵;


-----Z³ is a member independently selected from the group consisting of O; -NR³⁴²; NOR³⁴⁰; N(CN); C(CN)₂; CR³⁴⁰NO₂; CR³⁴⁰C(=O)OR³⁴³; CR³⁴⁰C(=O)NR³⁴⁰R³⁴¹; C(CN)NO₂; C(CN)C(=O)OR³⁴³; and C(CN)C(=O)NR³⁴⁰R³⁴¹; and,

-----Y is O or S;

- or said substituents defining R²_a and R²_b

comprise a moiety of partial Formula (4.0.0): -

--(- IV -)



(4.0.0)

---wherein the broken line indicates a single or double bond;

---X¹ is -CR⁴⁷²R⁴⁷³- where said broken line indicates a single bond; or -CR⁴⁷³- where said broken line indicates a double bond;

---X² is -CR⁴⁷⁵R⁴⁷⁷R⁴⁷⁸- or -C(=NOR⁴⁸¹)R⁴⁸²- where said broken line indicates a single bond; or -CR⁴⁷⁷R⁴⁷⁸ where said broken line indicates a double bond;

---R⁴⁷² is a member independently selected from the group consisting of H; hydroxy; bromo, chloro, or fluoro; and -OR⁴⁷⁹;

---R⁴⁷³ is each a member independently selected from the group consisting of cyano; cyanomethyl; benzyloxy; -R⁴⁷⁵; -CO₂R⁴⁷⁵; -CO₂(CH₂)_n(C₆-C₁₀) aryl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NR⁴⁷⁵(CH₂)_n(C₆-C₁₀) aryl; -(CH₂)_n(C₆-C₁₀) aryl; and -(CH₂)_n(5- to 10-membered heteroaryl); where n is 0, 1, 2, or 3; each R⁴⁷³ group is substituted by 0 to 3 substituents R⁴⁷⁴; and each R⁴⁷³ group is substituted by 0 or 1 substituent R⁴⁸⁰;

----R⁴⁷⁴ is each a member independently selected from the group consisting of bromo; chloro; fluoro; cyano; nitro; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; -OR⁴⁷⁵; (C₃-C₇) cycloalkoxy; -NR⁴⁷⁵R⁴⁷⁶; -NR⁴⁷⁵OR⁴⁷⁶; -S(O)_mR⁴⁷⁵ where m is 0, 1, or 2; -CO₂R⁴⁷⁵; -C(=O)R⁴⁷⁵; -SO₂NR⁴⁷⁵R⁴⁷⁶; -C(=O)NR⁴⁷⁵R⁴⁷⁶; -CR⁴⁷⁵R⁴⁷⁶SO₂NR⁴⁷⁵R⁴⁷⁶; -CR⁴⁷⁵R⁴⁷⁶C(=O)NR⁴⁷⁵R⁴⁷⁶; -NHSO₂R⁴⁷⁵; -NHSO₂NR⁴⁷⁵R⁴⁷⁶; -NHC(=O)NR⁴⁷⁵R⁴⁷⁶; -NHC(=O)(C₁-C₆) alkyl; and -NHC(=O)O(C₁-C₆) alkyl;

----R⁴⁷⁵ and R⁴⁷⁶ are each a member independently selected from the group consisting of H; and (C₁-C₆) alkyl;

----R⁴⁷⁷ is a member independently selected from the group consisting of -R⁴⁷³; 2-oxo-pyridyl; 3-oxo-pyridyl; 4-oxo-pyridyl; 2-oxo-pyrrolyl; 4-oxo-thiazolyl; 4-oxo-piperidyl; 2-oxo-quinolyl; 4-oxo-quinolyl; 1-oxo-isoquinolyl; 4-oxo-oxazolyl; 5-oxo-pyrazolyl; 5-oxo-isoxazolyl; and 4-oxo-isoxazolyl; where each of said R⁴⁷⁷ groups is substituted by 0 to 3 substituents R⁴⁷⁴;

----R⁴⁷⁸ is a member independently selected from the group consisting of -R⁴⁷⁵; cyano; -(CH₂)_p(C₆-C₁₀) aryl; and -(CH₂)_p(5- to 10-membered heteroaryl); where p is 1, 2, or 3; and where each said R⁴⁷⁸ group is substituted by 0 to 3 substituents R⁴⁷⁴;

----R⁴⁷⁹ is a member independently selected from the group consisting of formyl; carbamoyl; thiocarbamyl; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₁-C₄) alkoxy(C₁-C₄) alkyl-; and (C₁-C₆) alkanoyl; where said alkyl moieties of each of said R⁴⁷⁹ groups is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; hydroxy; and (C₁-C₄) alkoxy;

----R⁴⁸⁰ is a member independently selected from the group consisting of cyclobutyl; cyclopentyl; cyclohexyl; 2-cyclobuten-1-yl; 2-cyclopenten-1-yl; 3-cyclopenten-1-yl; 2,4-cyclopentadien-1-yl; 3,5-cyclohexadien-1-yl; pyrrolyl; pyrrolidinyl; dioxolanyl; imidazolyl; oxazolyl; imidazolidinyl; pyrazolyl; pyrazolidinyl; pyranyl; piperidinyl; 1,4-dioxanyl; morpholinyl; 1,4-dithianyl; thiomorpholinyl; piperazinyl; 1,3,5-trithianyl; oxazinyl; isoxazinyl; oxathiazinyl; and oxadiazinyl; where each of said R⁴⁸⁰ groups is substituted by 0 to 2 (C₁-C₂) alkyl;


----R⁴⁸¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₂-C₆) alkynyl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NH(C₆-C₁₀) aryl; -C(Y)(C₁-C₆) alkoxy; -C(Y)(C₆-C₁₀) aryloxy; and -C(Y)(C₁-C₆) alkyl;

----R⁴⁸² is a member independently selected from the group consisting of phenyl and pyridinyl;
 where each of said R⁴⁸² groups is substituted by 0 to 3 substituents independently selected
 from the group consisting of bromo; chloro; fluoro; (C₁-C₄) alkyl; hydroxy; (C₁-C₄) alkoxy;
 -NR⁴⁷⁵R⁴⁷⁶; and -S(O)_mR⁴⁷⁵, where m is 0, 1, or 2; and,


-----Y is O or S;

- or , said substituents defining R²_a and R²_b comprise a
 moiety of partial Formulas (5.0.0) through (5.0.13), inclusive: -


--(- V -)




(5.0.0)




(5.0.1)




(5.0.2)




(5.0.3)




(5.0.4)




(5.0.5)




(5.0.6)




(5.0.7)




(5.0.8)




(5.0.9)




(5.0.10)



(5.0.11)




(5.0.12)




(5.0.13)

44. (New): A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with an amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, which is therapeutically sufficient to treat or prevent stasis in all or any part or parts of the stomach of a patient in need of such treatment, wherein said stasis results from hypomotility in said stomach or part thereof, and said amount is sufficient to restore normal motility to said patient; wherein said inhibitor of phosphodiesterase-4 (PDE4) comprises a compound of Formula (IA) or (IB);



(IA)



(IB)

and to pharmaceutically acceptable salts thereof, wherein:

-R is a member independently selected from the group consisting of hydrogen, (C₁-C₉) alkyl; -(CH₂)_n(C₃-C₁₀) cycloalkyl wherein n is 0, 1, or 2; (C₁-C₆) alkoxy(C₁-C₆) alkyl; (C₂-C₆) alkenyl; -(CH₂)_n(C₃-C₉) heterocyclyl wherein n is 0, 1, or 2; and -(Z¹)_b(Z²)_c(C₆-C₁₀) aryl wherein b and c independently 0 or 1, Z¹ is (C₁-C₆) alkylene or (C₂-C₆) alkenylene, and Z² is O, S, SO₂, or NR¹¹⁹; and further wherein said heterocyclyl is a member independently selected from the group consisting of acridinyl; benzimidazolyl; benzodioxolane; 1,3-benzodioxol-5-yl; benzo[b]furanyl; benzo[b]thiophenyl; benzoxazolyl; benzthiazolyl; carbazolyl; cinnolinyl; 2,3-dihydrobenzofuranyl; 1,3-dioxane; 1,3-dioxolane; 1,3-dithiane; 1,3-dithiolane; furanyl; imidazolidinyl; imidazolyl; 1H-indazolyl; indolinyl; indolyl; 3H-indolyl; isoindolyl; isoquinolinyl; isothiazolyl; isoxazolyl; morpholinyl; 1,8-naphthyridinyl; oxadiazolyl; 1,3-oxathiolane; oxazolidinyl; oxazolyl; oxiranyl; parathiazinyl; phenazinyl; phenothiazinyl; phenoxazinyl; phthalazinyl; piperazinyl; piperidinyl; pteridinyl; pyranyl; pyrazinyl; pyrazolidinyl; pyrazolyl; pyrazolo[1,5-c]triazinyl; pyrazolyl; pyridazinyl; pyridyl; pyrimidinyl; pyrimidyl; pyrrolyl; pyrrolidinyl; purinyl; quinazolinyl; quinolinyl; 4H-quinoliziny; quinoxalinyl; tetrazolidinyl; tetrazolyl; thiadiazolyl; thiazolidinyl; thiazolyl; thienyl; thiomorpholinyl; triazinyl; and triazolyl; wherein said aryl is a carbocyclic moiety which is a member independently selected from the group consisting of benzyl; *cis*- and *trans*-decahydronaphthalenyl; 2,3-1H-dihydroindenyl


(indanyl); indenyl; 1-naphthalenyl; 2-naphthalenyl; phenyl; and 1,2,3,4-tetrahydronaphthalenyl; wherein said alkyl, alkenyl, alkoxyalkyl, heterocyclyl, and aryl moieties defining said R groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of bromo, chloro, or fluoro; hydroxy; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; (C₁-C₅) alkoxy; (C₃-C₆) cycloalkoxy; mono-, di-, and tri-fluoromethyl; nitro; -C(=O)OR¹¹⁹, -C(=O)NR¹¹⁹R¹²⁰, -NR¹¹⁹R¹²⁰ and -S(=O)₂NR¹¹⁹R¹²⁰;

-R¹ is a member independently selected from the group consisting of hydrogen; (C₁-C₉) alkyl; (C₂-C₃) alkenyl; phenyl; (C₃-C₇) cycloalkyl; and (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; wherein said alkyl, alkenyl and phenyl moieties defining said R¹ groups are substituted by 0 to 3 substituents where each said substituent comprises a member independently selected from the group consisting of methyl; ethyl; mono-, di-, and tri-fluoromethyl; bromo; chloro; and fluoro; and

-R²_a and R²_b are independently selected from the group consisting of hydrogen and hereinafter recited substituents, provided that one, but not both of R²_a and R²_b must be independently selected as hydrogen, wherein said substituents comprise moieties of the groups (- I -) through (- V -):

--(- I -)

--a moiety of partial Formulas (1.0.0), (1.0.1), (1.0.2), and (1.0.3):



---wherein the dashed lines in partial Formulas (1.0.0) and (1.0.1) independently and optionally represent a single or double bond, provided that in formula (1.0.0) both dashed lines cannot both represent double bonds at the same time;

---m is 0, 1, 2, 3, or 4, and when 2, may apply to a single carbon atom on the ring;

---R¹¹³ is a member selected from the group consisting of H; bromo; chloro; fluoro; cyano; (C₂-C₄) alkynyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting of phenyl, pyridyl and pyrimidinyl; (C₁-C₄) alkyl substituted by 0 to 6 bromo, chloro, or fluoro; -CH₂NHC(=O)C(=O)NH₂; cyclopropyl substituted by 0 or 1 substituent where said substituent is a member selected from the group consisting of R¹²¹; R¹²⁷; CH₂OR¹¹⁹; NR¹¹⁹R¹²⁰; CH₂NR¹¹⁹R¹²⁰; C(=O)OR¹¹⁹; C(=O)NR¹¹⁹R¹²⁰; C≡CR₁₁; C(Z)H; and -CH=CR¹²¹R¹²¹; provided that R¹¹³ is H in Formula (1.0.0) when the dashed line for the ring carbon of R¹¹³ attachment represents a double bond;

---R¹¹⁴ is a member selected from the group consisting of H; R¹¹⁶; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰;

$C(NCN)NR^{127}R^{124}$, $C(NCN)S(C_1-C_4)$ alkyl; $CR^{119}R^{120}OR^{124}$, $CR^{119}R^{120}SR^{124}$,
 $CR^{119}R^{120}S(O)_nR^{125}$ where n is 0, 1, or 2; $CR^{119}R^{120}NR^{124}R^{127}$; $CR^{119}R^{120}NR^{127}S(=O)_2R^{15}$;
 $CR^{119}R^{120}NR^{127}C(Y)R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)OR^{125}$; $CR^{119}R^{120}NR^{127}C(Y)NR^{127}R^{124}$;
 $CR^{119}R^{120}NR^{127}C(NCN)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(CR^{119}NO_2)S(C_1-C_4)$ alkyl;
 $CR^{119}R^{120}C(=O)OR^{125}$; $CR^{119}R^{120}C(Y)NR^{127}R^{124}$; $CR^{119}R^{120}C(NR^{127})NR^{127}R^{124}$;
 $CR^{119}R^{120}CN$; $CR^{119}R^{120}C(NOR^{120})R^{124}$; $CR^{119}R^{120}C(NOR^{124})R^{120}$;
 $CR^{119}R^{120}NR^{127}C(NR^{127})S(C_1-C_4)$ alkyl; $CR^{119}R^{120}NR^{127}C(NR^{127})NR^{127}R^{124}$;
 $CR^{119}R^{120}NR^{127}C(=O)C(=O)NR^{127}R^{124}$; $CR^{119}R^{120}NR^{127}C(=O)C(=O)OR^{124}$; tetrazolyl;
thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl;
triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; $CR^{119}R^{120}$ (tetrazolyl); $CR^{119}R^{120}$ (thiazolyl);
 $CR^{119}R^{120}$ (imidazolyl); $CR^{119}R^{120}$ (imidazolidinyl); $CR^{119}R^{120}$ (pyrazolyl);
 $CR^{119}R^{120}$ (thiazolidinyl); $CR^{119}R^{120}$ (oxazolyl); $CR^{119}R^{120}$ (oxazolidinyl); $CR^{119}R^{120}$ (triazolyl);
 $CR^{119}R^{120}$ (isoxazolyl); $CR^{119}R^{120}$ (oxadiazolyl); $CR^{119}R^{120}$ (thiadiazolyl);
 $CR^{119}R^{120}$ (morpholinyl); $CR^{119}R^{120}$ (piperidinyl); $CR^{119}R^{120}$ (piperazinyl); and
 $CR^{119}R^{120}$ (pyrrolyl); said heterocyclic groups being substituted by 0 to 3 substituents R^{124} ;
--- R^{115} is a member selected from the group consisting of R^{119} ; OR^{119} ; $-CH_2OR^{119}$; cyano;
 $C(=O)R^{119}$; $C(=O)OR^{119}$; $C(=O)NR^{119}R^{120}$; and $NR^{119}R^{120}$; provided that R^{115} is absent when
the dashed line in partial Formula (1.0.0) represents a double bond; or
--- R^{114} and R^{115} are taken together to form $=O$ or $=R^{118}$; or
--- R^{115} is hydrogen and R^{114} is OR^{124} ; SR^{124} ; $S(O)_nR^{125}$, where n is 0, 1, or 2; $S(=O)_2NR^{127}R^{124}$;
 $NR^{127}R^{124}$; $NR^{124}C(=O)R^{119}$; $NR^{127}C(Y)R^{124}$; $NR^{127}C(=O)OR^{125}$; $NR^{127}C(Y)NR^{127}R^{124}$;
 $NR^{127}S(=O)_2NR^{127}R^{124}$; $NR^{127}C(NCN)NR^{127}R^{124}$; $NR^{127}S(=O)_2R^{125}$;
 $NR^{127}C(CR^{119}NO_2)NR^{127}R^{124}$; $NR^{127}C(NCN)S(C_1-C_4)$ alkyl;

$\text{NR}^{127}\text{C}(\text{CR}^{119}\text{NO}_2)\text{S}(\text{C}_1\text{-C}_4)\text{ alkyl}$; $\text{NR}^{127}\text{C}(\text{NR}^{127})\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{NR}^{127}\text{R}^{124}$;
or $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{OR}^{124}$;

--- R^{116} is a member independently selected from the group consisting of methyl and ethyl substituted by 0 to 5 bromo, chloro, or fluoro, wherein m may be 2 with respect to a single ring carbon atom to which R^{116} is attached;

--- R^{117} is a member independently selected from the group consisting of OR^{124} ; SR^{124} ;
 $\text{SO}_2\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{127}\text{R}^{124}$; $\text{NR}^{124}\text{C}(=\text{O})\text{R}^{119}$; $\text{NR}^{127}\text{C}(\text{Y})\text{R}^{124}$; $\text{NR}^{127}\text{C}(=\text{O})\text{OR}^{125}$; $\text{S}(\text{O})_n\text{R}_{12}$
where n is 0, 1, or 2; $\text{OS}(=\text{O})_2\text{R}^{122}$; OR^{122} ; $\text{OC}(=\text{O})\text{NR}^{123}\text{R}^{122}$; $\text{OC}(=\text{O})\text{R}^{123}$; $\text{OC}(=\text{O})\text{OR}^{123}$;
 $\text{O}(\text{CR}^{122}\text{R}^{123})_m\text{OR}^{122}$ where m is 0, 1, or 2; $\text{CR}^{119}\text{R}^{120}\text{OR}^{124}$; $\text{CR}^{119}\text{R}^{120}\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{Y})\text{R}^{124}$;
 $\text{C}(=\text{O})\text{OR}^{124}$; $\text{C}(\text{Y})\text{NR}^{127}\text{R}^{124}$; CN ; $\text{C}(\text{NR}^{127})\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NOR}^{119})\text{R}^{124}$;
 $\text{C}(=\text{O})\text{NR}^{119}\text{NR}^{119}\text{C}(=\text{O})\text{R}^{119}$; $\text{C}(=\text{O})\text{NR}^{119}\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NOR}^{124})\text{R}^{119}$; $\text{C}(\text{NR}^{119})\text{NR}^{127}\text{R}^{124}$;
 $\text{C}(\text{NR}^{124})\text{NR}^{119}\text{R}^{120}$; $\text{C}(\text{NCN})\text{NR}^{127}\text{R}^{124}$; $\text{C}(\text{NCN})\text{S}(\text{C}_1\text{-C}_4)\text{ alkyl}$; tetrazolyl; thiazolyl;
imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl;
isoxazolyl; oxadiazolyl; and thiadiazolyl; where the recited heterocyclic groups are
substituted by 0 to 3 substituents where said substituent is R^{124} ;

--- R^{118} is a member independently selected from the group consisting of $-\text{NR}^{125}$;
 $-\text{NCR}^{119}\text{R}^{120}(\text{C}_2\text{-C}_6)\text{ alkenyl}$; $-\text{NOR}^{124}$; $-\text{NOR}^{129}$; $-\text{NOCR}^{119}\text{R}^{120}(\text{C}_2\text{-C}_6)\text{ alkenyl}$;
 $-\text{NNR}^{119}\text{R}^{124}$; $-\text{NNR}^{119}\text{R}^{129}$; $-\text{NCN}$; $-\text{NNR}^{119}\text{C}(\text{Y})\text{NR}^{119}\text{R}^{124}$; $-\text{C}(\text{CN})_2$; $-\text{CR}^{124}\text{CN}$;
 $-\text{CR}^{124}\text{C}(=\text{O})\text{OR}^{119}$; $-\text{CR}^{124}\text{C}(=\text{O})\text{NR}^{119}\text{R}^{124}$; $-\text{C}(\text{CN})\text{NO}_2$; $-\text{C}(\text{CN})\text{C}(=\text{O})\text{O}(\text{C}_1\text{-C}_4)\text{ alkyl}$;
 $-\text{C}(\text{CN})\text{OC}(=\text{O})\text{O}(\text{C}_1\text{-C}_4)\text{ alkyl}$; $-\text{C}(\text{CN})(\text{C}_1\text{-C}_4)\text{ alkyl}$; $-\text{C}(\text{CN})\text{C}(=\text{O})\text{NR}^{119}\text{R}^{124}$; 2-(1,3-
dithiane), 2-(1,3-dithiolane), dimethylthio ketal, diethylthio ketal, 2-(1,3-dioxolane), 2-(1,3-
dioxane), 2-(1,3-oxathiolane); dimethyl ketal and diethyl ketal;

----R¹¹⁹ and R¹²⁰ are each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl substituted by 0 to 3 fluorine atoms;

----R¹²¹ is a member independently selected from the group consisting of fluoro and R¹²⁰;

----R¹²² is a member independently selected from the group consisting of (C₁-C₆) alkyl; (C₂-C₃) alkenyl; (C₃-C₇) cycloalkyl; (C₃-C₇) cycloalkyl(C₁-C₂) alkyl; (C₆-C₁₀) aryl; and (C₃-C₉) heterocyclyl; where said aryl and heterocyclyl are as defined under R above; and where said R¹²² groups are substituted with 0 to 3 substituents independently selected from the group consisting essentially of methyl; ethyl; mono-, di-, and tri-fluoromethyl; and bromo, chloro, or fluoro;

----R¹²³ is a member independently selected from the group consisting of hydrogen and R¹²²;

----R¹²⁴ is a member independently selected from the group consisting of hydrogen and R¹²⁵; or when R¹²⁴ and R¹²⁷ appear together as NR¹²⁷R¹²⁴ then R¹²⁷ and R¹²⁴ may be taken together with the nitrogen to which they are attached to form a 5- to 7-membered ring optionally containing one additional heteroatom selected from O, N and S;

----R¹²⁵ is a member independently selected from the group consisting of (C₁-C₆) alkyl and -(CR¹¹⁹R¹²⁰)_nR¹²⁶, where n is 0, 1, or 2 and R¹²⁶ and said (C₁-C₆) alkyl are substituted by 0 to 3 substituents where each said substituent is a member independently selected from the group consisting of bromo; chloro; fluoro; nitro; cyano; NR¹²⁰R¹²⁷; C(=O)R¹¹⁹; OR¹¹⁹; C(=O)NR¹²⁰R¹²⁷; OC(=O)NR¹²⁰R¹²⁷; NR¹²⁷C(=O)NR¹²⁷R¹²⁰; NR¹²⁷C(=O)R¹²⁰; NR₁₇C(=O)O(C₁-C₄) alkyl; C(NR¹²⁷)NR¹²⁷R¹²⁰; C(NCN)NR¹²⁷R¹²⁰; C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)S(C₁-C₄) alkyl; NR¹²⁷C(NCN)NR¹²⁷R¹²⁰; NR¹²⁷S(=O)₂(C₁-C₄) alkyl; S(O)_n(C₁-C₄) alkyl; where n is 0, 1, or 2;

$\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{NR}^{127}\text{R}^{120}$, $\text{NR}^{127}\text{C}(=\text{O})\text{C}(=\text{O})\text{R}^{127}$; thiazolyl; imidazolyl; oxazolyl; pyrazolyl; triazolyl; tetrazolyl; and (C₁-C₂) alkyl substituted with 0 to 3 fluorine atoms;

----R¹²⁶ is a member independently selected from the group consisting of (C₃-C₇) cycloalkyl; pyridyl; pyrimidyl; pyrazolyl; imidazolyl; triazolyl; pyrrolyl; piperazinyl; piperidinyl; morpholinyl; furanyl; thienyl; thiazolyl; quinolinyl; naphthyl; and phenyl;

----R¹²⁷ is a member independently selected from the group consisting of OR¹¹⁹ and R¹²⁰;

----R¹²⁸ is a member independently selected from the group consisting of H; C(Y)R¹²⁴; C(=O)OR¹²⁴; C(Y)NR¹²⁷R¹²⁴; CN; C(NR¹²⁷)NR¹²⁷R¹²⁴; C(NOR¹¹⁹)R¹²⁴; C(=O)NR¹¹⁹NR¹¹⁹C(=O)R¹¹⁹; C(=O)NR¹¹⁹NR¹²⁷R¹²⁴; C(NOR¹²⁴)R¹¹⁹; C(NR¹¹⁹)NR¹²⁷R¹²⁴; C(NR¹²⁴)NR¹¹⁹R¹²⁰; C(NCN)NR¹²⁷R¹²⁴; C(NCN)S(C₁-C₄) alkyl; CR¹¹⁹R¹²⁰OR¹²⁴; CR¹¹⁹R¹²⁰SR¹²⁴; CR¹¹⁹R¹²⁰S(O)_nR¹²⁵, where n is 0, 1, or 2; CR¹¹⁹R¹²⁰NR¹²⁴R¹²⁷; CR¹¹⁹R¹²⁰NR¹²⁷S(=O)₂R¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(=O)OR¹²⁵; CR¹¹⁹R¹²⁰NR¹²⁷C(Y)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(NCN)NR¹²⁷R¹²⁴; CR¹¹⁹R¹²⁰NR¹²⁷C(CR₉NO₂)S(C₁-C₄) alkyl; tetrazolyl; thiazolyl; imidazolyl; imidazolidinyl; pyrazolyl; thiazolidinyl; oxazolyl; oxazolidinyl; triazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; wherein said recited heterocyclic groups are substituted by 0 to 3 substituents where each said substituent is independently selected from the group consisting essentially of R¹²⁴;

----R¹²⁹ is a member independently selected from the group consisting of -C(=O)R¹²; -C(=O)NR¹¹⁹R¹²⁴; -S(=O)₂R¹²⁵; and -S(=O)₂NR¹¹⁹R¹²⁴;

----Y is O or S; and,

---Z is O; NR¹²⁷; NCN; C(-CN)₂; CR¹¹⁹CN; CR¹¹⁹NO₂; CR¹¹⁹C(=O)OR¹¹⁹;
 CR¹¹⁹C(=O)NR¹¹⁹R¹²⁰; C(-CN)C(=O)O(C₁-C₄) alkyl); and C(-CN)C(=O)NR¹¹⁹R¹²⁰;

- or, said substituents defining R²_a and R²_b comprise: -

--(- II -)

--a member selected from the group consisting of R²²⁹;

-C(=O)NR²²²(CHR²²²)_mC(=O)NR²²²O(CH₂)_q(C₆-C₁₀) aryl);

-C(=NR²⁴²)NH(CH₂)_p(C₆-C₁₀) aryl; -C(=O)NR²¹⁸(CHR²²²)_mC(=O)NR²²²(CH₂)_pOR²²²;

-C(=O)NR²²²(CHR²²²)_mS(C₁-C₄) alkyl; -C[=NOC(=O)R²³⁵]R²³⁶;

-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹SO₂(CH₂)_pA;


-CR²²⁷R²²⁸CHR²³⁸NR²¹⁹P(=O)(OR²²²)C(=O)(C₁-C₄) alkyl;


-CR²²⁷R²³⁸CHR²³⁸NR²¹⁹P(=O)[(C₁-C₄) alkoxy]₂, -Z³-R²¹⁷; and

-(CR²²⁷R²²⁸)_mNR²¹⁹(C(O))_qR²²⁰ wherein p is 0, 1, or 2; m is 1, 2, 3, 4, 5, or 6; and q is 1 or 2;

- or, said substituents defining R²_a and R²_b comprise a moiety of

partial Formulas (2.0.0) through (2.0.8), inclusive: -





---wherein in said partial Formulas (2.0.0)-(2.0.8), the structures of partial Formulas (2.0.5) and (2.0.6) are attached to the nucleus of Formula (IA) or (IB) at carbons 5, 6, or 7 of said partial Formulas (2.0.5) and (2.0.6); the dashed line in partial Formulas (2.0.2) and (2.0.3) indicates a single bond or double bond, except that R²¹⁶ is absent in partial Formulas (2.0.2) and (2.0.3) where said dashed line indicates a double bond; n is 0 or an integer of 1 or 2; p is 0, 1, 2, 3, 4, 5, or 6; and m is 0 or 1;

---R²¹³ is a member independently selected from the group consisting of -C(=O)N(CH₃)(OCH₃) and -(CH₂)_nOH, where n is 0, 1, 2, 3, or 4;

---R²¹⁴ and R²¹⁵ are independently selected from the group consisting of H; ethyl; -CO₂H; and -C(=O)NHOH;

---R²¹⁶ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₆) alkyl; (C₁-C₆) alkoxy; -OC(=O)(C₁-C₆) alkyl and -OC(=O)(C₆-C₁₀) aryl;

---R²¹⁷ is a member independently selected from the group consisting of (C₆-C₁₀) aryl and a 5- to 10-membered heterocyclyl, wherein said R²¹⁷ groups are substituted by 0 to 3 substituents independently selected from the group consisting of bromo, chloro, or fluoro; trifluoromethyl; cyano; nitro; -CO₂R²²², (C₁-C₄) alkoxy; -OC(=O)(C₁-C₄) alkyl;

$\text{-NR}^{222}\text{C(=O)(C}_1\text{-C}_4\text{) alkyl; -C(=O)NH}_2\text{; -C(=O)NHOH; -C(=O)O(C}_1\text{-C}_4\text{) alkyl;}$
 $(\text{C}_1\text{-C}_4\text{) alkyl; -S(O)}_n\text{R}^{222}$ where n is 0, 1, or 2; benzoyl; $\text{-NR}^{222}\text{R}^{223}$, -OR^{222} ,
 $(\text{C}_1\text{-C}_6\text{) alkanoyl; -Y}^1\text{-(C}_6\text{-C}_{10}\text{) aryl; -C(=O)O(C}_6\text{-C}_{10}\text{) aryl; -NH(C}_6\text{-C}_{10}\text{) aryl;}$
 $\text{-C(=O)NH(C}_6\text{-C}_{10}\text{) aryl; -C(=O)NR}^{222}\text{O(CH}_2\text{)}_n\text{(C}_6\text{-C}_{10}\text{) aryl, where n is 1, 2, or 3; and}$
 $\text{-SO}_2\text{NH(C}_6\text{-C}_{10}\text{) aryl;}$

---R^{218} is a member independently selected from the group consisting of H; $(\text{C}_1\text{-C}_6\text{) alkyl; and}$
 $\text{-(CH}_2\text{)}_n\text{(C}_6\text{-C}_{10}\text{) aryl, where n is 0, 1, 2, 3, or 4;}$

---R^{219} is a member independently selected from the group consisting of H; -OR^{222} ; $\text{-(CH}_2\text{)}_m\text{A ;}$
 $\text{and -CH}_2\text{O(CH}_2\text{)}_m\text{A, where m is 0, 1, or 2;}$

---R^{220} is a member independently selected from the group consisting of $(\text{C}_1\text{-C}_4\text{) alkyl; -OR}^{222}$,
 $\text{-CR}^{222}\text{R}^{223}\text{OR}^{222}$; $\text{-CR}^{222}\text{R}^{223}\text{NR}^{222}\text{R}^{223}$; $\text{-CR}^{222}(\text{OR}^{223})\text{CR}^{222}\text{R}^{223}\text{OR}^{222}$;
 $2,2\text{-dimethyl-1,3-dioxolan-4-yl; -NR}^{222}\text{C(=O)NR}^{222}\text{R}^{223}$, $\text{-S(CR}^{222}\text{R}^{223})_n\text{CH}_3$ where n is 0, 1,
2, 3, 4, or 5; $\text{-NR}^{222}(\text{CH}_2)_q(\text{pyridyl})$ where q is 0 or 1; $\text{-P(=O)[(C}_1\text{-C}_4\text{) alkoxy]}_2$; $\text{-NR}^{222}\text{R}^{223}$;
 $\text{-NR}^{222}\text{OR}^{223}$; $\text{-NR}^{222}\text{NR}^{223}\text{R}^{221}$, $\text{-NR}^{222}\text{CH}_2\text{R}^{224}$; $\text{-OCH}_2\text{NR}^{222}\text{C(=O)R}^{224}$;
 $\text{-OCH}_2\text{C(=O)NR}^{225}\text{R}^{226}$, $\text{-OCHR}^{222}\text{OC(=O)(C}_1\text{-C}_4\text{) alkyl; -OCHR}^{222}\text{C(=O)(C}_1\text{-C}_3\text{) alkoxy;}$
 $\text{-O(CH}_2\text{)}_m\text{R}^{221}$; and $\text{-NR}^{222}(\text{CH}_2)_m\text{R}^{221}$ where m is 0, 1, or 2;

---R^{221} is a member independently selected from the group consisting of H and A;

---R^{222} and R^{223} are each a member independently selected from the group consisting of H and
 $(\text{C}_1\text{-C}_4\text{) alkyl;}$

---R^{224} is a member independently selected from the group consisting of methyl and phenyl;

---R^{225} is a member independently selected from the group consisting of H; methyl; ethyl; and
 $\text{-CH}_2\text{CH}_2\text{OH;}$

---R²²⁶ is a member independently selected from the group consisting of H; methyl; ethyl;
 -CH₂C(=O)NH₂; and -CH₂CH₂OH;


---R²²⁷ is each a member independently selected from the group consisting of H; hydroxy;
 cyano; halo; (C₁-C₃) alkyl; (C₁-C₃) alkoxy; -NR²²²R²²³; -C(=O)OR²²²; -C(=O)R²²²;
 -CH=CR²²²R²²³; -C≡CR²²²; -CH₂NR²²²R²²³; -CH₂OR²²²; -C(=O)NR²²²R²²³; -C(Y⁵)H; and
 -CH₂NR₁₂C(=O)C(=O)NR²²²R²²³; provided that when R²²⁷ is hydroxy then R²²⁸ is H or
 (C₁-C₄) alkyl;

---R²²⁸ is each a member independently selected from the group consisting of H; fluoro; cyano;
 and (C₁-C₄) alkyl; where said methyl is substituted by 0 to 3 substituents each comprising a
 fluorine atom; or

---R²²⁷ and R²²⁸ are taken together to form an oxo (=O) moiety;

---R²²⁹ is a member independently selected from the group consisting of phenyl; naphthyl;
 pyrrolyl; furanyl; thienyl; oxazolyl; pyridinyl; pyrimidinyl; pyridazinyl; quinolinyl;
 isoquinolinyl; 5,6,7,8-tetrahydroquinolinyl; and 5,6,7,8-tetrahydroisoquinolinyl, where said
 R²²⁹ groups, except said phenyl, are substituted by 0 to 3 substituents R²³³, and wherein said
 phenyl R²²⁹ group is substituted by 0 to 3 substituents independently selected from the group
 consisting of R²³³ and R²³⁴;

---R²³⁰ is a member independently selected from the group consisting of -C(=O)R²³¹;
 -C(=O)C(=O)R²³¹, -C(=O)C(Y²)C(=O)R²³¹ and a moiety of partial Formula (2.0.9):



(2.0.9)

wherein:

----R²³¹ is a member independently selected from the group consisting of H; -OR²³²; -NHR²³²; -NHOH; -NHNH₂; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is 0, 1, 2, 3, or 4;

----R²³² is a member independently selected from the group consisting of H; (C₁-C₈) alkyl; -(CH₂)_nY³(phenyl) and -(CH₂)_nY³(pyridyl) where n is 0, 1, 2, 3, or 4;

----R²³³ is each a member independently selected from the group consisting of bromo; chloro; fluoro; (C₁-C₆) alkyl; (C₁-C₇) alkoxy; (C₂-C₆) alkylenedioxy; trifluoromethyl; -NR²²²R²²³; nitro; -C(NR²²²)NR²²²R²²³; -C(=O)NR²²²R²²³C(=O)R²²²; -C(NOR²²²)R²²³; -C(NCN)NR²²²R²²³; -C(NCN)SR²²²; -(CH₂)_m(CN) where m is 0, 1, 2, or 3; hydroxy; -C(=O)R²²²; -C(=O)NR²²²OR²²³; -C(=O)NR²²²NR²²²R²²³; -OC(=O)NR²²²R²²³; -NR²²²C(=O)R²²²; -C(=O)C(=O)NR²²²R²²³; -CO₂R²²²; -SO₂R²²²; -SO₂NR²²²R²²³; -C(=O)NR²²²R²²³; -NR²²²SO₂R²²³; and -NR²²²C(=O)NR²²²R²²³;

----R²³⁴ is each a member independently selected from the group consisting of imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl; thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl, where each of said foregoing R²³⁴ substituents is substituted by 0 to 3 substituents R²³³;

----R²³⁵ is a member independently selected from the group consisting of -NR²²²R²²³; -NH(C₆-C₁₀) aryl; (C₁-C₆) alkoxy; and (C₆-C₁₀) aryloxy;

----R²³⁶ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl and -(CH₂)_mY⁴(phenyl) where m is 0, 1, 2, 3, or 4 and the phenyl moiety of said -(CH₂)_mY⁴(phenyl)R²³⁶ group is substituted by 0 to 3 substituents independently selected

from the group consisting of bromo, chloro, and fluoro; $-OR^{222}$; (C_1-C_6) alkanoyloxy; (C_6-C_{10}) aryloxy; $-NR^{222}R^{223}$; $-NH(C_6-C_{10})$ aryl; and $-NHC(=O)(C_1-C_4)$ alkyl;

----- R^{237} is each a member independently selected from the group consisting of bromo; chloro; fluoro; $-(CH_2)_pNR^{222}C(=O)CH_3$ where p is an integer of from 1, 2, 3, or 4, and; (C_1-C_4) alkoxy; nitro; cyano; $-NR^{222}R^{223}$; $-CO_2R^{222}$; $-OR^{222}$; $-C(Y^1)NR^{222}R^{223}$; $-NR^{222}C(NCN)S(C_1-C_3)$ alkyl; $-NR^{222}C(NCN)NR^{222}R^{223}$; $-NR^{222}C(=O)NR^{222}R^{223}$; $-NR^{222}C(=O)C(=O)NR^{222}R^{223}$; $-C(=NR^{222})NR^{222}R^{223}$; $-S(O)_mCH_3$ where m is 0, 1, or 2; $-C(=NR^{222})S(C_1-C_3)$ alkyl; $-NR^{222}SO_2(C_1-C_3)$ alkyl; $-OC(=O)R^{222}$; $-OC(=O)NR^{222}R^{223}$; $-NR^{222}SO_2CF_3$; $-NR^{222}C(=O)C(=O)OR^{222}$; $-NR^{222}C(=O)R^{222}$; $-NR^{222}C(=O)OR^{222}$; imidazolyl; thiazolyl; oxazolyl; pyrazolyl; triazolyl; and tetrazolyl;

----- R^{238} is a member independently selected from the group consisting of H; fluoro; cyano; and (C_1-C_2) alkyl, where said alkyl is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; $-C(=O)NR^{222}R^{223}$; and $-C(=O)OR^{222}$;

----- R^{239} is a member independently selected from the group consisting of phenyl substituted by 0 to 2 substituents independently selected from the group consisting of $-NR^{222}R^{223}$, nitro, halo, $-OR^{222}$, $-NHR^{240}$, $-NR^{240}R^{241}$, and $-C(=O)OR^{222}$;

----- R^{240} and R^{241} are each a member independently selected from the group consisting of (C_1-C_8) alkyl and (C_2-C_8) alkenyl;

----- R^{242} is pyridin-4-yl substituted by 0 to 2 substituents independently selected from the group consisting of bromo, chloro, or fluoro; and (C_1-C_4) alkyl;

-----A is each a member independently selected from the group consisting of (C_1-C_6) alkyl; pyridyl; morpholinyl; piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; triazolyl;

quinoliny; phenyl; and naphthyl; wherein the foregoing A groups are substituted with 0 to 3 substituents R^{237} ; or A is $-(CH_2)_qS(C_1-C_4)$ alkyl wherein q is an integer of 1 or 2;

-----W is a member independently selected from the group consisting of O; NOH; NNH_2 ; $NOC(=O)CH_3$; and $NNHC(=O)CH_3$;

-----Y¹ is O or S;

-----Y² is O, NOH or H₂;

-----Y³ is a bond or $-CH=CH-$;

-----Y⁴ is a bond, O, S, or $-NH-$;

-----Y⁵ is a member independently selected from the group consisting of O; NR^{222} ; NOR^{222} ; NCN ; $C(CN)_2$; $CR^{222}NO_2$; $CR^{222}C(=O)OR^{222}$; $CR^{222}C(=O)NR^{222}R^{223}$; $C(CN)NO_2$; $C(CN)C(=O)OR^{222}$; and $C(CN)C(=O)NR^{222}R^{223}$; and

-----Z³ is a member independently selected from the group consisting of $-NR^{222}-$; $-(CH_2)_m-$; $-CH_2C(=O)NH-$; $-NHCH_2C(=O)-$; $-CH_2C(Y^1)CH_2-$; $-CH=CH-$; $-C\equiv C-$; $-CH(Y^1H)-$; $-C(Y^1)-$; $-CH_2C(Y^1)-$; $-C(Y^1)CH_2-$; $-C(Y_1)C(Y_1)-$; $-CH_2NR^{222}-$; $-CH_2-Y^1-$; $-C(Y^1)NR^{218}(CHR^{222})_n-$; $-NR^{218}C(Y^1)(CHR^{222})_n-$; $-NHCH_2-$; $-Y^1-CH_2-$; $-SOCH_2-$; $-CH_2SO-$; $-SO_2CH_2-$; $-CH_2SO_2-$; $-OC(Y^1)-$; $-N=N-$; $-NHSO_2-$; $-SO_2NH-$; $-C(Y^1)C(Y^1)NH-$; $-NHC(=O)O-$; $-OC(=O)NH-$; and $-NHC(=O)NH-$; wherein for said Z₃ moieties n is 0, 1, 2, 3, or 4; and m is from 1, 2, and 3;


- or said substituents defining R_a^2 and R_b^2 comprise: -

--(- III -)


--a member independently selected from the group consisting of 2-oxo-4-pyrrolyl; pyrazolyl; 2-oxo-3,4-dihydro-5-pyrimidyl; 2-oxo-3,4-dihydro-4-pyrimidyl; 2-oxo-tetrahydro-4-pyrimidyl; 2-oxo-tetrahydro-5-pyrimidyl; 2-oxo-4-pyrimidyl; and 2-oxo-5-pyrimidyl; wherein each of said R_a^2 and R_b^2 groups is substituted by 0, 1, 2, 3, or 4 R^{236} groups;

- or, said substituents defining R_a^2 and R_b^2 comprise a


moiety of partial Formulas (3.0.0) through (3.0.19), inclusive: -




(3.0.0)




(3.0.1)




(3.0.2)




(3.0.3)




(3.0.4)




(3.0.5)




(3.0.6)




(3.0.7)




(3.0.8)




(3.0.9)




(3.10)




(3.11)




(3.12)




(3.13)




(3.14)




(3.15)




(3.16)



(3.17)



(3.18)



(3.19)

----wherein in said partial Formulas (3.0.0) through (3.0.19), q is 0 or 1 in partial Formula

(3.0.1); n is 0, 1, or 2 in partial Formula (3.0.2); and the dashed lines appearing in formulas (3.0.1), (3.0.3), (3.0.6), (3.0.7), (3.0.8), (3.0.9) and (3.0.14) represent a double bond or a single bond;

-----X¹ is O or S;

-----X² in formula (3.0.10) and where the dashed line in formula (3.0.9) represents a double bond, is a member independently selected from the group consisting of CR³³⁵; CR³³⁶; CR³⁴⁶; and COC(=O)NR³³⁹R³⁴²; or, where the dashed line in formula (3.0.9) represents a single bond, X² is a member independently selected from the group consisting of CR³³⁵R³³⁹; CR³³⁶R³³⁹; and CR³⁴⁶R³³⁹;

-----X³ is a member independently selected from the group consisting of C(=Z³); C(S); and CR³³⁶R³⁴⁰;

-----X⁴ is a member independently selected from the group consisting of -(CH₂)_m- where m is 0, 1, or 2;

-----X⁵ is a bond or -CH₂-;

-----X⁶ is a member independently selected from the group consisting of -CH₂- and -C(=O)-;

-----R³³³ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₄) alkoxy; -CHR³³⁷(O)_q(CH₂)_mA where q is 0 or 1, and m is 0, 1, or 2;

-----R³³⁴ is a member independently selected from the group consisting of H; hydroxy;

(C₁-C₄) alkyl; (C₁-C₂) alkoxy; -OC(=O)CH₃; (C₂-C₃) alkenyl; and phenyl(C₁-C₂) alkyl-;

-----R³³⁵ is a member independently selected from the group consisting of H; hydroxy;

-(CH₂)_mA where m is 0, 1, or 2; (C₁-C₆) alkyl; and (C₂-C₃) alkanoyl; where said alkyl group

is substituted by 0 to 3 substituents independently selected from the group consisting of

bromo; chloro; fluoro; nitro; -NR³⁴⁰R³⁴¹; -CO₂R³⁴⁰; -OR³⁴⁰; -OC(=O)R³⁴⁰; -C(=O)R³⁴⁰;

cyano; -C(=Y)NR³⁴⁰R³⁴¹; -NR³⁴⁰C(=Y)NR³⁴⁰R³⁴¹; -NR³⁴⁰C(=Y)R³⁴⁰; -NR³⁴⁰C(=O)OR³⁴⁰;

-C(NR³⁴⁰)NR³⁴⁰R³⁴¹; -C(NCN)NR³⁴⁰R³⁴¹; -C(NCN)SR³⁴⁰; -NR³⁴⁰SO₂R³⁴⁰; -S(O)_mR³⁴⁰,

where m is 0, 1, or 2; -NR³⁴⁰SO₂CF₃; -NR³⁴⁰C(=O)C(=O)NR³⁴⁰R³⁴¹;

-NR³⁴⁰C(=O)C(=O)OR³⁴⁰; imidazolyl; and 1-(NHR³⁴⁰)-2-imidazolyl;

-----R³³⁶ is each a member independently selected from the group consisting of H; bromo;

chloro; fluoro; cyano; R³⁴³; cyclopropyl substituted by 0 or 1 substituent independently

selected from the group consisting of R³³⁹; -OR³⁴⁰; -CH₂OR³⁴⁰; -NR³⁴⁰R³⁴²; -CH₂NR³⁴⁰R³⁴²;

-C(=O)OR³⁴⁰; -C(=O)NR³⁴⁰R³⁴²; -CH=CR³³⁹R³³⁹; -C≡CR³³⁹; and -C(=Z³)H;

-----R³³⁷ is a member independently selected from the group consisting of H; -C(=O)R³³⁸;

imidazolyl; pyrazolyl; triazolyl; tetrazolyl; oxazolyl; isoxazolyl; oxadiazolyl; thiadiazolyl;

thiazolyl; oxazolidinyl; thiazolidinyl; and imidazolidinyl;

-----R³³⁸ is each a member independently selected from the group consisting of -OR³⁴⁰;

-NR³⁴⁰R³⁴²; and -R³⁴³;

-----R³³⁹ is each a member independently selected from the group consisting of H; bromo;

chloro; fluoro; and (C₁-C₄) alkyl substituted by 0 to 3 fluorine atoms;

- R³⁴⁰ and R³⁴¹ are each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl;
- R³⁴² is each a member independently selected from the group consisting of -OR³⁴⁰ and -R³⁴⁰;
- R³⁴³ is (C₁-C₄) alkyl;
- R³⁴⁴ is each a member independently selected from the group consisting of bromo; chloro; fluoro; nitro; cyano; -NR³⁴⁰R³⁴⁶; -NR³⁴⁶R³⁴²; -C(=Z³)R³³⁸; -S(O)_mR³⁴³ where m is 0, 1, and 2; -OR³⁴²; -OC(=O)NR³⁴⁰R³⁴²; -C(NR³⁴²)NR³⁴⁰R³⁴²; -C(NR³⁴⁰)SR³⁴³; -OC(=O)CH₃; -C(NCN)NR³⁴⁰R³⁴²; -C(S)NR³⁴⁰R³⁴²; -NR³⁴²C(=O)R³⁴⁷; -C(=O)R³⁴⁷; oxazolyl; imidazolyl; thiazolyl; pyrazolyl; triazolyl; and tetrazolyl;
- R³⁴⁵ is each a member independently selected from the group consisting of hydrogen and (C₁-C₄) alkyl substituted by 0, 1, 2 or 3 fluorine atoms;
- R³⁴⁶ is each a member independently selected from the group consisting of H; -R³⁴³; -C(=O)R³⁴³; -C(=O)C(=O)R³³⁸; -C(=O)NR³⁴⁰R³⁴²; -S(O)_mR³⁴³ where m is 0, 1, or 2; -C(NCN)SR³⁴³; -C(NCN)R³⁴³; -C(NR³⁴²)R³⁴³; -C(NR³⁴²)SR³⁴³; and -C(NCN)NR³⁴⁰R³⁴²;
- R³⁴⁷ is each a member independently selected from the group consisting of -R³⁴³; -C(=O)R³⁴³; oxazolidinyl; oxazolyl; thiazolyl; pyrazolyl; triazolyl; tetrazolyl; imidazolyl; imidazolidinyl; thiazolidinyl; isoxazolyl; oxadiazolyl; thiadiazolyl; morpholinyl; piperidinyl; piperazinyl; and pyrrolyl; where each of said recited R³⁴⁷ heterocyclic groups is substituted by 0 to 2 (C₁-C₂) alkyl groups;
- R³⁴⁸ is each a member independently selected from the group consisting of H; (C₁-C₅) alkyl; (C₂-C₅) alkenyl; benzyl; and phenethyl;

- R³⁴⁹ is a member independently selected from the group consisting of H; (C₁-C₅) alkyl; (C₁-C₅) alkanoyl; and benzoyl;
- R³⁵⁰ is a member independently selected from the group consisting of H; (C₁-C₄) alkyl; carboxy; aminocarbonyl; (C₁-C₆) alkyl substituted by 0 or 1 carboxy, -(CH₂)_mC(=O)(C₁-C₆) alkoxy; or -(CH₂)_m(C₆-C₁₀) aryl; where m is 0, 1, or 2;
- R³⁵¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; -C(=Y)R³⁵²; -C(=Y)NH₂; -C(=O)OR³⁵²; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4, or 5; and X⁷ is a bond or -CH=CH-; and where said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵² is a member independently selected from the group consisting of (C₁-C₆) alkyl (C₃-C₈) cycloalkyl; -(CH₂)_m(C₆-C₁₀) aryl; and -(CH₂)_nX⁷(pyridyl) where n is 0, 1, 2, 3, 4, or 5; and X⁷ is a bond or -CH=CH-; and where said pyridyl moiety is substituted by 0 or 1 bromo, chloro, or fluoro;
- R³⁵³ is a member independently selected from the group consisting of H; -R³⁴⁵; (C₁-C₃) alkyl substituted by 0 or 1 hydroxy, or (C₁-C₃) alkoxy(C₁-C₃) alkyl;
- R³⁵⁴ is a member independently selected from the group consisting of H; -R³⁴⁵; carboxy; (C₁-C₃) alkoxy(C₁-C₃) alkyl-; (C₃-C₇) cycloalkyl; and (C₁-C₅) alkyl substituted by 0 or 1 -NR³⁴⁰R³⁴¹; or
- R³⁵³ and R³⁵⁴ are taken together to form -CH₂OCH₂OCH₂-;
- R³⁵⁵ is a member independently selected from the group consisting of H; hydroxy; (C₁-C₄) alkyl substituted by 0 or 1 substituent selected from the group consisting of hydroxy; -C(=O)R³⁴⁰; -NR³⁴⁰R³⁴¹; -(CH₂)_mNHC(=O)R³⁴⁰; -(CH₂)_mNHC(=O)R³⁴³;

$-(CH_2)_mCO_2R^{340}$; $-(CH_2)_mC(=O)NR^{340}R^{341}$; $-(CH_2)_mC(=O)N(OH)R^{340}$;
 $-(CH_2)_mSO_2NR^{340}R^{341}$; $-(CH_2)_mPO_3H_2$; $-(CH_2)_mSO_2NHC(=O)R^{343}$; and
 $-(CH_2)_mSO_2NHC(=O)(phenyl)$, where m is 0, 1, 2, 3, or 4;

-----R³⁵⁶ is a member independently selected from the group consisting of H; (C₁-C₄) alkyl;
 phenyl; $-NR^{340}R^{341}$; and $-NR^{340}(C_1-C_4)$ alkanoyl;

-----R³⁵⁷ is a member independently selected from the group consisting of $-R^{340}$; $-CH_2CO_2R^{343}$;
 and $-CH_2C(=O)NR^{340}R^{341}$;

-----R³⁵⁸ is a member independently selected from the group consisting of $-C(=O)R^{340}$;
 $-C(=O)(C_6-C_{10})$ aryl; $-C(=O)(C_3-C_9)$ heteroaryl; $-CO_2R^{340}$; $-C(=O)NR^{340}R^{341}$; cyano; nitro;
 $-CH_2OH$; $-NR^{340}SO_2R^{340}$; $-NHSO_2(C_6-C_{10})$ aryl; $-NHCO_2(C_1-C_4)$ alkyl; $-NR^{340}C(=O)R^{340}$;
 and $-NHCO_2(C_6-C_{10})$ aryl;

-----R³⁵⁹ is a member independently selected from the group consisting of $-R^{345}$; cyano;
 carboxy; formyl; $-C(=O)R^{340}$; and (C₁-C₄) alkanoyl;

-----R³⁶⁰ is a member independently selected from the group consisting of cyano; $-NR^{340}R^{341}$;
 $-SO_2(C_1-C_4)$ alkyl; $-SO_2(C_6-C_{10})$ aryl; $-C(=O)R^{340}$; $-C(=O)(C_6-C_{10})$ aryl;
 $-C(=O)(C_3-C_9)$ heteroaryl; $-C(=O)NR^{340}R^{341}$; and $-CO_2R^{340}$;

-----R³⁶¹ and R³⁶² are each a member independently selected from the group consisting of H;
 cyano; nitro; $-CO_2R^{340}$; $-C(=O)NR^{340}R^{341}$; $-CH_2OH$; $-C(=O)R^{340}$; $-NHCO_2R^{340}$; and
 $-NHSO_2R^{340}$;

-----A is a member independently selected from the group consisting of pyridyl; morpholinyl;
 piperidinyl; imidazolyl; thienyl; pyrimidyl; thiazolyl; phenyl; and naphthyl; where each of
 said A groups is substituted by 0 to 2 substituents R³⁴⁴ or by 1 substituent R³⁴⁵;


-----Z³ is a member independently selected from the group consisting of O; -NR³⁴²; NOR³⁴⁰; N(CN); C(CN)₂; CR³⁴⁰NO₂; CR³⁴⁰C(=O)OR³⁴³; CR³⁴⁰C(=O)NR³⁴⁰R³⁴¹; C(CN)NO₂; C(CN)C(=O)OR³⁴³; and C(CN)C(=O)NR³⁴⁰R³⁴¹; and,

-----Y is O or S;

- or said substituents defining R²_a and R²_b

comprise a moiety of partial Formula (4.0.0): -

--(- IV -)



(4.0.0)

---wherein the broken line indicates a single or double bond;

---X¹ is -CR⁴⁷²R⁴⁷³ - where said broken line indicates a single bond; or -CR⁴⁷³ - where said broken line indicates a double bond;

---X² is -CR⁴⁷⁵R⁴⁷⁷R⁴⁷⁸ - or -C(=NOR⁴⁸¹)R⁴⁸² - where said broken line indicates a single bond; or -CR⁴⁷⁷R⁴⁷⁸ where said broken line indicates a double bond;

---R⁴⁷² is a member independently selected from the group consisting of H; hydroxy; bromo, chloro, or fluoro; and -OR⁴⁷⁹;

---R⁴⁷³ s each a member independently selected from the group consisting of cyano; cyanomethyl; benzyloxy; -R⁴⁷⁵; -CO₂R⁴⁷⁵; -CO₂(CH₂)_n(C₆-C₁₀) aryl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NR⁴⁷⁵(CH₂)_n(C₆-C₁₀) aryl; -(CH₂)_n(C₆-C₁₀) aryl; and -(CH₂)_n(5- to 10-membered

heteroaryl); where n is 0, 1, 2, or 3; each R^{473} group is substituted by 0 to 3 substituents R^{474} ; and each R^{473} group is substituted by 0 or 1 substituent R^{480} ;

---- R^{474} is each a member independently selected from the group consisting of bromo; chloro; fluoro; cyano; nitro; (C_1-C_6) alkyl; (C_2-C_6) alkenyl; $-OR^{475}$; (C_3-C_7) cycloalkoxy; $-NR^{475}R^{476}$; $-NR^{475}OR^{476}$; $-S(O)_mR^{475}$ where m is 0, 1, or 2; $-CO_2R^{475}$; $-C(=O)R^{475}$; $-SO_2NR^{475}R^{476}$; $-C(=O)NR^{475}R^{476}$; $-CR^{475}R^{476}SO_2NR^{475}R^{476}$; $-CR^{475}R^{476}C(=O)NR^{475}R^{476}$; $-NHSO_2R^{475}$; $-NHSO_2NR^{475}R^{476}$; $-NHC(=O)NR^{475}R^{476}$; $-NHC(=O)(C_1-C_6)$ alkyl; and $-NHC(=O)O(C_1-C_6)$ alkyl);

---- R^{475} and R^{476} are each a member independently selected from the group consisting of H; and (C_1-C_6) alkyl;

---- R^{477} is a member independently selected from the group consisting of $-R^{473}$; 2-oxo-pyridyl; 3-oxo-pyridyl; 4-oxo-pyridyl; 2-oxo-pyrrolyl; 4-oxo-thiazolyl; 4-oxo-piperidyl; 2-oxo-quinolyl; 4-oxo-quinolyl; 1-oxo-isoquinolyl; 4-oxo-oxazolyl; 5-oxo-pyrazolyl; 5-oxo-isoxazolyl; and 4-oxo-isoxazolyl; where each of said R^{477} groups is substituted by 0 to 3 substituents R^{474} ;

---- R^{478} is a member independently selected from the group consisting of $-R^{475}$; cyano; $-(CH_2)_p(C_6-C_{10})$ aryl; and $-(CH_2)_p(5- \text{ to } 10\text{-membered heteroaryl})$; where p is 1, 2, or 3; and where each said R^{478} group is substituted by 0 to 3 substituents R^{474} ;

---- R^{479} is a member independently selected from the group consisting of formyl; carbamoyl; thiocarbamyl; (C_1-C_6) alkyl; (C_2-C_6) alkenyl; (C_1-C_4) alkoxy (C_1-C_4) alkyl-; and (C_1-C_6) alkanoyl; where said alkyl moieties of each of said R^{479} groups is substituted by 0

to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; hydroxy; and (C₁-C₄) alkoxy;

-----R⁴⁸⁰ is a member independently selected from the group consisting of cyclobutyl; cyclopentyl; cyclohexyl; 2-cyclobuten-1-yl; 2-cyclopenten-1-yl; 3-cyclopenten-1-yl; 2,4-cyclopentadien-1-yl; 3,5-cyclohexadien-1-yl; pyrrolyl; pyrrolidinyl; dioxolanyl; imidazolyl; oxazolyl; imidazolidinyl; pyrazolyl; pyrazolidinyl; pyranyl; piperidinyl; 1,4-dioxanyl; morpholinyl; 1,4-dithianyl; thiomorpholinyl; piperazinyl; 1,3,5-trithianyl; oxazinyl; isoxazinyl; oxathiazinyl; and oxadiazinyl; where each of said R⁴⁸⁰ groups is substituted by 0 to 2 (C₁-C₂) alkyl;


----R⁴⁸¹ is a member independently selected from the group consisting of H; (C₁-C₆) alkyl; (C₂-C₆) alkenyl; (C₂-C₆) alkynyl; -C(Y)NR⁴⁷⁵R⁴⁷⁶; -C(Y)NH(C₆-C₁₀) aryl; -C(Y)(C₁-C₆) alkoxy; -C(Y)(C₆-C₁₀) aryloxy; and -C(Y)(C₁-C₆) alkyl;

----R⁴⁸² is a member independently selected from the group consisting of phenyl and pyridinyl; where each of said R⁴⁸² groups is substituted by 0 to 3 substituents independently selected from the group consisting of bromo; chloro; fluoro; (C₁-C₄) alkyl; hydroxy; (C₁-C₄) alkoxy; -NR⁴⁷⁵R⁴⁷⁶; and -S(O)_mR⁴⁷⁵, where m is 0, 1, or 2; and,


-----Y is O or S;

- or , said substituents defining R²_a and R²_b comprise a moiety of partial Formulas (5.0.0) through (5.0.13), inclusive: -


--(- V -)




(5.0.0)




(5.0.1)




(5.0.2)




(5.0.3)




(5.0.4)




(5.0.5)




(5.0.6)




(5.0.7)




(5.0.8)




(5.0.9)




(5.0.10)



(5.0.11)



(5.0.12)




(5.0.13)

IN THE ABSTRACT:


Replace the Abstract with the replacement Abstract of the Disclosure set forth on the next page.

ABSTRACT OF THE DISCLOSURE

A method of treating or preventing stasis in all or any part or parts of the stomach of a patient, wherein the status results from hypomotility, by administration to the patient of a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4) wherein the PDE4 inhibitor is a compound of Formula (IA) or (IB):




(IA)



(IB)

wherein, in a preferred embodiment, R is cyclopentyl or cyclohexyl; R¹ is C₁-C₂ alkyl; one of R²_a and R²_b is hydrogen and the other substituent of a partial formula (1.0.0) having the formula



(1.0.0)

wherein the dashed line represents a single bond; m is 0; R¹¹³ and R¹¹⁴ are in a cis relationship to each other; R¹¹³ is cyano; R¹¹⁵ hydrogen; and R¹¹⁴ is carboxy, -CH²OH or -CH²C(=O)NH₂.

In addition, pharmaceutical compositions, which include a compound of Formula (IA) or (IB),
for effectuation of the method.